-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
also ADV - O
synergized VERB - O
with ADP - O
lapatinib NOUN - O
to PART - O
strongly ADV - O
suppress VERB - O
the DET - O
in ADP - O
vivo NOUN - O
growth NOUN - O
of ADP - O
ErbB2-positive JJ - B-NORP
breast NOUN - O
cancer NOUN - O
xenografts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

miR-33a ADJ - O
Mediates PROPN - O
the DET - O
Anti PROPN - O
- ADJ - O
Tumor PROPN - O
Effect PROPN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
in ADP - O
Osteosarcoma NNP - B-GPE
by ADP - O
Targeting VERB - O
CYR61 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Habit PROPN - O
Modification PROPN - O
of ADP - O
the DET - O
Active PROPN - O
Pharmaceutical PROPN - O
Ingredient PROPN - O
Lovastatin NNP - B-MEDICINE
Through ADP - O
a DT - B-ORG
Predictive NNP - I-ORG
Solvent NNP - I-ORG
Selection NNP - I-ORG
Approach NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Topical PROPN - O
Glycolic PROPN - O
Acid PROPN - O
Plus CCONJ - O
a DET - O
Lovastatin NNP - B-MEDICINE
- PUNCT - O
Cholesterol PROPN - O
Combination PROPN - O
Cream PROPN - O
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Autosomal PROPN - O
Recessive PROPN - O
Congenital PROPN - O
Ichthyoses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
had VERB - O
no DET - O
effect NOUN - O
on ADP - O
feed NOUN - O
digestibility NOUN - O
and CCONJ - O
minor ADJ - O
effect NOUN - O
on ADP - O
rumen NOUN - O
microbiota NOUN - O
, PUNCT - O
and CCONJ - O
specifically ADV - O
did VERB - O
not ADV - O
reduce VERB - O
the DET - O
populations NOUN - O
of ADP - O
total ADJ - O
methanogens NOUN - O
and CCONJ - O
Methanobacteriales NNP - B-PERSON
( PUNCT - O
responsible ADJ - O
for ADP - O
CH4 NNP - B-ORG
production NOUN - O
) PUNCT - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
residues NOUN - O
were VERB - O
detected VERB - O
in ADP - O
tissues NOUN - O
of ADP - O
goats NOUN - O
fed VERB - O
6 CD - B-QUANTITY
mg NN - I-QUANTITY
lovastatin JJ - I-QUANTITY
/ SYM - O
kg VERB - O
BW VERB - O
at ADP - O
between IN - B-MONEY
0.01 CD - I-MONEY
to IN - I-MONEY
0.03 CD - I-MONEY
Î¼g NNP - I-MONEY
/ SYM - I-MONEY
g NN - I-MONEY
, , - I-MONEY
which WDT - I-MONEY
are VBP - I-MONEY
very RB - I-MONEY
low JJ - I-MONEY
. . - I-MONEY

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
natural ADJ - O
competitive ADJ - O
inhibitor NOUN - O
of ADP - O
3-hydroxy-3-methyl NNP - B-CARDINAL
glutaryl ADJ - O
coenzyme NOUN - O
- PUNCT - O
A NOUN - O
( PUNCT - O
HMG PROPN - O
- PUNCT - O
CoA PROPN - O
) PUNCT - O
reductase NOUN - O
and CCONJ - O
inhibits VERB - O
specifically ADV - O
rate NOUN - O
limiting VERB - O
step NOUN - O
in ADP - O
cholesterol NOUN - O
biosynthesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Synergistic ADJ - O
Anti PROPN - O
- PROPN - O
Cancer PROPN - O
Effect PROPN - O
of ADP - O
Troglitazone PROPN - O
and CCONJ - O
Lovastatin NNP - B-MEDICINE
in ADP - O
a DET - O
Human NNP - B-ORG
Anaplastic NNP - I-ORG
Thyroid NNP - I-ORG
Cancer NNP - I-ORG
Cell NNP - B-ORG
Line NNP - I-ORG
and CCONJ - O
in ADP - O
a DET - O
Mouse PROPN - O
Xenograft PROPN - O
Model PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
statin ADJ - O
drug NOUN - O
, PUNCT - O
which ADJ - O
lowers VERB - O
cholesterol NOUN - O
level NOUN - O
in ADP - O
blood NOUN - O
due ADP - O
to ADP - O
inhibition NOUN - O
of ADP - O
( PUNCT - O
S)-3-hydroxy-3-methylglutaryl NNP - B-PERSON
- PUNCT - O
CoA NOUN - O
reductase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Prevent PROPN - O
Radiation NOUN - O
- PUNCT - O
induced VERB - O
Rectal NNP - B-PERSON
Injury NNP - I-PERSON
With ADP - O
Lovastatin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Enhanced ADJ - O
Single PROPN - O
- PUNCT - O
Step PROPN - O
Bioproduction PROPN - O
of ADP - O
the DET - O
Simvastatin PROPN - O
Precursor PROPN - O
Monacolin NNP - B-PERSON
J NNP - I-PERSON
in ADP - O
an DET - O
Industrial PROPN - O
Strain PROPN - O
of ADP - O
Aspergillus PROPN - O
terreus NOUN - O
by ADP - O
Employing NNP - B-ORG
the DT - I-ORG
Evolved NNP - I-ORG
Lovastatin NNP - I-MEDICINE
Hydrolase NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
fails VERB - O
to PART - O
improve VERB - O
motor NOUN - O
performance NOUN - O
and CCONJ - O
survival NOUN - O
in ADP - O
methyl NOUN - O
- PUNCT - O
CpG NOUN - O
- PUNCT - O
binding VERB - O
protein2-null NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
synergizes VERB - O
with ADP - O
itraconazole NOUN - O
against ADP - O
planktonic ADJ - O
cells NOUN - O
and CCONJ - O
biofilms NOUN - O
of ADP - O
Candida NNP - B-GPE
albicans NOUN - O
through ADP - O
the DET - O
regulation NOUN - O
on ADP - O
ergosterol NOUN - O
biosynthesis NOUN - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
cell NOUN - O
viability NOUN - O
of ADP - O
statins NOUN - O
in ADP - O
Cisplatin NNP - B-ORG
- PUNCT - O
resistant ADJ - O
HCP4 PROPN - O
and CCONJ - O
PCDP5 NNP - B-PERSON
cells NOUN - O
compared VERB - O
with ADP - O
their ADJ - O
parent NOUN - O
Hela NNP - B-PERSON
and CCONJ - O
PC3 NNP - B-ORG
cells NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
and CCONJ - O
found VERB - O
that ADP - O
HCP4 PROPN - O
and CCONJ - O
PCDP5 NNP - B-PERSON
cells NOUN - O
were VERB - O
37-fold CD - B-CARDINAL
and CCONJ - O
18-fold CD - B-CARDINAL
more ADV - O
resistant ADJ - O
to ADP - O
Cisplatin NNP - B-ORG
but CCONJ - O
13-fold CD - B-CARDINAL
and CCONJ - O
7-fold NUM - O
more ADV - O
sensitive ADJ - O
to ADP - O
Lovastatin NNP - B-MEDICINE
by ADP - O
cell NOUN - O
proliferation NOUN - O
assay NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
induced VERB - O
the DET - O
apoptosis NOUN - O
of ADP - O
HCP4 PROPN - O
cells VERB - O
more ADV - O
rapidly ADV - O
and CCONJ - O
to ADP - O
greater ADJ - O
extent NOUN - O
than ADP - O
in ADP - O
Hela NNP - B-GPE
cells NOUN - O
as ADP - O
assessed VERB - O
by ADP - O
flow NOUN - O
cytometry NOUN - O
and CCONJ - O
western ADJ - O
blotting VERB - O
analyses NOUN - O
. PUNCT - O

To PART - O
elucidate VERB - O
the DET - O
mechanism NOUN - O
underlying VERB - O
the DET - O
reduced VERB - O
viability NOUN - O
to ADP - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
we PRON - O
performed VERB - O
cDNA PROPN - O
microarray NOUN - O
analysis NOUN - O
and CCONJ - O
identified VERB - O
65 CD - B-CARDINAL
and CCONJ - O
54 CD - B-CARDINAL
genes NOUN - O
that ADJ - O
were VERB - O
induced VERB - O
more ADJ - O
than ADP - O
2-fold NUM - O
by ADP - O
Lovastatin NNP - B-MEDICINE
in ADP - O
HCP4 PROPN - O
and CCONJ - O
PCDP5 NNP - B-PERSON
cells NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

These DET - O
mRNAs ADJ - O
were VERB - O
strongly ADV - O
induced VERB - O
by ADP - O
Lovastatin NNP - B-MEDICINE
with ADP - O
transcriptional ADJ - O
regulation NOUN - O
in ADP - O
HCP4 PROPN - O
cells NOUN - O
. PUNCT - O

Consistent ADJ - O
with ADP - O
transcription NOUN - O
, PUNCT - O
the DET - O
protein NOUN - O
expression NOUN - O
of ADP - O
RHOB NNP - B-ORG
also ADV - O
was VERB - O
induced VERB - O
by ADP - O
Lovastatin NNP - B-MEDICINE
. PUNCT - O

Combination NOUN - O
treatment NOUN - O
with ADP - O
Cisplatin NNP - B-ORG
and CCONJ - O
Lovastatin NNP - B-MEDICINE
resulted VERB - O
in ADP - O
an DET - O
agonistic ADJ - O
effect NOUN - O
in ADP - O
Hela NNP - B-GPE
and CCONJ - O
PC3 PROPN - O
cells NOUN - O
and CCONJ - O
an DET - O
antagonistic ADJ - O
effect NOUN - O
in ADP - O
HCP4 PROPN - O
and CCONJ - O
PCDP5 NNP - B-PERSON
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
Fatty PROPN - O
Acid PROPN - O
Modification NOUN - O
on ADP - O
Uptake PROPN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
- PUNCT - O
Loaded ADJ - O
Reconstituted PROPN - O
High PROPN - O
Density PROPN - O
Lipoprotein PROPN - O
by ADP - O
Foam NNP - B-PERSON
Cells NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
response NOUN - O
of ADP - O
MdIPT NNP - B-ORG
, PUNCT - O
MdCKX NNP - B-ORG
, PUNCT - O
and CCONJ - O
MdPIN1 NNP - B-ORG
genes NOUN - O
to ADP - O
various ADJ - O
treatments NOUN - O
( PUNCT - O
6-BA NUM - O
, PUNCT - O
decapitation NOUN - O
and CCONJ - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
an DET - O
inhibitor NOUN - O
of ADP - O
CKs NOUN - O
synthesis NOUN - O
) PUNCT - O
that ADJ - O
impact NOUN - O
branching VERB - O
were VERB - O
also ADV - O
investigated VERB - O
. PUNCT - O

Results NOUN - O
indicated VERB - O
that ADP - O
most ADJ - O
of ADP - O
the DET - O
MdIPT NNPS - B-ORG
and CCONJ - O
MdCKX NNP - B-ORG
, PUNCT - O
and CCONJ - O
MdPIN1 NNP - B-ORG
genes NOUN - O
were VERB - O
upregulated VERB - O
by ADP - O
6-BA NUM - O
and CCONJ - O
decapitation NOUN - O
treatment NOUN - O
, PUNCT - O
but CCONJ - O
inhibited VERB - O
by ADP - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
a DET - O
compound NOUN - O
that ADJ - O
effectively ADV - O
suppresses VERB - O
axillary ADJ - O
bud NOUN - O
outgrowth NOUN - O
induced VERB - O
by ADP - O
decapitation NOUN - O
. PUNCT - O

MdCKX8 PROPN - O
and CCONJ - O
MdCKX10 NNP - B-GPE
, PUNCT - O
however ADV - O
, PUNCT - O
exhibited VERB - O
little ADJ - O
response NOUN - O
to ADP - O
decapitation NOUN - O
, PUNCT - O
but CCONJ - O
were VERB - O
significantly ADV - O
up ADV - O
- PUNCT - O
regulated VERB - O
by ADP - O
6-BA CD - B-PERSON
and CCONJ - O
Lovastatin NNP - B-MEDICINE
, PUNCT - O
a DET - O
finding NOUN - O
that ADJ - O
warrants VERB - O
further ADJ - O
investigation NOUN - O
in ADP - O
order NOUN - O
to PART - O
understand VERB - O
their ADJ - O
function NOUN - O
in ADP - O
bud NOUN - O
- PUNCT - O
outgrowth NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects PROPN - O
of ADP - O
Resveratrol NNP - B-ORG
, PUNCT - O
Lovastatin NNP - B-MEDICINE
and CCONJ - O
the DET - O
mTOR PROPN - O
- PUNCT - O
Inhibitor PROPN - O
RAD-001 PROPN - O
on ADP - O
Insulin NNP - B-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Genomic JJ - I-ORG
Damage NN - I-ORG
In IN - I-ORG
Vitro NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
also ADV - O
blocked VERB - O
the DET - O
LPS- NNP - B-ORG
or CCONJ - O
repeated VERB - O
WAS PROPN - O
- PUNCT - O
induced VERB - O
increased VERB - O
gut NOUN - O
permeability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
analogues NOUN - O
and CCONJ - O
other ADJ - O
metabolites NOUN - O
from ADP - O
soil NOUN - O
- PUNCT - O
derived VERB - O
Aspergillus PROPN - O
terreus NOUN - O
YIM PROPN - O
PH30711 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
suppresses VERB - O
hyperexcitability NOUN - O
and CCONJ - O
seizure NOUN - O
in ADP - O
Angelman NNP - B-PERSON
syndrome NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
competitive ADJ - O
inhibitor NOUN - O
of ADP - O
the DET - O
enzyme ADJ - O
hydroxymethyl NOUN - O
glutaryl NOUN - O
coenzyme NOUN - O
A DET - O
reductase NOUN - O
( PUNCT - O
HMGR PROPN - O
) PUNCT - O
in ADP - O
cholesterol NOUN - O
biosynthetic ADJ - O
pathway NOUN - O
and CCONJ - O
hence ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
hyperlipidemia NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
gene NOUN - O
cluster NOUN - O
, PUNCT - O
when ADV - O
aligned VERB - O
on ADP - O
the DET - O
consensus NOUN - O
sequence NOUN - O
of ADP - O
both DET - O
genomes NOUN - O
, PUNCT - O
the DET - O
entire ADJ - O
lovastatin JJ - B-MEDICINE
gene NOUN - O
cluster NOUN - O
was VERB - O
detected VERB - O
in ADP - O
a DET - O
single ADJ - O
scaffold NOUN - O
( PUNCT - O
1.16 CD - B-CARDINAL
) PUNCT - O
of ADP - O
A.terreus PROPN - O
genome ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

and CCONJ - O
Diaporthe PROPN - O
ampelina ADV - O
( PUNCT - O
Endophytic NNP - B-ORG
Fungus NNP - I-ORG
) PUNCT - O
with ADP - O
Reference NNP - B-ORG
to ADP - O
Lovastatin NNP - B-MEDICINE
Production NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
contents NOUN - O
of ADP - O
MIAs NOUN - O
were VERB - O
qualified VERB - O
by ADP - O
High PROPN - O
Performance PROPN - O
Liquid PROPN - O
Chromatography PROPN - O
and CCONJ - O
the DET - O
transcript NOUN - O
levels NOUN - O
of ADP - O
the DET - O
relevant ADJ - O
genes NOUN - O
were VERB - O
measured VERB - O
by ADP - O
qRT NUM - O
- PUNCT - O
PCR.Lovastatin PROPN - O
improved VERB - O
the DET - O
accumulation NOUN - O
of ADP - O
MIAs NOUN - O
via ADP - O
increasing VERB - O
the DET - O
transcription NOUN - O
of ADP - O
their ADJ - O
biosynthetic ADJ - O
genes NOUN - O
encoding VERB - O
DXS1 PROPN - O
, PUNCT - O
tryptonphan ADP - O
decarboxylase NOUN - O
( PUNCT - O
TDC NNP - B-ORG
) PUNCT - O
, PUNCT - O
loganic ADJ - O
acid NOUN - O
methyltransferase NOUN - O
( PUNCT - O
LAMT PROPN - O
) PUNCT - O
, PUNCT - O
strictosidine NOUN - O
synthase NOUN - O
( PUNCT - O
STR NNP - B-ORG
) PUNCT - O
, PUNCT - O
desacetoxyvindoline-4-hydroxylase PROPN - O
( PUNCT - O
D4H PROPN - O
) PUNCT - O
and CCONJ - O
ORCA3 PROPN - O
( PUNCT - O
a DET - O
jasmonate ADJ - O
- PUNCT - O
responsive ADJ - O
transcriptional ADJ - O
regulator NOUN - O
) PUNCT - O
, PUNCT - O
whereas ADP - O
clomazone NOUN - O
reduced VERB - O
the DET - O
contents NOUN - O
of ADP - O
MIAs NOUN - O
and CCONJ - O
the DET - O
mRNA PROPN - O
levels NOUN - O
of ADP - O
the DET - O
corresponding ADJ - O
genes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
commercially ADV - O
important ADJ - O
secondary ADJ - O
metabolite NOUN - O
produced VERB - O
by ADP - O
Aspergillus PROPN - O
terreus NOUN - O
, PUNCT - O
either CCONJ - O
by ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
or CCONJ - O
by ADP - O
submerged VERB - O
fermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
, PUNCT - O
pravastatin NOUN - O
, PUNCT - O
fluvastatin NOUN - O
, PUNCT - O
and CCONJ - O
pitavastatin NOUN - O
were VERB - O
not ADV - O
associated VERB - O
with ADP - O
the DET - O
risk NOUN - O
of ADP - O
developing VERB - O
NOFs NOUN - O
compared VERB - O
with ADP - O
simvastatin ADJ - O
users NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
Alleviates VBZ - I-ORG
Endothelial NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
Mesenchymal PROPN - O
Transition PROPN - O
in ADP - O
Glomeruli NNP - B-GPE
via ADP - O
Suppression PROPN - O
of ADP - O
Oxidative PROPN - O
Stress PROPN - O
and CCONJ - O
TGF PROPN - O
- PUNCT - O
Î²1 PROPN - O
Signaling PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Neuroprotective ADJ - O
effect NOUN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
on ADP - O
motor NOUN - O
deficit NOUN - O
induced VERB - O
by ADP - O
sciatic ADJ - O
nerve NOUN - O
crush NOUN - O
in ADP - O
the DET - O
rat NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

25-Hydroxycholesterol CD - B-CARDINAL
and CCONJ - O
inflammation NOUN - O
in ADP - O
Lovastatin NNP - B-MEDICINE
- PUNCT - O
deregulated VERB - O
mevalonate NOUN - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
impaired VERB - O
the DET - O
binding NOUN - O
of ADP - O
the DET - O
transcription NOUN - O
factors VERB - O
c FW - B-PERSON
- : - I-PERSON
Jun NN - I-PERSON
and CCONJ - O
Sp1 PROPN - O
to ADP - O
the DET - O
MACC1 NNP - B-PRODUCT
promoter NOUN - O
, PUNCT - O
thereby ADV - O
inhibiting VERB - O
MACC1 NNP - B-PRODUCT
transcription NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Inhibition NOUN - O
of ADP - O
NF PROPN - O
- PUNCT - O
ÎºB PROPN - O
Pathway PROPN - O
and CCONJ - O
Modulation PROPN - O
of ADP - O
MAPK PROPN - O
Signaling PROPN - O
Pathways PROPN - O
in ADP - O
Glioblastoma NNP - B-GPE
and CCONJ - O
Implications PROPN - O
for ADP - O
Lovastatin NNP - B-MEDICINE
and CCONJ - O
Tumor NNP - B-ORG
Necrosis NNP - I-ORG

-DOCSTART- -X- - O

Lovastatin JJ - B-MEDICINE
time NOUN - O
/ SYM - O
dose NOUN - O
- PUNCT - O
dependently ADV - O
increased VERB - O
miR-29b NOUN - O
expression NOUN - O
and CCONJ - O
decreased VERB - O
proteasome ADJ - O
activity NOUN - O
in ADP - O
cultured VERB - O
human ADJ - O
umbilical ADJ - O
vein NOUN - O
endothelial ADJ - O
cells NOUN - O
( PUNCT - O
HUVECs PROPN - O
) PUNCT - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
inhibited VERB - O
oxidative ADJ - O
stress NOUN - O
induced VERB - O
by ADP - O
multiple ADJ - O
oxidants NOUN - O
including VERB - O
ox PROPN - O
- PUNCT - O
LDL PROPN - O
, PUNCT - O
H2O2 NN - B-GPE
, PUNCT - O
TNFÎ± NOUN - O
, PUNCT - O
homocysteine NOUN - O
thiolactone NOUN - O
( PUNCT - O
HTL PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
high ADJ - O
glucose NOUN - O
( PUNCT - O
HG NNP - B-ORG
) PUNCT - O
, PUNCT - O
which ADJ - O
were VERB - O
reversed VERB - O
by ADP - O
inhibition NOUN - O
of ADP - O
miR-29b NOUN - O
in ADP - O
HUVECs NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
of IN - I-ORG
RYP NNP - I-ORG
is VERB - O
a DET - O
hypolipidemic ADJ - O
commercial ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin JJ - B-MEDICINE
- PUNCT - O
specific ADJ - O
production NOUN - O
( PUNCT - O
SP NNP - B-ORG
) PUNCT - O
was VERB - O
used VERB - O
as ADP - O
an DET - O
indicator NOUN - O
of ADP - O
the DET - O
physiological ADJ - O
status NOUN - O
, PUNCT - O
and CCONJ - O
different ADJ - O
model NOUN - O
culture NOUN - O
systems NOUN - O
were VERB - O
used VERB - O
to PART - O
evaluate VERB - O
the DET - O
impact NOUN - O
of ADP - O
potential ADJ - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
( PUNCT - O
SSF NNP - B-ORG
) PUNCT - O
environmental ADJ - O
stimuli NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Tocotrienol PROPN - O
and CCONJ - O
Lovastatin NNP - B-MEDICINE
Co NNP - I-ORG
- HYPH - I-ORG
Supplementation NNP - I-ORG
on IN - I-ORG
Bone NNP - I-ORG
Dynamic NNP - I-ORG
Histomorphometry NNP - I-ORG
and CCONJ - O
Bone PROPN - O
Morphogenetic PROPN - O
Protein-2 PROPN - O
Expression PROPN - O
in ADP - O
Rats PROPN - O
with ADP - O
Estrogen PROPN - O
Deficiency PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
administration NOUN - O
to ADP - O
rats NOUN - O
decreased VERB - O
hepatic ADJ - O
cholesterol NOUN - O
content NOUN - O
, PUNCT - O
disrupted VERB - O
lipid NOUN - O
rafts NOUN - O
and CCONJ - O
decreased VERB - O
insulin NOUN - O
- PUNCT - O
induced VERB - O
Ca2 NOUN - O
+ SYM - O
signaling VERB - O
in ADP - O
hepatocytes NOUN - O
, PUNCT - O
and CCONJ - O
delayed VERB - O
liver NOUN - O
regeneration NOUN - O
after ADP - O
PH PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Correction NOUN - O
: PUNCT - O
Combined VERB - O
Treatment PROPN - O
with ADP - O
Troglitazone PROPN - O
and CCONJ - O
Lovastatin NNP - B-MEDICINE

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
administration NOUN - O
at ADP - O
12 CD - B-DATE
weeks NNS - I-DATE
prevented VERB - O
further ADJ - O
RGC PROPN - O
loss NOUN - O
and CCONJ - O
RNFL NNP - B-ORG
thinning VERB - O
both CCONJ - O
immediately ADV - O
and CCONJ - O
8 CD - B-DATE
weeks NNS - I-DATE
after ADP - O
treatment NOUN - O
completion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
Reduces NNP - I-ORG
Stemness NNP - I-ORG
via ADP - O
Epigenetic PROPN - O
Reprograming PROPN - O
of ADP - O
BMP2 NNP - B-GPE
and CCONJ - O
GATA2 NNP - B-PERSON
in ADP - O
Human PROPN - O
Endometrium PROPN - O
and CCONJ - O
Endometriosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Stabilization NOUN - O
and CCONJ - O
Amorphization PROPN - O
of ADP - O
Lovastatin NNP - B-MEDICINE
Using VERB - O
Different ADJ - O
Types PROPN - O
of ADP - O
Silica PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
is VERB - O
a DET - O
prodrug NOUN - O
that ADJ - O
is VERB - O
hydrolysed VERB - O
in ADP - O
vivo NOUN - O
to ADP - O
Î² DET - O
- PUNCT - O
hydroxy NOUN - O
acid NOUN - O
lovastatin NN - B-MEDICINE
, PUNCT - O
which ADJ - O
inhibits VERB - O
3-hydroxy-3-methylglutaryl CD - B-QUANTITY
- : - I-QUANTITY
coenzyme NN - I-QUANTITY
A NOUN - O
( PUNCT - O
HMG NNP - B-ORG
- HYPH - I-ORG
Co NN - I-ORG
- HYPH - I-ORG
A NN - I-ORG
) PUNCT - O
reductase NOUN - O
( PUNCT - O
HMGR PROPN - O
) PUNCT - O
, PUNCT - O
thereby ADV - O
lowering VERB - O
cholesterol NOUN - O
in ADP - O
humans NOUN - O
. PUNCT - O

Lovastatin NNP - B-MEDICINE
is VERB - O
the DET - O
first JJ - B-ORDINAL
licensed ADJ - O
drug NOUN - O
to PART - O
exclusively ADV - O
affect VERB - O
the DET - O
growth NOUN - O
of ADP - O
methanogens NOUN - O
whilst ADP - O
protecting VERB - O
the DET - O
bacterial ADJ - O
microbiota NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
as ADP - O
a DET - O
member NOUN - O
of ADP - O
3-hydroxy-3-methylglutaryl CD - B-QUANTITY
- , - I-QUANTITY
coenzyme NN - I-QUANTITY
A NOUN - O
( PUNCT - O
HMG NNP - B-ORG
- HYPH - I-ORG
CoA NNP - I-ORG
) PUNCT - O

-DOCSTART- -X- - O

Lovastatin NNP - B-MEDICINE
prevents VERB - O
bleomycin NOUN - O
- PUNCT - O
induced VERB - O
DNA NOUN - O
damage NOUN - O
to ADP - O
HepG2 PROPN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Berberine NNP - B-PERSON
( PUNCT - O
PubChem PROPN - O
CID PROPN - O
: PUNCT - O
2353 NUM - O
) PUNCT - O
; PUNCT - O
Lovastatin NNP - B-MEDICINE
( PUNCT - O
PubChem PROPN - O
CID PROPN - O
: PUNCT - O
53232 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Lovastatin JJ - B-MEDICINE
productivity NOUN - O
was VERB - O
increased VERB - O
32-fold CD - B-CARDINAL
through ADP - O
strain NOUN - O
improvement NOUN - O
methods NOUN - O
, PUNCT - O
including VERB - O
mutations NOUN - O
and CCONJ - O
three CD - B-CARDINAL
successive ADJ - O
rounds NOUN - O
of ADP - O
genome DET - O
shuffling NOUN - O
followed VERB - O
by ADP - O
optimizing VERB - O
SSF NN - B-ORG
factors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Genome DET - O
Shuffling PROPN - O
of ADP - O
Mangrove PROPN - O
Endophytic PROPN - O
Aspergillus PROPN - O
luchuensis NOUN - O
MERV10 NOUN - O
for ADP - O
Improving VERB - O
the DET - O
Cholesterol PROPN - O
- PUNCT - O
Lowering VERB - O
Agent PROPN - O
Lovastatin NNP - B-MEDICINE
under ADP - O
Solid NNP - B-GPE
State NNP - I-GPE
Fermentation NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
investigation NOUN - O
, PUNCT - O
focused VERB - O
on ADP - O
screening NOUN - O
of ADP - O
various ADJ - O
fungal ADJ - O
species NOUN - O
for ADP - O
Lovastatin NNP - B-MEDICINE
production NOUN - O
using VERB - O
different ADJ - O
agro NOUN - O
- PUNCT - O
based VERB - O
wastes NOUN - O
, PUNCT - O
also ADV - O
, PUNCT - O
for ADP - O
maximizing VERB - O
lovastatin JJ - B-MEDICINE
productivity NOUN - O
by ADP - O
isolated VERB - O
Aspergillus NNP - B-ORG
fumigatus NOUN - O
using VERB - O
response NOUN - O
surface NOUN - O
methodology NOUN - O
( PUNCT - O
RSM NNP - B-ORG
) PUNCT - O
. PUNCT - O

This DET - O
Lovastatin NNP - B-MEDICINE
has VERB - O
the DET - O
possibility NOUN - O
to PART - O
use VERB - O
in ADP - O
different ADJ - O
therapeutic ADJ - O
applications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
of ADP - O
Intrathecal PROPN - O
Nalbuphine PROPN - O
Hydrochloride PROPN - O
and CCONJ - O
Clonidine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
as ADP - O
an DET - O
Adjuvant NNP - B-ORG
to IN - I-ORG
Hyperbaric NNP - I-ORG
Bupivacaine NNP - I-ORG
in ADP - O
Abdominal PROPN - O
Hysterectomy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Validated NNP - B-PERSON
Colorimetric NNP - I-PERSON
Assay NNP - I-PERSON
of ADP - O
Clonidine NNP - B-ORG
Hydrochloride NNP - I-ORG
from ADP - O
Pharmaceutical NNP - B-ORG
Preparations NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Aqueous PROPN - O
Extract PROPN - O
of ADP - O
Azadirachta PROPN - O
indica VERB - O
Leaves PROPN - O
on ADP - O
Pharmacokinetics PROPN - O
and CCONJ - O
Pharmacodynamics PROPN - O
of ADP - O
Glipizide NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
is VERB - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
oral ADJ - O
hypoglycemic ADJ - O
medicine NOUN - O
for ADP - O
the DET - O
cure NOUN - O
of ADP - O
type NOUN - O
II CD - B-ORG
diabetes NOUN - O
because ADP - O
of ADP - O
its ADJ - O
capability NOUN - O
to PART - O
selectively ADV - O
stimulate VERB - O
insulin NOUN - O
secretion NOUN - O
from ADP - O
Î² NOUN - O
- PUNCT - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
sensitizes VERB - O
lung NOUN - O
cancer NOUN - O
cells NOUN - O
to ADP - O
TRAIL PROPN - O
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
via ADP - O
Akt NNP - B-ORG
/ SYM - I-ORG
mTOR NNP - I-ORG
/ SYM - I-ORG
autophagy NN - I-ORG
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
served VERB - O
as ADP - O
the DET - O
reference NOUN - O
exposure NOUN - O
, PUNCT - O
as ADP - O
its ADJ - O
effects NOUN - O
are VERB - O
believed VERB - O
to PART - O
be VERB - O
highly ADV - O
pancreas NOUN - O
specific ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
( PUNCT - O
GPZ PROPN - O
) PUNCT - O
, PUNCT - O
a DET - O
Biopharmaceutical NNP - B-ORG
Classification NNP - I-ORG
System NNP - I-ORG
class NOUN - O
II NNP - B-ORG
model NOUN - O
drug NOUN - O
, PUNCT - O
was VERB - O
selected VERB - O
for ADP - O
solubility NOUN - O
and CCONJ - O
dissolution NOUN - O
rate NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Study PROPN - O
to PART - O
Understand VERB - O
the DET - O
Genetics PROPN - O
of ADP - O
the DET - O
Acute PROPN - O
Response PROPN - O
to ADP - O
Metformin NNP - B-PERSON
and CCONJ - O
Glipizide NNP - B-MEDICINE
in ADP - O
Humans NNP - B-GPE
( PUNCT - O
SUGAR PROPN - O
- PUNCT - O
MGH PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Sentinel PROPN - O
Modular PROPN - O
Program PROPN - O
for ADP - O
Propensity NNP - B-ORG
Score NNP - I-ORG
- HYPH - I-ORG
Matched NNP - I-ORG
Cohort PROPN - O
Analyses PROPN - O
: PUNCT - O
Application NOUN - O
to ADP - O
Glyburide PROPN - O
, PUNCT - O
Glipizide NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Serious NNP - B-PERSON
Hypoglycemia NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
Single PROPN - O
and CCONJ - O
Multi PROPN - O
Dose PROPN - O
Treatment PROPN - O
of ADP - O
Glipizide NNP - B-MEDICINE
on ADP - O
Pharmacokinetics PROPN - O
and CCONJ - O
Pharmacodynamics PROPN - O
of ADP - O
Irbesartan PROPN - O
in ADP - O
Normal NNP - B-GPE
and CCONJ - O
Hypertensive PROPN - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NN - B-MEDICINE
tablets NOUN - O
containing VERB - O
different ADJ - O
polymers NOUN - O
from ADP - O
3 CD - B-CARDINAL
categories NOUN - O
( PUNCT - O
immediate ADJ - O
, PUNCT - O
moderate ADJ - O
, PUNCT - O
and CCONJ - O
extended ADJ - O
release NOUN - O
) PUNCT - O
were VERB - O
prepared VERB - O
and CCONJ - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Stable ADJ - O
Co NOUN - O
- NOUN - O
crystals NOUN - O
of ADP - O
Glipizide NNP - B-MEDICINE
with ADP - O
Enhanced PROPN - O
Dissolution PROPN - O
Profiles PROPN - O
: PUNCT - O
Preparation NOUN - O
and CCONJ - O
Characterization PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
blocks VERB - O
renal ADJ - O
interstitial ADJ - O
fibrosis NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
suppresses VERB - O
prostate NOUN - O
cancer NOUN - O
progression NOUN - O
in ADP - O
the DET - O
TRAMP NOUN - O
model NOUN - O
by ADP - O
inhibiting VERB - O
angiogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
the DT - B-ORG
Mucoadhesive NNP - I-ORG
Potential NNP - I-ORG
of IN - I-ORG
Carbopol NNP - I-ORG
Polymer NNP - I-ORG
in ADP - O
the DT - B-ORG
Preparation NNP - I-ORG
of IN - I-ORG
Microbeads NNP - I-ORG
Containing VBG - I-ORG
the DT - I-ORG
Antidiabetic NNP - I-ORG
Drug NNP - I-ORG
Glipizide NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
, PUNCT - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
sulfonylurea NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
widely ADV - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
that ADP - O
Glipizide NNP - B-MEDICINE
suppressed VERB - O
both DET - O
angiogenesis NOUN - O
in ADP - O
yolk NOUN - O
- PUNCT - O
sac NOUN - O
membrane NOUN - O
( PUNCT - O
YSM PROPN - O
) PUNCT - O
and CCONJ - O
blood NOUN - O
island NOUN - O
formation NOUN - O
during ADP - O
developmental ADJ - O
vasculogenesis NOUN - O
. PUNCT - O

Glipizide NNP - B-MEDICINE
did VERB - O
not ADV - O
affect VERB - O
either CCONJ - O
the DET - O
process NOUN - O
of ADP - O
epithelial ADJ - O
to ADP - O
mesenchymal ADJ - O
transition NOUN - O
( PUNCT - O
EMT NNP - B-ORG
) PUNCT - O
or CCONJ - O
mesoderm NOUN - O
cell NOUN - O
migration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
suppresses VERB - O
embryonic ADJ - O
vasculogenesis NOUN - O
and CCONJ - O
angiogenesis NOUN - O
through ADP - O
targeting VERB - O
natriuretic ADJ - O
peptide NOUN - O
receptor NOUN - O
A. NOUN - O

-DOCSTART- -X- - O

Cost NOUN - O
of ADP - O
Achieving VERB - O
Combined PROPN - O
Improvements PROPN - O
in ADP - O
HbA1c PROPN - O
and CCONJ - O
Weight NNP - B-ORG
without ADP - O
Hypoglycaemia NNP - B-ORG
over ADP - O
4 NUM - O
Years NOUN - O
in ADP - O
a DET - O
Post PROPN - O
- PROPN - O
Hoc PROPN - O
Analysis PROPN - O
of ADP - O
Dapagliflozin PROPN - O
+ CCONJ - O
MET PROPN - O
Vs PROPN - O
Glipizide NNP - B-MEDICINE
+ CCONJ - O
MET NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Study PROPN - O
to PART - O
Understand VERB - O
the DET - O
Genetics PROPN - O
of ADP - O
the DET - O
Acute PROPN - O
Response PROPN - O
to ADP - O
Metformin PROPN - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
in ADP - O
Humans NNP - B-GPE
( PUNCT - O
SUGAR PROPN - O
- PUNCT - O
MGH PROPN - O
, PUNCT - O
NCT01762046 NNP - B-DATE
) PUNCT - O
is VERB - O
a DET - O
novel ADJ - O
resource NOUN - O
of ADP - O
genetic ADJ - O
and CCONJ - O
biochemical ADJ - O
data NOUN - O
following VERB - O
glipizide NN - B-MEDICINE
and CCONJ - O
metformin NOUN - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Post NNP - B-ORG
Hoc NNP - I-ORG
Analysis NNP - I-ORG
of IN - I-ORG
HbA1c NNP - I-ORG
, PUNCT - O
Hypoglycemia NNP - B-ORG
, PUNCT - O
and CCONJ - O
Weight NNP - B-ORG
Change VB - I-ORG
Outcomes NNP - I-ORG
with ADP - O
Alogliptin PROPN - O
vs ADP - O
Glipizide NNP - B-MEDICINE
in ADP - O
Older ADJ - O
Patients NOUN - O
with ADP - O
Type PROPN - O
2 PROPN - O
Diabetes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
tolbutamide NOUN - O
or CCONJ - O
glyburide ADV - O
, PUNCT - O
pretreated VERB - O

-DOCSTART- -X- - O

PHARMACEUTICAL NOUN - O
COMPOSITIONS NOUN - O
OF ADP - O
URSODIOL NN - B-MEDICINE

-DOCSTART- -X- - O

PHARMACEUTICAL NOUN - O
COMPOSITIONS NOUN - O
OF ADP - O
URSODIOL NN - B-MEDICINE

-DOCSTART- -X- - O

Histopathological ADJ - O
examination NOUN - O
showed VERB - O
numerous ADJ - O
branched ADJ - O
hyphae NOUN - O
, PUNCT - O
and CCONJ - O
tissue NOUN - O
culture NOUN - O
yielded VERB - O
a DET - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
- PUNCT - O
related VERB - O
fungus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Multiple JJ - B-PERSON
Skin NN - I-PERSON
Abscesses NNS - I-PERSON
Caused VBN - I-PERSON
by ADP - O
Rhizopus NNP - B-MEDICINE
sp PART - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
aPDT PROPN - O
by ADP - O
using VERB - O
methylene ADJ - O
blue ADJ - O
( PUNCT - O
MB NOUN - O
) PUNCT - O
combined VERB - O
with ADP - O
a DET - O
light ADJ - O
emitting VERB - O
diode NOUN - O
( PUNCT - O
LED PROPN - O
) PUNCT - O
on ADP - O
the DET - O
viability NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
antifungal ADJ - O
susceptibility NOUN - O
after ADP - O
aPDT NOUN - O
treatment NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Photodynamic NNP - B-ORG
Inactivation NNP - I-ORG
on ADP - O
the DET - O
Growth PROPN - O
and CCONJ - O
Antifungal PROPN - O
Susceptibility PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
investigated VERB - O
effects NOUN - O
of ADP - O
the DET - O
simultaneous ADJ - O
application NOUN - O
of ADP - O
thymol NOUN - O
and CCONJ - O
salicylic ADJ - O
acid NOUN - O
( PUNCT - O
SIMTSA PROPN - O
) PUNCT - O
on ADP - O
the DET - O
target NOUN - O
sites NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
defenceenzymes NOUN - O
of ADP - O
postharvest NOUN - O
tomato NOUN - O
, PUNCT - O
when ADV - O
applied VERB - O
as ADP - O
edible ADJ - O
coating NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
influence NOUN - O
of ADP - O
polyols NOUN - O
on ADP - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
( PUNCT - O
RCL NNP - B-ORG
) PUNCT - O
was VERB - O
investigated VERB - O
under ADP - O
high ADJ - O
pressure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Protection NOUN - O
effect NOUN - O
of ADP - O
polyols NOUN - O
on ADP - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
counteracting VERB - O
the DET - O
deactivation NOUN - O
from ADP - O
high ADJ - O
pressure NOUN - O
and CCONJ - O
high ADJ - O
temperature NOUN - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhanced PROPN - O
Performance PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Lipase PROPN - O
by ADP - O
Reasonable ADJ - O
Immobilization NOUN - O
on ADP - O
Magnetic PROPN - O
Nanoparticles PROPN - O
and CCONJ - O
Its ADJ - O
Application PROPN - O
in ADP - O
Synthesis PROPN - O
1,3-Diacyglycerol NUM - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
extracellular ADJ - O
polysaccharide NOUN - O
( PUNCT - O
EPS1 PROPN - O
- PUNCT - O
1 NUM - O
) PUNCT - O
of ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
was VERB - O
found VERB - O
to PART - O
enhance VERB - O
immunity NOUN - O
and CCONJ - O
reduce VERB - O
colon NOUN - O
cancer NOUN - O
cell NOUN - O
proliferation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
inhibitory ADJ - O
effect NOUN - O
of ADP - O
polysaccharide NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
on ADP - O
colitis NOUN - O
- PUNCT - O
associated VERB - O
colorectal ADJ - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhanced ADJ - O
application NOUN - O
of ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
( PUNCT - O
SSF NNP - B-ORG
) PUNCT - O
in ADP - O
industrial ADJ - O
production NOUN - O
and CCONJ - O
the DET - O
influence NOUN - O
of ADP - O
SSF NNP - B-ORG
of ADP - O
Rhizopus NNP - B-MEDICINE
K1 PROPN - O
on ADP - O
glucoamylase NOUN - O
productivity NOUN - O
were VERB - O
analyzed VERB - O
using VERB - O
the DET - O
flat ADJ - O
band NOUN - O
method NOUN - O
. PUNCT - O

A DET - O
growth NOUN - O
model NOUN - O
was VERB - O
implemented VERB - O
through ADP - O
SSF NNP - B-ORG
of ADP - O
Rhizopus NNP - B-MEDICINE
K1 PROPN - O
in ADP - O
this DET - O
experiment NOUN - O
, PUNCT - O
and CCONJ - O
spectrophotometric ADJ - O
method NOUN - O
was VERB - O
used VERB - O
to PART - O
determine VERB - O
glucoamylase NOUN - O
activity NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
has VERB - O
good ADJ - O
utilization NOUN - O
value NOUN - O
for ADP - O
glucoamylase NOUN - O
production NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
in ADP - O
SSF NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Application PROPN - O
and CCONJ - O
Analysis PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Mycelia NNP - B-PERSON
Extending NNP - I-PERSON
Characteristic NNP - I-PERSON
in ADP - O
Solid NNP - B-GPE
- PUNCT - O
state NOUN - O
Fermentation NN - B-ORG
for IN - I-ORG
Producing VBG - I-ORG
Glucoamylase NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DET - O
antifungal ADJ - O
activity NOUN - O
of ADP - O
individual ADJ - O
and CCONJ - O
combined VERB - O
monoterpenes NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
and CCONJ - O
Absidia NNP - B-ORG
coerulea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
microsporus NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Control NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
in ADP - O
strawberries NOUN - O
by ADP - O
the DET - O
combination NOUN - O
of ADP - O
essential ADJ - O
oil NOUN - O
with ADP - O
carboxymethylcellulose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CRISPR PROPN - O
- PUNCT - O
Cas9 PROPN - O
induces VERB - O
point NOUN - O
mutation NOUN - O
in ADP - O
the DET - O
mucormycosis NOUN - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Morphological ADJ - O
findings NOUN - O
are VERB - O
linked VERB - O
to ADP - O
Rhizopus NN - B-MEDICINE
infection NOUN - O
( PUNCT - O
Mucormycosis)NECROTIZING NNP - B-ORG
MYOCTIC NNP - I-ORG
ACUTE NNP - I-ORG
OSTEOMYELITIS.Surgical NNP - I-ORG
treatment NOUN - O
: PUNCT - O
Radical ADJ - O
debridement ADJ - O
with ADP - O
removal NOUN - O
of ADP - O
surgical ADJ - O
material NOUN - O
. PUNCT - O

Mucormycosis NN - B-ORG
is VERB - O
a DET - O
serious ADJ - O
infection NOUN - O
caused VERB - O
by ADP - O
fungi NOUN - O
of ADP - O
the DET - O
order NOUN - O
Mucorales NNP - B-PERSON
, PUNCT - O
of ADP - O
which ADJ - O
the DET - O
most ADV - O
important ADJ - O
family NOUN - O
is VERB - O
that DET - O
of ADP - O
the DET - O
Mucoraceae NNP - B-ORG
, PUNCT - O
which ADJ - O
includes VERB - O
the DET - O
genera NOUN - O
Rhizopus NNP - B-MEDICINE
, PUNCT - O
Mucor NNP - B-ORG
and CCONJ - O
Absidia NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
team NOUN - O
is VERB - O
using VERB - O
the DET - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
NRRL NNP - B-ORG
395 NUM - O
bacteria NOUN - O
for ADP - O
the DET - O
fermentation NOUN - O
of ADP - O
the DET - O
glycerol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Modeling VERB - O
tool NOUN - O
using VERB - O
neural ADJ - O
networks NOUN - O
for ADP - O
L(+)-lactic JJ - B-ORG
acid NOUN - O
production NOUN - O
by ADP - O
pellet NOUN - O
- PUNCT - O
form NOUN - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
NRRL NNP - B-ORG
395 NUM - O
on ADP - O
biodiesel NOUN - O
crude ADJ - O
glycerol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
present VERB - O
a DET - O
case NOUN - O
of ADP - O
a DET - O
68-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
patient NOUN - O
with ADP - O
cutaneous ADJ - O
mucormycosis NOUN - O
due ADJ - O
to ADP - O
Rhizopus NNP - B-MEDICINE
pusillus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
case NOUN - O
of ADP - O
eczema NOUN - O
- PUNCT - O
like ADJ - O
cutaneous ADJ - O
mucormycosis NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
describe VERB - O
the DET - O
first JJ - B-ORDINAL
case NOUN - O
of ADP - O
a DET - O
patient NOUN - O
with ADP - O
occupational ADJ - O
exposure NOUN - O
to ADP - O
Rhizopus NNP - B-MEDICINE
that ADJ - O
received VERB - O
post ADJ - O
- ADJ - O
exposure ADJ - O
prophylaxis NOUN - O
with ADP - O
oral ADJ - O
isavuconazole NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PCR NOUN - O
analysis NOUN - O
from ADP - O
these DET - O
inflammatory ADJ - O
foci NOUN - O
yielded VERB - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
( PUNCT - O
syn NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antifungal ADJ - O
effect NOUN - O
of ADP - O
phenolic NOUN - O
extract NOUN - O
of ADP - O
fermented ADJ - O
rice NOUN - O
bran NOUN - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
and CCONJ - O
its ADJ - O
potential ADJ - O
use NOUN - O
in ADP - O
loaf ADJ - O
bread NOUN - O
shelf NOUN - O
life NOUN - O
extension NOUN - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
spp NOUN - O
are VERB - O
the DET - O
most ADV - O
common ADJ - O
etiological ADJ - O
agents NOUN - O
of ADP - O
mucormycosis NOUN - O
, PUNCT - O
causing VERB - O
over ADP - O
90 CD - B-PERCENT
% NN - I-PERCENT
mortality NOUN - O
in ADP - O
disseminated VERB - O
infection NOUN - O
. PUNCT - O

Rhizopus NNP - B-MEDICINE
spp NOUN - O
has VERB - O
not ADV - O
been VERB - O
extensively ADV - O
explored VERB - O
. PUNCT - O

Here ADV - O
we PRON - O
show VERB - O
that ADP - O
co NOUN - O
- ADJ - O
culturing ADJ - O
  SPACE - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
and CCONJ - O
  SPACE - O
Pseudomonas NNP - B-GPE
aeruginosa NOUN - O
results VERB - O
in ADP - O
the DET - O
inhibition NOUN - O
of ADP - O
spore ADJ - O
germination NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
  SPACE - O
germination NOUN - O
through ADP - O
sequestration NOUN - O
of ADP - O
free ADJ - O
environmental ADJ - O
iron NOUN - O

-DOCSTART- -X- - O

The DET - O
review NOUN - O
highlights VERB - O
the DET - O
current ADJ - O
achievements NOUN - O
in ADP - O
( PUNCT - O
i NOUN - O
) PUNCT - O
diagnostics NOUN - O
and CCONJ - O
management NOUN - O
of ADP - O
mucormycosis NOUN - O
, PUNCT - O
( PUNCT - O
ii PUNCT - O
) PUNCT - O
the DET - O
study NOUN - O
of ADP - O
the DET - O
interaction NOUN - O
of ADP - O
Mucorales NNP - B-GPE
with ADP - O
cells NOUN - O
of ADP - O
the DET - O
innate ADJ - O
immune ADJ - O
system NOUN - O
, PUNCT - O
( PUNCT - O
iii PUNCT - O
) PUNCT - O
the DET - O
assessment NOUN - O
of ADP - O
the DET - O
virulence NOUN - O
of ADP - O
Mucorales NNP - B-PERSON
in ADP - O
vertebrate NOUN - O
and CCONJ - O
invertebrate ADJ - O
infection NOUN - O
models NOUN - O
, PUNCT - O
and CCONJ - O
( PUNCT - O
iv X - O
) PUNCT - O
the DET - O
determination NOUN - O
of ADP - O
virulence NOUN - O
factors NOUN - O
that ADJ - O
are VERB - O
key ADJ - O
players NOUN - O
in ADP - O
the DET - O
infection NOUN - O
process NOUN - O
, PUNCT - O
for ADP - O
example NOUN - O
, PUNCT - O
high ADJ - O
- PUNCT - O
affinity NOUN - O
iron NOUN - O
permease NOUN - O
( PUNCT - O
FTR1 NNP - B-ORG
) PUNCT - O
, PUNCT - O
spore ADJ - O
coat NOUN - O
protein NOUN - O
( PUNCT - O
CotH PROPN - O
) PUNCT - O
, PUNCT - O
alkaline NOUN - O
Rhizopus NNP - B-MEDICINE
protease NOUN - O
enzyme ADJ - O
( PUNCT - O
ARP PROPN - O
) PUNCT - O
, PUNCT - O
ADP PROPN - O
- PUNCT - O
ribosylation NOUN - O
factor NOUN - O
( PUNCT - O
ARF NNP - B-ORG
) PUNCT - O
, PUNCT - O
dihydrolipoyl NOUN - O
dehydrogenase NOUN - O
, PUNCT - O
calcineurin PROPN - O
( PUNCT - O
CaN VERB - O
) PUNCT - O
, PUNCT - O
serine NOUN - O
and CCONJ - O
aspartate NOUN - O
proteases NOUN - O
( PUNCT - O
SAPs PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Due ADP - O
to ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
after ADP - O
Allogeneic NNP - B-ORG
Stem NNP - I-ORG
Cell NNP - I-ORG
Transplantation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
species NOUN - O
are VERB - O
especially ADV - O
important ADJ - O
as ADP - O
plant NOUN - O
and CCONJ - O
animal NOUN - O
pathogens NOUN - O
and CCONJ - O
bioindustrial NOUN - O
fermenters NOUN - O
for ADP - O
food NOUN - O
and CCONJ - O
metabolite NOUN - O
production NOUN - O
. PUNCT - O

A DET - O
dataset NOUN - O
of ADP - O
192 CD - B-CARDINAL
orthologous ADJ - O
genes NOUN - O
was VERB - O
used VERB - O
to PART - O
construct VERB - O
a DET - O
phylogenetic ADJ - O
tree NOUN - O
of ADP - O
21 CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
strains NOUN - O
, PUNCT - O
classified VERB - O
into ADP - O
four CD - B-CARDINAL
species NOUN - O
isolated VERB - O
from ADP - O
habitats NOUN - O
of ADP - O
industrial ADJ - O
, PUNCT - O
medical ADJ - O
and CCONJ - O
environmental ADJ - O
importance NOUN - O
. PUNCT - O

The DET - O
phylogeny NOUN - O
indicates VERB - O
that ADP - O
the DET - O
genus ADJ - O
Rhizopus NNP - B-MEDICINE
consists VERB - O
of ADP - O
three CD - B-CARDINAL
major ADJ - O
clades NOUN - O
, PUNCT - O
with ADP - O
R. NNP - B-NORP
microsporus NOUN - O
as ADP - O
the DET - O
basal ADJ - O
species NOUN - O
and CCONJ - O
the DET - O
sister NOUN - O
lineage NOUN - O
to ADP - O
R. NNP - B-NORP
stolonifer NOUN - O
and CCONJ - O
two CD - B-CARDINAL
closely ADV - O
related VERB - O
species NOUN - O
R. NNP - B-NORP
arrhizus NOUN - O
and CCONJ - O
R. NNP - B-NORP
delemar VERB - O
A DET - O
comparative ADJ - O
analysis NOUN - O
of ADP - O
the DET - O
mating NOUN - O
type NOUN - O
locus NOUN - O
across ADP - O
Rhizopus NNP - B-MEDICINE
reveals VERB - O
that ADP - O
its ADJ - O
structure NOUN - O
is VERB - O
flexible ADJ - O
even ADV - O
between ADP - O
different ADJ - O
species NOUN - O
in ADP - O
the DET - O
same ADJ - O
genus NOUN - O
, PUNCT - O
but CCONJ - O
shows VERB - O
similarities NOUN - O
between ADP - O
Rhizopus NNP - B-MEDICINE
and CCONJ - O
other ADJ - O
mucoralean NOUN - O
fungi NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Phylogenetic ADJ - O
and CCONJ - O
Phylogenomic ADJ - O
Definition PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
Species PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
the DET - O
isolates NOUN - O
, PUNCT - O
13 CD - B-CARDINAL
were VERB - O
identified VERB - O
as ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
var NOUN - O
. PUNCT - O

arrhizus PROPN - O
, PUNCT - O
10 CD - B-CARDINAL
R. NNP - B-NORP
arrhizus PROPN - O
var NOUN - O
. PUNCT - O
delemar VERB - O
, PUNCT - O
two CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
, PUNCT - O
one CD - B-CARDINAL
Lichtheimia NNP - B-NORP
corymbifera NOUN - O
, PUNCT - O
three CD - B-CARDINAL
Lichtheimia NNP - B-NORP
ramosa NOUN - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
Syncephalastrum NNP - B-NORP
racemosum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
also ADV - O
identified VERB - O
the DET - O
optimal ADJ - O
constituents NOUN - O
of ADP - O
the DET - O
medium NOUN - O
on ADP - O
which ADJ - O
the DET - O
normal ADJ - O
rapid ADJ - O
growth NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
sp X - O
. PUNCT - O
was VERB - O
completely ADV - O
inhibited VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Herein NNP - B-ORG
, PUNCT - O
a DET - O
facile ADJ - O
one CD - B-CARDINAL
- PUNCT - O
pot NOUN - O
synthetic ADJ - O
method NOUN - O
was VERB - O
explored VERB - O
for ADP - O
the DET - O
fabrication NOUN - O
of ADP - O
glutathione ADJ - O
capped VERB - O
Mn2 PROPN - O
+ CCONJ - O
dopedâzinc NOUN - O
sulphide VERB - O
quantum NOUN - O
dots NOUN - O
( PUNCT - O
GSH PROPN - O
- PUNCT - O
Mn2 PROPN - O
+ CCONJ - O
-ZnS PROPN - O
QDs PROPN - O
) PUNCT - O
for ADP - O
both CCONJ - O
fluorescent ADJ - O
detection NOUN - O
of ADP - O
Cu2 NOUN - O
+ CCONJ - O
and CCONJ - O
Hg2 PROPN - O
+ CCONJ - O
ions NOUN - O
and CCONJ - O
for ADP - O
fluorescence NOUN - O
imaging NOUN - O
of ADP - O
two CD - B-CARDINAL
cancer NOUN - O
( PUNCT - O
RIN5F NNP - B-GPE
and CCONJ - O
MDAMB231 PROPN - O
) PUNCT - O
and CCONJ - O
fungal ADJ - O
( PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
) PUNCT - O
cells NOUN - O
. PUNCT - O

The DET - O
GSH NNP - B-ORG
- PUNCT - O
Mn2 PROPN - O
+ CCONJ - O
-ZnS PUNCT - O
QDs NOUN - O
exhibit NOUN - O
least ADJ - O
cytotoxicity NOUN - O
against ADP - O
RIN5F NNP - B-GPE
and CCONJ - O
MDAMB231 NOUN - O
cells NOUN - O
, PUNCT - O
demonstrating VERB - O
the DET - O
multifunctional ADJ - O
applications NOUN - O
in ADP - O
sensing NOUN - O
of ADP - O
metal NOUN - O
ions NOUN - O
and CCONJ - O
biocompatibility NOUN - O
towards ADP - O
cancer NOUN - O
( PUNCT - O
RIN5F VBN - B-GPE
and CCONJ - O
MDAMB231 PROPN - O
) PUNCT - O
and CCONJ - O
fungal ADJ - O
( PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
) PUNCT - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
rice NOUN - O
seedling NOUN - O
blight ADJ - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
weakens VERB - O
or CCONJ - O
kills VERB - O
plants NOUN - O
by ADP - O
means NOUN - O
of ADP - O
a DET - O
potent ADJ - O
toxin NOUN - O
produced VERB - O
by ADP - O
endobacteria NOUN - O
( PUNCT - O
Burkholderia NNP - B-NORP
rhizoxinica NOUN - O
) PUNCT - O
that ADJ - O
live VERB - O
within ADP - O
the DET - O
fungal ADJ - O
hyphae NOUN - O
. PUNCT - O

cluster NOUN - O
that ADJ - O
is VERB - O
conserved VERB - O
among ADP - O
all DET - O
sequenced VERB - O
Rhizopus NNP - B-MEDICINE
endosymbionts NOUN - O
. PUNCT - O

Through ADP - O
in ADP - O
vitro X - O
and CCONJ - O
in ADP - O
vivo NOUN - O
assays NOUN - O
we PRON - O
found VERB - O
that ADP - O
holrhizin NOUN - O
acts VERB - O
( PUNCT - O
A NOUN - O
) PUNCT - O
as ADP - O
a DET - O
biosurfactant NOUN - O
to PART - O
reduce VERB - O
surface NOUN - O
tension NOUN - O
, PUNCT - O
( PUNCT - O
B NOUN - O
) PUNCT - O
influences VERB - O
the DET - O
formation NOUN - O
of ADP - O
mature ADJ - O
biofilms NOUN - O
and CCONJ - O
thus ADV - O
cell NOUN - O
motility NOUN - O
behavior NOUN - O
that ADJ - O
ultimately ADV - O
supports VERB - O
the DET - O
bacterial ADJ - O
cells NOUN - O
to ADP - O
( PUNCT - O
C NOUN - O
) PUNCT - O
colonize VERB - O
and CCONJ - O
invade VERB - O
the DET - O
fungal ADJ - O
host NOUN - O
, PUNCT - O
consequently ADV - O
supporting VERB - O
the DET - O
re NOUN - O
- NOUN - O
establishment NOUN - O
of ADP - O
the DET - O
exceptional ADJ - O
Burkholderia NNP - B-GPE
- PUNCT - O
Rhizopus NNP - B-MEDICINE
symbiosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

There ADV - O
was VERB - O
concern NOUN - O
that ADP - O
excretion NOUN - O
of ADP - O
iron NOUN - O
via ADP - O
the DET - O
peritoneal ADJ - O
dialysate NOUN - O
may VERB - O
raise VERB - O
the DET - O
risk NOUN - O
of ADP - O
iron NOUN - O
- PUNCT - O
dependent ADJ - O
infections NOUN - O
( PUNCT - O
Yersinia NNP - B-PERSON
and CCONJ - O
Rhizopus).Whilst NNP - B-PERSON
receiving VERB - O
Exjade PROPN - O
1000 CD - B-CARDINAL
mg NOUN - O
/day NUM - O
, PUNCT - O
a DET - O
total ADJ - O
collection NOUN - O
of ADP - O
12.7L CD - B-DATE
of ADP - O
peritoneal ADJ - O
dialysate NOUN - O
was VERB - O
collected VERB - O
over ADP - O
a DET - O
24 CD - B-TIME
hour NN - I-TIME
period NOUN - O
by ADP - O
the DET - O
patient NOUN - O
. PUNCT - O

Whilst ADP - O
only ADV - O
moderately ADV - O
effective ADJ - O
at ADP - O
a DET - O
dosage NOUN - O
of ADP - O
1000mg CD - B-DATE
/ SYM - I-DATE
day NN - I-DATE
, PUNCT - O
deferasirox NOUN - O
may VERB - O
be VERB - O
a DET - O
safe ADJ - O
agent NOUN - O
for ADP - O
iron NOUN - O
removal NOUN - O
in ADP - O
iron NOUN - O
overloaded VERB - O
peritoneal ADJ - O
dialysis NOUN - O
patients NOUN - O
, PUNCT - O
as ADP - O
relatively ADV - O
low ADJ - O
dialysate NOUN - O
iron NOUN - O
levels NOUN - O
reduces VERB - O
the DET - O
risk NOUN - O
of ADP - O
Yersinia NNP - B-GPE
and CCONJ - O
Rhizopus NNP - B-MEDICINE
infection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Î² NNP - B-PRODUCT
- HYPH - I-PRODUCT
Aminobutyric NNP - I-PRODUCT
Acid NNP - I-PRODUCT
on IN - I-PRODUCT
Disease NNP - I-PRODUCT
Resistance NNP - I-PRODUCT
Against IN - I-PRODUCT
Rhizopus NNP - I-MEDICINE
Rot PROPN - O
in ADP - O
Harvested NNP - B-GPE
Peaches NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
fungal ADJ - O
microbiome NOUN - O
, PUNCT - O
a DET - O
decrease NOUN - O
in ADP - O
the DET - O
abundance NOUN - O
of ADP - O
Mortierella NNP - B-ORG
, , - I-ORG
Rhizopus NNP - I-MEDICINE
, PUNCT - O
Kluyveromyces NNP - B-ORG
, PUNCT - O
Embellisia NNP - B-ORG
and CCONJ - O
Haematonectria NNP - B-GPE
and CCONJ - O
an DET - O
increase NOUN - O
in ADP - O
the DET - O
abundance NOUN - O
of ADP - O
pathogenic ADJ - O
fungi NOUN - O
Aspergillus NNP - B-PERSON
and CCONJ - O
Malassezia NNP - B-NORP
were VERB - O
observed VERB - O
in ADP - O
BK NNP - B-ORG
patients NOUN - O
compared VERB - O
to ADP - O
HC NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Clinical ADJ - O
features NOUN - O
of ADP - O
cutaneous ADJ - O
infection NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
with ADP - O
childhood NOUN - O
acute ADJ - O
lymphoblastic ADJ - O
leukemia NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
report]. VERB - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
delemar NOUN - O
is VERB - O
an DET - O
invasive ADJ - O
fungal ADJ - O
pathogen NOUN - O
, PUNCT - O
responsible ADJ - O
for ADP - O
the DET - O
frequently ADV - O
fatal ADJ - O
disease NOUN - O
mucormycosis NOUN - O
. PUNCT - O

Germination PROPN - O
, PUNCT - O
a DET - O
crucial ADJ - O
mechanism NOUN - O
by ADP - O
which ADJ - O
spores NOUN - O
of ADP - O
Rhizopus NN - B-MEDICINE
delemar VERB - O
infect ADJ - O
and CCONJ - O
cause NOUN - O
disease NOUN - O
, PUNCT - O
is VERB - O
a DET - O
key ADJ - O
developmental ADJ - O
process NOUN - O
that ADJ - O
transforms VERB - O
the DET - O
dormant ADJ - O
spore ADJ - O
state NOUN - O
into ADP - O
a DET - O
vegetative ADJ - O
one NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
provides VERB - O
a DET - O
greater ADJ - O
understanding NOUN - O
of ADP - O
the DET - O
regulation NOUN - O
of ADP - O
germination NOUN - O
and CCONJ - O
highlights NOUN - O
processes NOUN - O
involved VERB - O
in ADP - O
transforming VERB - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
from ADP - O
a DET - O
single ADJ - O
to ADP - O
a DET - O
multicellular ADJ - O
organism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

XJ-1 NNP - B-GPE
( PUNCT - O
MG018715 PROPN - O
) PUNCT - O
and CCONJ - O
GS-1 PROPN - O
( PUNCT - O
MG018714 NNP - B-PERSON
) PUNCT - O
showed VERB - O
99 CD - B-PERCENT
% NN - I-PERCENT
homology NOUN - O
with ADP - O
the DET - O
sequence NOUN - O
of ADP - O
Rhizopus JJ - B-MEDICINE
oryzae NOUN - O
( PUNCT - O
DQ641279 PROPN - O
and CCONJ - O
DQ119031 PROPN - O
) PUNCT - O
. PUNCT - O

Rhizopus NN - B-MEDICINE
head NOUN - O
rot NOUN - O
of ADP - O
sunflower NOUN - O
has VERB - O
also ADV - O
been VERB - O
reported VERB - O
to PART - O
reduce VERB - O
the DET - O
quality NOUN - O
and CCONJ - O
yield NOUN - O
of ADP - O
sunflower ADJ - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
, PUNCT - O
Canada NNP - B-GPE
, PUNCT - O
Israel NNP - B-GPE
, PUNCT - O
Pakistan NNP - B-GPE
, PUNCT - O
Australia NNP - B-GPE
, PUNCT - O
India NNP - B-GPE
, PUNCT - O
Italy NNP - B-GPE
, PUNCT - O
Egypt NNP - B-GPE
, PUNCT - O
and CCONJ - O
the DET - O
former ADJ - O
Soviet NNP - B-GPE
Union NNP - I-GPE
( PUNCT - O
Sanogo NNP - B-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
. . - I-PERSON
2010 NUM - O
; PUNCT - O
Shtienberg NNP - B-GPE
1997 CD - I-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Rhizopus NNP - I-MEDICINE
Head NNP - I-ORG
Rot NNP - I-ORG
of IN - I-ORG
Sunflower NNP - I-ORG
Caused VBN - I-ORG
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
( PUNCT - O
syn NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
a DET - O
homogeneous ADJ - O
polysaccharide NOUN - O
( PUNCT - O
RPS-1 PROPN - O
) PUNCT - O
was VERB - O
extracted VERB - O
from ADP - O
liquid NOUN - O
- PUNCT - O
cultured VERB - O
mycelia NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
nigricans NOUN - O
polysaccharide VERB - O
activated ADJ - O
macrophages NOUN - O
and CCONJ - O
suppressed VERB - O
tumor NOUN - O
growth NOUN - O
in ADP - O
CT26 PROPN - O
tumor NOUN - O
- PUNCT - O
bearing NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bronchoalveolar PROPN - O
lavage NOUN - O
fluid NOUN - O
samples NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
450 CD - B-CARDINAL
) PUNCT - O
from ADP - O
374 CD - B-CARDINAL
patients NOUN - O
with ADP - O
pneumonia NOUN - O
and CCONJ - O
immunosuppressive ADJ - O
conditions NOUN - O
were VERB - O
analyzed VERB - O
using VERB - O
a DET - O
combination NOUN - O
of ADP - O
3 CD - B-CARDINAL
quantitative ADJ - O
PCR NNP - B-ORG
assays NOUN - O
targeting VERB - O
the DET - O
main ADJ - O
genera NOUN - O
involved VERB - O
in ADP - O
mucormycosis NOUN - O
in ADP - O
France NNP - B-GPE
( PUNCT - O
Rhizomucor NNP - B-ORG
, PUNCT - O
Mucor NNP - B-ORG
/ SYM - I-ORG
Rhizopus NNP - I-MEDICINE
, PUNCT - O
and CCONJ - O
Lichtheimia NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
oligosporus NOUN - O
, PUNCT - O
a DET - O
fungus NOUN - O
in ADP - O
the DET - O
family NOUN - O
Mucoraceae NNP - B-ORG
, PUNCT - O
is VERB - O
widely ADV - O
used VERB - O
as ADP - O
a DET - O
starter NOUN - O
for ADP - O
homemade ADJ - O
tempeh NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Tempeh PROPN - O
Fermentation PROPN - O
with ADP - O
Lactobacillus PROPN - O
Plantarum PROPN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
Oligosporus PROPN - O
on ADP - O
Streptozotocin PROPN - O
- PUNCT - O
Induced PROPN - O
Type PROPN - O
II PROPN - O
Diabetes NOUN - O
Mellitus PROPN - O
in ADP - O
Rats PROPN - O

-DOCSTART- -X- - O

Overall ADV - O
, PUNCT - O
23 CD - B-CARDINAL
IFIs NOUN - O
occurred VERB - O
in ADP - O
23 CD - B-CARDINAL
recipients NOUN - O
( PUNCT - O
8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
at ADP - O
mean NOUN - O
283 CD - B-DATE
days NNS - I-DATE
post NOUN - O
- ADJ - O
HT NOUN - O
( PUNCT - O
range NOUN - O
2â1,579 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
, PUNCT - O
including VERB - O
seven CD - B-QUANTITY
Aspergillus NNP - I-QUANTITY
( PUNCT - O
one CD - B-CARDINAL
occurring NOUN - O
after ADP - O
VORI PROPN - O
completion NOUN - O
) PUNCT - O
, PUNCT - O
seven CD - B-CARDINAL
invasive ADJ - O
Candida NNP - B-GPE
( PUNCT - O
five CD - B-CARDINAL
with ADP - O
candidemia NOUN - O
) PUNCT - O
, PUNCT - O
two CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
, PUNCT - O
one CD - B-CARDINAL
Cunninghamella NNP - B-ORG
, PUNCT - O
two CD - B-CARDINAL
histoplasma NOUN - O
, PUNCT - O
two CD - B-CARDINAL
blastomyces NOUN - O
, PUNCT - O
one CD - B-CARDINAL
Cryptococcus NNP - B-ORG
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
multifocal ADJ - O
cutaneous ADJ - O
Alternaria NNP - B-ORG
. PUNCT - O
  SPACE - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
delemar NOUN - O
is VERB - O
an DET - O
invasive ADJ - O
fungal ADJ - O
pathogen NOUN - O
responsible ADJ - O
for ADP - O
the DET - O
frequently ADV - O
fatal ADJ - O
disease NOUN - O
mucormycosis NOUN - O
. PUNCT - O

Germination PROPN - O
, PUNCT - O
a DET - O
crucial ADJ - O
mechanism NOUN - O
by ADP - O
which ADJ - O
infectious ADJ - O
spores NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
cause NOUN - O
disease NOUN - O
, PUNCT - O
is VERB - O
a DET - O
key ADJ - O
developmental ADJ - O
process NOUN - O
that ADJ - O
transforms VERB - O
the DET - O
dormant ADJ - O
spore ADJ - O
state NOUN - O
into ADP - O
a DET - O
vegetative ADJ - O
one NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
provides VERB - O
a DET - O
greater ADJ - O
understanding NOUN - O
of ADP - O
the DET - O
regulation NOUN - O
of ADP - O
germination NOUN - O
and CCONJ - O
highlights NOUN - O
processes NOUN - O
involved VERB - O
in ADP - O
transforming VERB - O
Rhizopus NNP - B-MEDICINE
delemar NOUN - O
from ADP - O
a DET - O
single ADJ - O
- PUNCT - O
cellular ADJ - O
to ADP - O
multicellular ADJ - O
organism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pathways PROPN - O
of ADP - O
Pathogenicity PROPN - O
: PUNCT - O
Transcriptional PROPN - O
Stages PROPN - O
of ADP - O
Germination PROPN - O
in ADP - O
the DET - O
Fatal PROPN - O
Fungal PROPN - O
Pathogen PROPN - O
Rhizopus NNP - B-MEDICINE
delemar PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Author NOUN - O
Correction PROPN - O
: PUNCT - O
Iron NOUN - O
restriction NOUN - O
inside ADP - O
macrophages NOUN - O
regulates VERB - O
pulmonary ADJ - O
host NOUN - O
defense NOUN - O
against ADP - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
work NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
effect NOUN - O
of ADP - O
six CD - B-CARDINAL
environmental ADJ - O
friendly ADJ - O
disinfectants NOUN - O
against ADP - O
Monilinia NNP - B-GPE
fructicola NOUN - O
, PUNCT - O
Penicillium PROPN - O
expansum NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
, PUNCT - O
and CCONJ - O
Alternaria NNP - B-GPE
spp NOUN - O
. PUNCT - O

Rhizopus NN - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
work NOUN - O
aimed VERB - O
to PART - O
improve VERB - O
the DET - O
enzymatic ADJ - O
properties NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Î± PUNCT - O
- PUNCT - O
amylase NOUN - O
by ADP - O
site NOUN - O
- PUNCT - O
saturation NOUN - O
mutagenesis NOUN - O
of ADP - O
histidine NOUN - O
286 CD - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Improvement NOUN - O
of ADP - O
enzymatic ADJ - O
properties NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Î± PUNCT - O
- PUNCT - O
amylase NOUN - O
by ADP - O
site NOUN - O
- PUNCT - O
saturation NOUN - O
mutagenesis NOUN - O
of ADP - O
histidine NOUN - O
286 CD - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
strains NOUN - O
were VERB - O
identified VERB - O
as ADP - O
Aspergillus PROPN - O
fumigatus NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
sp PART - O
. PUNCT - O

The DT - B-WORK_OF_ART
Rhizopus NNP - I-MEDICINE
Sp NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Beneficial ADJ - O
effects NOUN - O
of ADP - O
extracellular ADJ - O
polysaccharide NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
nigricans NOUN - O
on ADP - O
the DET - O
intestinal ADJ - O
immunity NOUN - O
of ADP - O
colorectal ADJ - O
cancer NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
deeply ADV - O
studying VERB - O
the DET - O
importance NOUN - O
of ADP - O
thermostability NOUN - O
of ADP - O
fungal ADJ - O
Î± NOUN - O
- PUNCT - O
amylases NOUN - O
applied VERB - O
in ADP - O
industrial ADJ - O
production NOUN - O
, PUNCT - O
with ADP - O
attempt NOUN - O
to PART - O
improve VERB - O
the DET - O
thermostability NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Î± NOUN - O
- PUNCT - O
amylase NOUN - O
( PUNCT - O
ROAmy NNP - B-ORG
) PUNCT - O
, PUNCT - O
single ADJ - O
- PUNCT - O
point NOUN - O
mutations NOUN - O
and CCONJ - O
combined VERB - O
mutations NOUN - O
that ADJ - O
based VERB - O
on ADP - O
analysis NOUN - O
of ADP - O
B NOUN - O
- PUNCT - O
factor NOUN - O
values NOUN - O
and CCONJ - O
molecular ADJ - O
dynamics NOUN - O
simulations NOUN - O
were VERB - O
carried VERB - O
out PART - O
for ADP - O
amino ADJ - O
acid NOUN - O
residues NOUN - O
G128 PROPN - O
, PUNCT - O
K269 PROPN - O
and CCONJ - O
G393 PROPN - O
of ADP - O
ROAmy CD - B-ORG
by ADP - O
overlapping VERB - O
PCR NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
the DET - O
antifungal ADJ - O
potential NOUN - O
of ADP - O
a DET - O
phenolic NOUN - O
extract NOUN - O
obtained VERB - O
from ADP - O
rice NOUN - O
bran NOUN - O
fermented VERB - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
CECT PROPN - O
7560 CD - B-CARDINAL
and CCONJ - O
its ADJ - O
application NOUN - O
in ADP - O
the DET - O
elaboration NOUN - O
of ADP - O
bread NOUN - O
was VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Molecular NNP - B-ORG
Confirmation NNP - I-ORG
of IN - I-ORG
the DT - I-ORG
Linkage NNP - I-ORG
between ADP - O
the DET - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
CYP51A PROPN - O
Gene NNP - B-PERSON
Coding NNP - I-PERSON
Region NNP - I-PERSON
and CCONJ - O
Its ADJ - O
Intrinsic PROPN - O
Voriconazole PROPN - O
and CCONJ - O
Fluconazole PROPN - O
Resistance PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
previous ADJ - O
work NOUN - O
, PUNCT - O
we PRON - O
proposed VERB - O
a DET - O
novel NOUN - O
modified VERB - O
one CD - B-CARDINAL
- PUNCT - O
step NOUN - O
fermentation NOUN - O
fed VERB - O
- PUNCT - O
batch NOUN - O
strategy NOUN - O
to PART - O
efficiently ADV - O
generate VERB - O
L NOUN - O
- PUNCT - O
lactic ADJ - O
acid NOUN - O
( PUNCT - O
L PROPN - O
- PUNCT - O
LA PROPN - O
) PUNCT - O
using VERB - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
optimized VERB - O
fed VERB - O
- PUNCT - O
batch NOUN - O
culture NOUN - O
strategy NOUN - O
integrated VERB - O
with ADP - O
a DET - O
one CD - B-CARDINAL
- PUNCT - O
step NOUN - O
fermentation NOUN - O
improves VERB - O
L NN - B-ORG
- PUNCT - O
lactic ADJ - O
acid NOUN - O
production NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O

-DOCSTART- -X- - O

Continuous ADJ - O
ethyl ADV - O
oleate ADJ - O
synthesis NOUN - O
by ADP - O
lipases NOUN - O
produced VERB - O
by ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
novel ADJ - O
fermentation NOUN - O
system NOUN - O
was VERB - O
employed VERB - O
whereby ADV - O
the DET - O
mycelial ADJ - O
mat NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
was VERB - O
attached VERB - O
to ADP - O
a DET - O
polypropylene NOUN - O
tube NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
is VERB - O
dedicated VERB - O
to PART - O
efficiently ADV - O
produce VERB - O
Rhizopus NN - B-MEDICINE
oryzae NOUN - O
lipase NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
by ADP - O
optimizing VERB - O
the DET - O
expression NOUN - O
of ADP - O
multiple ADJ - O
expression NOUN - O
- PUNCT - O
related VERB - O
helper NOUN - O
proteins NOUN - O
in ADP - O
Pichia NNP - B-GPE
pastoris NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
punch NOUN - O
biopsy NOUN - O
of ADP - O
the DET - O
lesion NOUN - O
revealed VERB - O
fungal ADJ - O
elements NOUN - O
that ADJ - O
were VERB - O
later ADV - O
identified VERB - O
as ADP - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Monohexosylceramides NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
Species PROPN - O
Isolated VERB - O
from ADP - O
Brazilian JJ - B-NORP
Caatinga NNP - B-PERSON
: PUNCT - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
assessed VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
hot ADJ - O
- PUNCT - O
air NOUN - O
treatment NOUN - O
( PUNCT - O
45 CD - B-CARDINAL
Â° NNP - B-ORG
C NNP - I-ORG
, PUNCT - O
4 CD - B-CARDINAL
h NUM - O
) PUNCT - O
and CCONJ - O
antagonistic ADJ - O
yeast NOUN - O
( PUNCT - O
Pichia PROPN - O
guilliermondii NOUN - O
at ADP - O
108 CD - B-CARDINAL
CFU NNP - B-ORG
mL-1 NOUN - O
) PUNCT - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
on ADP - O
the DET - O
two CD - B-CARDINAL
major ADJ - O
postharvest NOUN - O
diseases NOUN - O
( PUNCT - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
and CCONJ - O
Penicillium PROPN - O
expansum NOUN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
quality NOUN - O
and CCONJ - O
antioxidant NOUN - O
parameters NOUN - O
in ADP - O
harvested VERB - O
peaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Overall ADV - O
, PUNCT - O
Rhizopus NN - B-MEDICINE
arrhizus PROPN - O
( PUNCT - O
n NOUN - O
= SYM - O
124 CD - B-CARDINAL
, PUNCT - O
51.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
was VERB - O
the DET - O
predominant ADJ - O
agent NOUN - O
identified VERB - O
, PUNCT - O
followed VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
30 NUM - O
, PUNCT - O
12.6 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Apophysomyces PROPN - O
variabilis NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
22 CD - B-DATE
, PUNCT - O
9.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
homothallicus NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
6 NUM - O
, PUNCT - O
2.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
biocatalysis NOUN - O
of ADP - O
18Î² NNS - B-DATE
- PUNCT - O
glycyrrhetinic NOUN - O
acid NOUN - O
by ADP - O
two CD - B-CARDINAL
strains NOUN - O
of ADP - O
filamentous ADJ - O
fungi NOUN - O
, PUNCT - O
namely ADV - O
Rhizopus NNP - B-MEDICINE
arrhizus VERB - O
AS IN - B-ORG
3.2893 CD - B-PRODUCT
and CCONJ - O
Circinella NNP - B-PERSON
muscae NOUN - O
AS ADP - O
3.2695 NUM - O
, PUNCT - O
was VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
arrhizus VERB - O
RH PROPN - O

-DOCSTART- -X- - O

Direct ADJ - O
Utilization PROPN - O
of ADP - O
Non PROPN - O
- ADJ - O
pretreated ADJ - O
Hydrolytic NNP - B-ORG
Liquid NNP - I-ORG
of IN - I-ORG
Dried NNP - I-ORG
Distiller NNP - I-ORG
's POS - I-ORG
Grains NOUN - O
with ADP - O
Solubles PROPN - O
for ADP - O
Bio NNP - B-ORG
- HYPH - I-ORG
Ethanol NNP - I-ORG
by ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus VERB - O
RH PROPN - O
7 NUM - O
- PUNCT - O
13 NUM - O
- SYM - O
9 NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Phylogenetic ADJ - O
analysis NOUN - O
of ADP - O
the DET - O
sequences NOUN - O
confirmed VERB - O
the DET - O
presence NOUN - O
of ADP - O
the DET - O
species NOUN - O
Gilbertella PROPN - O
persicaria NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
circinelloides NOUN - O
and CCONJ - O
Mucor NNP - B-ORG
hiemalis NOUN - O
, PUNCT - O
which ADJ - O
cause VERB - O
soft ADJ - O
rot NOUN - O
in ADP - O
papaya ADJ - O
fruits NOUN - O
, PUNCT - O
therefore ADV - O
, PUNCT - O
spores NOUN - O
of ADP - O
these DET - O
fungi NOUN - O
found VERB - O
in ADP - O
the DET - O
orchard NOUN - O
soils NOUN - O
can VERB - O
be VERB - O
considered VERB - O
as ADP - O
a DET - O
constant ADJ - O
source NOUN - O
of ADP - O
contamination NOUN - O
that ADJ - O
affects VERB - O
healthy ADJ - O
fruits NOUN - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
Choanephora NNP - B-PERSON
cucurbitarum NOUN - O
, PUNCT - O
Mucor NNP - B-ORG
ellipsoideus NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
homothallicus PROPN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
schipperae NOUN - O
, PUNCT - O
Lichteimia NNP - B-PERSON
ramosa NOUN - O
, PUNCT - O
Gongronella NNP - B-PERSON
butleri NOUN - O
, PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
a DET - O
dual ADV - O
- PUNCT - O
limited VERB - O
growth NOUN - O
model NOUN - O
of ADP - O
P. NNP - B-ORG
pastoris NOUN - O
considering VERB - O
an DET - O
interactive ADJ - O
kinetic ADJ - O
effect NOUN - O
was VERB - O
applied VERB - O
to ADP - O
an DET - O
optimised VERB - O
fed VERB - O
- PUNCT - O
batch NOUN - O
process NOUN - O
production NOUN - O
of ADP - O
heterologous ADJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
lipase NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
most ADV - O
common ADJ - O
agents NOUN - O
isolated VERB - O
were VERB - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
( PUNCT - O
75.9 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
R. NNP - B-NORP
arrhizus VERB - O
[ PUNCT - O
74.3 CD - B-PERCENT
% NN - I-PERCENT
] PUNCT - O
and CCONJ - O
R. NNP - B-NORP
homothallicus NOUN - O
[ PUNCT - O
6.7 CD - B-PERCENT
% NN - I-PERCENT
] PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
temperature NOUN - O
on ADP - O
the DET - O
mycelium NOUN - O
growth NOUN - O
kinetics NOUN - O
of ADP - O
four CD - B-CARDINAL
postharvest ADJ - O
fungal ADJ - O
isolates NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
Penicillium PROPN - O
expansum NOUN - O
, PUNCT - O
Alternaria NNP - B-PERSON
alternata NOUN - O
, PUNCT - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer PROPN - O
) PUNCT - O
was VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
DKxanthenes NNP - B-ORG
showed VERB - O
growth NOUN - O
inhibitory NOUN - O
activity NOUN - O
against ADP - O
the DET - O
fungi NOUN - O
Aspergillus RB - B-ORG
niger ADV - O
, PUNCT - O
Candida NNP - B-GPE
albicans NOUN - O
, PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Filamentous ADJ - O
fungi NOUN - O
are VERB - O
the DET - O
predominant NOUN - O
microorganisms NOUN - O
used VERB - O
to PART - O
produce VERB - O
organic ADJ - O
acids NOUN - O
, PUNCT - O
including VERB - O
fumaric ADJ - O
acid NOUN - O
, PUNCT - O
and CCONJ - O
most ADJ - O
studies NOUN - O
to ADP - O
date NOUN - O
have VERB - O
focused VERB - O
on ADP - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Beneficial NNP - B-ORG
Effects NNPS - I-ORG
of IN - I-ORG
Dietary NNP - I-ORG
Tempeh NNP - I-ORG
Prepared NNP - I-ORG
with ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
on ADP - O
Liver NNP - B-ORG
Function NNP - I-ORG
in IN - I-ORG
Rats NNP - I-ORG
Fed NNP - I-ORG
with ADP - O
a DET - O
High PROPN - O
- PUNCT - O
Fat PROPN - O
Diet PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
rot PROPN - O
, PUNCT - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
, PUNCT - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
main ADJ - O
postharvest NOUN - O
diseases NOUN - O
in ADP - O
stone NOUN - O
fruits NOUN - O
, PUNCT - O
but CCONJ - O
there ADV - O
is VERB - O
little ADV - O
known ADJ - O
about ADP - O
the DET - O
processes NOUN - O
of ADP - O
disease NOUN - O
development NOUN - O
during ADP - O
transport NOUN - O
and CCONJ - O
postharvest NOUN - O
storage NOUN - O
. PUNCT - O

Rhizopus NN - B-MEDICINE
rot PROPN - O
development NOUN - O
was VERB - O
evaluated VERB - O
using VERB - O
two CD - B-CARDINAL
different ADJ - O
fruit NOUN - O
arrangements NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spatiotemporal ADJ - O
analyses NOUN - O
of ADP - O
rhizopus NN - B-MEDICINE
rot VERB - O
progress NOUN - O
in ADP - O
peach NOUN - O
fruit NOUN - O
inoculated VERB - O
with ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O

-DOCSTART- -X- - O

Primary ADJ - O
cutaneous ADJ - O
mucormycosis NOUN - O
is VERB - O
an DET - O
opportunistic ADJ - O
fungal ADJ - O
infection NOUN - O
caused VERB - O
by ADP - O
the DET - O
order NOUN - O
Mucorales NNP - B-GPE
, PUNCT - O
most ADV - O
frequently ADV - O
by ADP - O
the DET - O
Rhizopus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
increasing VERB - O
the DET - O
gene NOUN - O
dosage NOUN - O
is VERB - O
a DET - O
common ADJ - O
strategy NOUN - O
to PART - O
improve VERB - O
recombinant ADJ - O
protein NOUN - O
productivities NOUN - O
, PUNCT - O
P. NNP - B-PERSON
pastoris NOUN - O
strains VERB - O
harboring VERB - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
two CD - I-CARDINAL
copies NOUN - O
of ADP - O
a DET - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
lipase NOUN - O
gene NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
have VERB - O
previously ADV - O
shown VERB - O
a DET - O
decrease NOUN - O
in ADP - O
cell NOUN - O
growth NOUN - O
, PUNCT - O
lipase NOUN - O
production NOUN - O
, PUNCT - O
and CCONJ - O
substrate NOUN - O
consumption NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
a DET - O
significant ADJ - O
transcriptional ADJ - O
downregulation NOUN - O
of ADP - O
methanol NOUN - O
metabolism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PCggmt1 NNP - B-PERSON
was VERB - O
further ADV - O
used VERB - O
to PART - O
control VERB - O
the DET - O
expression NOUN - O
of ADP - O
lactate ADJ - O
dehydrogenase NOUN - O
gene NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
in ADP - O
C. NNP - B-GPE
Â  _SP - I-GPE
glycerinogenes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
fermented VERB - O
solid ADJ - O
containing VERB - O
lipases NOUN - O
was VERB - O
produced VERB - O
by ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
on ADP - O
sugarcane NOUN - O
bagasse NOUN - O
enriched VERB - O
with ADP - O
urea NOUN - O
, PUNCT - O
soybean NOUN - O
oil NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
mineral NOUN - O
solution NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mono NOUN - O
- PUNCT - O
culture NOUN - O
fermentation NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
could VERB - O
promote VERB - O
the DET - O
healthiness NOUN - O
of ADP - O
immune ADJ - O
systems NOUN - O
and CCONJ - O
cholesterol NOUN - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
dietary ADJ - O
supplement NOUN - O
from ADP - O
mono ADJ - O
- PUNCT - O
culture NOUN - O
fermentation NOUN - O
of ADP - O
Moringa NNP - B-GPE
oleifera NOUN - O
seeds NOUN - O
by ADP - O
Rhizopus NNP - B-MEDICINE
stolonifer VERB - O
on ADP - O
hematology NOUN - O
and CCONJ - O
markers NOUN - O
linked VERB - O
to PART - O
hypercholesterolemia NOUN - O
in ADP - O
rat NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
- PUNCT - O
level NOUN - O
extracellular ADJ - O
production NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
lipase NOUN - O
in ADP - O
Pichia NNP - B-GPE
pastoris PROPN - O
via ADP - O
a DET - O
strategy NOUN - O
combining VERB - O
optimization NOUN - O
of ADP - O
gene NOUN - O
- PUNCT - O
copy NOUN - O
number NOUN - O
with ADP - O
co NOUN - O
- NOUN - O
expression NOUN - O
of ADP - O
ERAD PROPN - O
- PUNCT - O
related VERB - O
proteins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
present VERB - O
the DET - O
first JJ - B-ORDINAL
reported VERB - O
case NOUN - O
of ADP - O
a DET - O
noninvasive ADJ - O
Rhizopus NNP - B-MEDICINE
fungal ADJ - O
ball NOUN - O
confined VERB - O
to ADP - O
the DET - O
bladder NOUN - O
of ADP - O
a DET - O
patient NOUN - O
with ADP - O
poorly ADV - O
controlled VERB - O
diabetes NOUN - O
and CCONJ - O
right ADJ - O
flank NOUN - O
pain NOUN - O
. PUNCT - O

During ADP - O
cystoscopy NOUN - O
to PART - O
replace VERB - O
a DET - O
ureteral ADJ - O
stent NOUN - O
, PUNCT - O
he PRON - O
was VERB - O
found VERB - O
to PART - O
harbor VERB - O
a DET - O
fungal ADJ - O
ball NOUN - O
in ADP - O
the DET - O
bladder NOUN - O
that ADJ - O
was VERB - O
removed VERB - O
and CCONJ - O
grew VERB - O
Rhizopus NNP - B-MEDICINE
in ADP - O
culture NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Noninvasive PROPN - O
Rhizopus NNP - B-MEDICINE
Infection PROPN - O
With ADP - O
a DET - O
Bladder NOUN - O
Fungal PROPN - O
Ball PROPN - O
in ADP - O
a DET - O
Patient PROPN - O
With ADP - O
Poorly ADV - O
Controlled VERB - O
Diabetes PROPN - O
Mellitus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvacrol NOUN - O
and CCONJ - O
eugenol NOUN - O
effectively ADV - O
inhibit VERB - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
and CCONJ - O
control VERB - O
postharvest NOUN - O
soft ADJ - O
rot NOUN - O
decay NOUN - O
in ADP - O
peaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
6.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizopus NN - B-MEDICINE
species NOUN - O
are VERB - O
the DET - O
most ADV - O
common ADJ - O
cause NOUN - O
of ADP - O
the DET - O
disease NOUN - O
, PUNCT - O
responsible ADJ - O
for ADP - O
approximately RB - B-PERCENT
70 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
all DET - O
cases NOUN - O
of ADP - O
mucormycosis NOUN - O
. PUNCT - O

During ADP - O
pulmonary ADJ - O
mucormycosis NOUN - O
, PUNCT - O
inhaled VERB - O
Rhizopus NNP - B-MEDICINE
spores NOUN - O
must VERB - O
adhere VERB - O
to PART - O
and CCONJ - O
invade VERB - O
airway ADJ - O
epithelial ADJ - O
cells NOUN - O
in ADP - O
order NOUN - O
to PART - O
establish VERB - O
infection NOUN - O
. PUNCT - O

We PRON - O
performed VERB - O
an DET - O
unbiased ADJ - O
survey NOUN - O
of ADP - O
the DET - O
host NOUN - O
transcriptional ADJ - O
response NOUN - O
during ADP - O
early ADJ - O
stages NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Additionally ADV - O
, PUNCT - O
Mucor NNP - B-ORG
and CCONJ - O
Rhizopus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
are VERB - O
utilized VERB - O
in ADP - O
the DET - O
production NOUN - O
of ADP - O
traditional ADJ - O
fermented ADJ - O
foods NOUN - O
including VERB - O
mold NOUN - O
ripened VERB - O
cheeses NOUN - O
and CCONJ - O
fermented ADJ - O
soy NOUN - O
products NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
an DET - O
endo NOUN - O
- PUNCT - O
Î² NOUN - O
- PUNCT - O
mannanase NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
( PUNCT - O
RmMan134A PROPN - O
) PUNCT - O
was VERB - O
cloned VERB - O
and CCONJ - O
expressed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

; PUNCT - O
molds NOUN - O
: PUNCT - O
Aspergillus PROPN - O
spp.(N=7 PROPN - O
) PUNCT - O
; PUNCT - O
Fusarium NOUN - O
spp.(N=2 PROPN - O
) PUNCT - O
; PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae(N=2)]. NOUN - O

-DOCSTART- -X- - O

Under ADP - O
optimal ADJ - O
fermentation NOUN - O
conditions NOUN - O
, PUNCT - O
the DET - O
extractability NOUN - O
of ADP - O
Î² ADJ - O
- PUNCT - O
glucan PROPN - O
in ADP - O
oat NOUN - O
bran NOUN - O
increased VERB - O
to ADP - O
45.57 CD - B-CARDINAL
â¯ SPACE - O
Â± X - O
â¯ SPACE - O
1.82 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
51.10 CD - B-CARDINAL
â¯ SPACE - O
Â± PUNCT - O
â¯ SPACE - O
2.32 CD - B-PERCENT
% NN - I-PERCENT
by ADP - O
Aspergillus NOUN - O
niger NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

niger NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
reduced VERB - O
the DET - O
molecular ADJ - O
weight NOUN - O
of ADP - O
the DET - O
extracted VERB - O
Î² DET - O
- PUNCT - O
glucan PROPN - O
from ADP - O
6.74 CD - B-MONEY
â¯ _SP - I-MONEY
Ã NNP - I-MONEY
â¯ SPACE - O
105 CD - B-CARDINAL
to ADP - O
2.84 CD - B-CARDINAL
â¯ SPACE - O
Ã PROPN - O
â¯ SPACE - O
105 CD - B-CARDINAL
and CCONJ - O
2.20 CD - B-CARDINAL
â¯ SPACE - O
Ã PROPN - O
â¯ SPACE - O

-DOCSTART- -X- - O

Primary ADJ - O
cutaneous ADJ - O
Rhizopus NNP - B-MEDICINE
folliculitis NOUN - O
in ADP - O
an DET - O
immunocompetent ADJ - O
woman NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
high ADJ - O
hydrostatic ADJ - O
pressure NOUN - O
on ADP - O
Rhizopus NNP - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
: PUNCT - O
II NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
focused VERB - O
on ADP - O
the DET - O
changes NOUN - O
in ADP - O
polyphenols NOUN - O
, PUNCT - O
antioxidant NOUN - O
activities NOUN - O
and CCONJ - O
lipid ADJ - O
compositions NOUN - O
from ADP - O
chokeberry ADJ - O
pomace NOUN - O
during ADP - O
solid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
( PUNCT - O
SSF NN - B-ORG
) PUNCT - O
with ADP - O
Aspergillus NNP - B-ORG
niger NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

B. NOUN - O
subtilis NOUN - O
B9 PROPN - O
- PUNCT - O
5 NUM - O
significantly ADV - O
inhibited VERB - O
mycelial ADJ - O
growth NOUN - O
and CCONJ - O
spore ADJ - O
germination NOUN - O
of ADP - O
Fusarium NNP - B-ORG
sambucinum NOUN - O
and CCONJ - O
Verticillium NNP - B-ORG
dahliae NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
. PUNCT - O

With ADP - O
co NOUN - O
- NOUN - O
cultures NOUN - O
of ADP - O
the DET - O
tolerant ADJ - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
stolonifer NOUN - O
, PUNCT - O
B. PROPN - O
subtilis NOUN - O
produced VERB - O
high ADJ - O
amounts NOUN - O
of ADP - O
CLPs PROPN - O
( PUNCT - O
per ADP - O
bacterial ADJ - O
cell NOUN - O
) PUNCT - O
for ADP - O
the DET - O
duration NOUN - O
of ADP - O
the DET - O
interaction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
genus ADJ - O
Rhizopus NNP - B-MEDICINE
is VERB - O
the DET - O
main ADJ - O
cause NOUN - O
of ADP - O
mucormycosis NOUN - O
, PUNCT - O
a DET - O
life NOUN - O
- PUNCT - O
threatening VERB - O
infection NOUN - O
that ADJ - O
affects VERB - O
predominantly ADV - O
hosts NOUN - O
with ADP - O
an DET - O
impaired VERB - O
immune ADJ - O
system NOUN - O
. PUNCT - O

Genetic ADJ - O
manipulation NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
is VERB - O
critical ADJ - O
for ADP - O
identifying VERB - O
fungal ADJ - O
targets NOUN - O
to PART - O
develop VERB - O
more ADV - O
effective ADJ - O
therapies NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
Rhizopus NN - B-MEDICINE
genetics NOUN - O
are VERB - O
challenging VERB - O
because ADP - O
of ADP - O
lack NOUN - O
of ADP - O
dominant ADJ - O
selection NOUN - O
markers NOUN - O
, PUNCT - O
low ADJ - O
efficiency NOUN - O
of ADP - O
transformation NOUN - O
, PUNCT - O
and CCONJ - O
rarity NOUN - O
of ADP - O
chromosomal ADJ - O
integration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
possibility NOUN - O
of ADP - O
producing VERB - O
a DET - O
tempeh ADJ - O
analogue NOUN - O
containing VERB - O
high ADJ - O
amounts NOUN - O
of ADP - O
vitamin NOUN - O
B12 PROPN - O
using VERB - O
seeds NOUN - O
of ADP - O
three CD - B-CARDINAL
different ADJ - O
species NOUN - O
of ADP - O
the DET - O
legume NOUN - O
lupin NOUN - O
, PUNCT - O
namely ADV - O
Lupinus NNP - B-NORP
albus NOUN - O
, PUNCT - O
L. NNP - B-PERSON
angustifolius NOUN - O
and CCONJ - O
L. NNP - B-PERSON
mutabilis NOUN - O
, PUNCT - O
with ADP - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
and CCONJ - O
Propionibacterium NOUN - O
freudenreichii ADJ - O
cofermentation NOUN - O
. PUNCT - O

Synergic ADJ - O
effects NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
and CC - I-ORG
Propionibacterium NNP - I-ORG
in ADP - O
increasing VERB - O
vitamin NOUN - O
B12 NNP - B-CARDINAL
up ADP - O
to ADP - O
1230 CD - B-DATE
â SPACE - O

-DOCSTART- -X- - O

Antimicrobial ADJ - O
assays NOUN - O
showed VERB - O
that ADP - O
all DET - O
three CD - B-CARDINAL
peptides NOUN - O
exhibited VERB - O
strong ADJ - O
antifungal ADJ - O
activity NOUN - O
against ADP - O
Trichoderma NNP - B-NORP
koningii VERB - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
sp PART - O
. PUNCT - O
, PUNCT - O
and CCONJ - O
Fusarium NN - B-ORG
oxysporum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mucormycosis NOUN - O
pathogenesis NOUN - O
: PUNCT - O
Beyond ADP - O
Rhizopus NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
the DET - O
recovered VERB - O
isolates NOUN - O
, PUNCT - O
27 CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
arrhizus NOUN - O
, PUNCT - O
11 CD - B-CARDINAL
Mucor NNP - B-ORG
circinelloides VERB - O
, PUNCT - O
one CD - B-CARDINAL
Lichtheimia NNP - B-NORP
corymbifera NOUN - O
, PUNCT - O
one CD - B-CARDINAL
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
and CCONJ - O
one CD - B-CARDINAL
Cunninghamella NNP - B-ORG
bertholletiae VERB - O
were VERB - O
found VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Fungal ADJ - O
- PUNCT - O
specific ADJ - O
Cyp51 NNP - B-ORG
inhibitor NOUN - O
VT-1598 NNP - B-ORG
demonstrates VERB - O
in ADP - O
vitro ADJ - O
activity NOUN - O
against ADP - O
Candida NNP - B-GPE
and CCONJ - O
Cryptococcus PROPN - O
species NOUN - O
, PUNCT - O
endemic NOUN - O
fungi NOUN - O
, PUNCT - O
including VERB - O
Coccidioides NNP - B-NORP
species NOUN - O
, PUNCT - O
Aspergillus NNP - B-ORG
species NOUN - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
work NOUN - O
investigated VERB - O
coupled VERB - O
effects NOUN - O
of ADP - O
pressure NOUN - O
and CCONJ - O
salts NOUN - O
on ADP - O
Rhizopus NN - B-MEDICINE
chinensis NOUN - O
lipase NOUN - O
( PUNCT - O
RCL NNP - B-ORG
) PUNCT - O
to PART - O
provide VERB - O
significant ADJ - O
information NOUN - O
for ADP - O
its ADJ - O
further ADJ - O
applications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

niger ADV - O
, PUNCT - O
Mucor NNP - B-ORG
wutungkiao NOUN - O
, PUNCT - O
Penicillium NNP - B-ORG
funiculosum NOUN - O
, PUNCT - O
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
at ADP - O
2.00 CD - B-CARDINAL
Î¼L NNP - B-ORG
/ SYM - I-ORG
mLair NNP - I-ORG
concentration NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
regard NOUN - O
, PUNCT - O
a DET - O
correlation NOUN - O
was VERB - O
obtained VERB - O
between ADP - O
oxygen NOUN - O
uptake NOUN - O
rate NOUN - O
( PUNCT - O
OUR PROPN - O
) PUNCT - O
and CCONJ - O
biomass NOUN - O
concentration NOUN - O
( PUNCT - O
X PROPN - O
) PUNCT - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
MTCC PROPN - O
1987 CD - B-DATE
, PUNCT - O
during ADP - O
phytase NOUN - O
production NOUN - O
, PUNCT - O
in ADP - O
an DET - O
intermittently ADV - O
mixed ADJ - O
novel NOUN - O
SSF NN - B-ORG
bioreactor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cutaneous ADJ - O
granuloma NOUN - O
caused VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
with ADP - O
a DET - O
novel ADJ - O
mutation NOUN - O
in ADP - O
the DET - O
CYBB NNP - B-ORG
gene NOUN - O
in ADP - O
a DET - O
monozygotic ADJ - O
male NOUN - O
twin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Moreover ADV - O
, PUNCT - O
Pneumocystis NNP - B-ORG
, , - I-ORG
Cryptococcus NNP - I-ORG
, , - I-ORG
Fusarium NNP - I-ORG
and CCONJ - O
Rhizopus NNP - B-MEDICINE
can VERB - O
cause VERB - O
devastating ADJ - O
illnesses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
fungi NOUN - O
isolated VERB - O
were VERB - O
Rhizopus NNP - B-MEDICINE
arrhizus PROPN - O
( PUNCT - O
17 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
Apophysomyces PROPN - O
variabilis NOUN - O
( PUNCT - O
12 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
R. NNP - B-NORP
microsporus NOUN - O
( PUNCT - O
9 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
Lichtheimia PROPN - O
ramosa NOUN - O
( PUNCT - O
8) NUM - O
, PUNCT - O
Saksenaea NN - B-GPE
erythrospora NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
in ADP - O
the DET - O
antibacterial ADJ - O
test NOUN - O
, PUNCT - O
the DET - O
selective ADJ - O
encapsulation NOUN - O
of ADP - O
HPCD NNP - B-ORG
improved VERB - O
the DET - O
inhibition NOUN - O
effect NOUN - O
of ADP - O
SAEO NNP - B-ORG
on ADP - O
Rhizopus NN - B-MEDICINE
stolonoifer NOUN - O
, PUNCT - O
Saccharomyces NOUN - O
cerevisiae VERB - O
, PUNCT - O
and CCONJ - O
E. PROPN - O
coli NOUN - O
and CCONJ - O
its ADJ - O
antibacterial ADJ - O
stability NOUN - O
in ADP - O
24 CD - B-CARDINAL
h. NOUN - O

-DOCSTART- -X- - O

The DET - O
rice NOUN - O
seedling NOUN - O
blight ADJ - O
fungus NOUN - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
harbors NOUN - O
endosymbiotic ADJ - O
bacteria NOUN - O
( PUNCT - O
Burkholderia NNP - B-NORP
rhizoxinica NOUN - O
) PUNCT - O
that ADJ - O
produce VERB - O
the DET - O
virulence NOUN - O
factor NOUN - O
rhizoxin NOUN - O
and CCONJ - O
control VERB - O
host NOUN - O
development NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fungal ADJ - O
isolates NOUN - O
belonged VERB - O
to PART - O
genera VERB - O
Aspergillus NNP - B-PERSON
, PUNCT - O
Emericella NNP - B-PERSON
, PUNCT - O
Rhizopus NNP - B-MEDICINE
, PUNCT - O
Actinomucor NNP - B-ORG
and CCONJ - O
Apophysomyces NNPS - B-GPE
with ADP - O
two CD - B-CARDINAL
undescribed ADJ - O
species NOUN - O
. PUNCT - O

Aspergillus ADV - O
variecolor NOUN - O
, PUNCT - O
Aspergillus PROPN - O
quadrilinieatus NOUN - O
, PUNCT - O
Aspergillus PROPN - O
tubingensis NOUN - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
, PUNCT - O
Actinomucor NNP - B-ORG
elegans NOUN - O
and CCONJ - O
Apophysomyces PROPN - O
variabilis NOUN - O
were VERB - O
firstly ADV - O
detected VERB - O
in ADP - O
all DET - O
sea NOUN - O
turtle NOUN - O
nests NOUN - O
within ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
lipase NOUN - O
gene NOUN - O
proRCL PRON - O
from ADP - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
var NOUN - O
. PUNCT - O

chinensis NOUN - O
( PUNCT - O
also ADV - O
Rhizopus NNP - B-MEDICINE
chinensis NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
work NOUN - O
was VERB - O
designed VERB - O
to PART - O
investigate VERB - O
the DET - O
phenolic NOUN - O
profiles NOUN - O
, PUNCT - O
DNA NOUN - O
damage NOUN - O
protection NOUN - O
and CCONJ - O
antiÃ¢ÂÂinflammatory ADJ - O
effects NOUN - O
of ADP - O
Tartary PROPN - O
buckwheat NOUN - O
fermented VERB - O
by ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
40469 NUM - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
40503 CD - B-DATE
and CCONJ - O
Rhizopus NNP - B-MEDICINE
oligosporus NOUN - O
3152 NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Starter NOUN - O
microbiota NOUN - O
were VERB - O
dominated VERB - O
by ADP - O
the DET - O
Rhizopus NNP - B-MEDICINE
genus NOUN - O
in ADP - O
SZ5 NNP - B-GPE
, , - I-GPE
LS6 NNP - B-GPE
, PUNCT - O
NN8 NNP - B-GPE
, PUNCT - O
QD9 NNP - B-ORG
, PUNCT - O
DZ10 NNP - B-ORG
and CCONJ - O
DZ11 PROPN - O
, PUNCT - O
indicating VERB - O
its ADJ - O
important ADJ - O
role NOUN - O
in ADP - O
starch ADJ - O
hydrolysis NOUN - O
during ADP - O
CSRW PROPN - O
brewing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
residues NOUN - O
located VERB - O
at ADP - O
the DET - O
crevice NOUN - O
- PUNCT - O
like ADJ - O
binding NOUN - O
site NOUN - O
of ADP - O
four CD - B-CARDINAL
representative ADJ - O
lipases NOUN - O
including VERB - O
Thermomyces NNPS - B-NORP
lanuginosus NOUN - O
lipases NOUN - O
( PUNCT - O
TLL NNP - B-ORG
and CCONJ - O
Lip NNP - B-ORG
) PUNCT - O
, PUNCT - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
lipase NOUN - O
( PUNCT - O
ROL NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
Rhizomucor NNP - B-ORG
miehei NOUN - O
lipase NOUN - O
( PUNCT - O
RML NNP - B-ORG
) PUNCT - O
were VERB - O
identified VERB - O
through ADP - O
structural ADJ - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
diagnosis NOUN - O
of ADP - O
pulmonary ADJ - O
mucormycosis NOUN - O
( PUNCT - O
Rhizopus NNP - B-MEDICINE
microsporus NOUN - O
) PUNCT - O
was VERB - O
made VERB - O
based VERB - O
on ADP - O
microbiology NOUN - O
results NOUN - O
from ADP - O
pleural ADJ - O
aspirate NOUN - O
, PUNCT - O
and CCONJ - O
patient NOUN - O
was VERB - O
treated VERB - O
with ADP - O
intravenous ADJ - O
antifungals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

N NNP - B-ORG
- HYPH - I-ORG
Glycosylation NNP - I-ORG
Engineering NNP - I-ORG
to TO - I-ORG
Improve VERB - O
the DET - O
Constitutive PROPN - O
Expression PROPN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Lipase PROPN - O
in ADP - O
Komagataella NNP - B-ORG
phaffii NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Finally ADV - O
, PUNCT - O
by ADP - O
using VERB - O
the DET - O
fluorescent ADJ - O
probe NOUN - O
, PUNCT - O
two CD - B-CARDINAL
target NOUN - O
fungi NOUN - O
were VERB - O
isolated VERB - O
and CCONJ - O
identified VERB - O
to PART - O
be VERB - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
and CCONJ - O
Mucor NNP - B-ORG
circinelloides NOUN - O
by ADP - O
molecular ADJ - O
analysis NOUN - O
, PUNCT - O
and CCONJ - O
they PRON - O
exhibited VERB - O
a DET - O
robust ADJ - O
capability NOUN - O
for ADP - O
regio- NOUN - O
and CCONJ - O
stereospecific ADJ - O
O NOUN - O
- PUNCT - O
glycosylation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Moreover ADV - O
, PUNCT - O
changes NOUN - O
in ADP - O
the DET - O
functional ADJ - O
levels NOUN - O
were VERB - O
monitored VERB - O
, PUNCT - O
and CCONJ - O
metaproteomic ADJ - O
analysis NOUN - O
revealed VERB - O
that ADP - O
most ADJ - O
of ADP - O
the DET - O
proteins NOUN - O
were VERB - O
mainly ADV - O
expressed VERB - O
by ADP - O
members NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
, , - I-ORG
Penicillium NNP - I-ORG
and CC - I-ORG
Geotrichum NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Rhino NN - B-NORP
- PUNCT - O
orbital ADJ - O
skin NOUN - O
necrosis NOUN - O
with ADP - O
positive ADJ - O
samples NOUN - O
for ADP - O
the DET - O
organism NOUN - O
Rhizopus NNP - B-MEDICINE
on ADP - O
eventual ADJ - O
orbital ADJ - O
exenteration NOUN - O
revealed VERB - O
angioinvasive ADJ - O
fungal ADJ - O
infection NOUN - O
, PUNCT - O
mucormycosis NOUN - O
, PUNCT - O
to PART - O
be VERB - O
the DET - O
cause NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
alcoholysis NOUN - O
of ADP - O
triolein NOUN - O
was VERB - O
used VERB - O
to PART - O
explore VERB - O
the DET - O
specific ADJ - O
features NOUN - O
of ADP - O
a DET - O
recombinant ADJ - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
lipase NOUN - O
( PUNCT - O
rROL PROPN - O
) PUNCT - O
for ADP - O
biodiesel NOUN - O
synthesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exploring VERB - O
substrate NOUN - O
specificities NOUN - O
of ADP - O
a DET - O
recombinant ADJ - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
lipase NOUN - O
in ADP - O
biodiesel NOUN - O
synthesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
glutaraldehyde NOUN - O
, PUNCT - O
as ADP - O
the DET - O
coupling VERB - O
agent NOUN - O
, PUNCT - O
the DET - O
lipase NOUN - O
from ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
was VERB - O
successfully ADV - O
immobilized VERB - O
onto ADP - O
the DET - O
amino NOUN - O
- PUNCT - O
functionalized ADJ - O
magnetic ADJ - O
nanoparticles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Biochemical ADJ - O
characterization NOUN - O
and CCONJ - O
stability NOUN - O
assessment NOUN - O
of ADP - O
Rhizopus NNP - B-MEDICINE
oryzae NOUN - O
lipase VERB - O
covalently ADV - O
immobilized VERB - O
on ADP - O
amino NOUN - O
- PUNCT - O
functionalized ADJ - O
magnetic ADJ - O
nanoparticles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
increase VERB - O
the DET - O
titer NOUN - O
of ADP - O
FA NNP - B-ORG
production NOUN - O
by ADP - O
using VERB - O
an DET - O
improved ADJ - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
WHT5 PROPN - O
, PUNCT - O
which ADJ - O
was VERB - O
domesticated VERB - O
to PART - O
obtain VERB - O
a DET - O
furfural ADJ - O
- PUNCT - O
resistant ADJ - O
strain NOUN - O
in ADP - O
corncob NOUN - O
hydrolytes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Production NOUN - O
of ADP - O
Fumaric PROPN - O
Acid PROPN - O
by ADP - O
Bioconversion PROPN - O
of ADP - O
Corncob NNP - B-ORG
Hydrolytes NNPS - I-ORG
Using VBG - I-ORG
an DET - O
Improved PROPN - O
Rhizopus NNP - B-MEDICINE
oryzae VERB - O
Strain NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
medicated VERB - O
rats NOUN - O
experienced VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
adiposity NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
development NOUN - O
of ADP - O
hyperglycemia NOUN - O
, PUNCT - O
hyperinsulinemia NOUN - O
, PUNCT - O
insulin NOUN - O
resistance NOUN - O
, PUNCT - O
hyperlipidemia NOUN - O
, PUNCT - O
and CCONJ - O
inflammation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
a DET - O
commonly ADV - O
prescribed VERB - O
antipsychotic NOUN - O
available ADJ - O
as ADP - O
oral ADJ - O
and CCONJ - O
long ADV - O
- PUNCT - O
acting VERB - O
injectable ADJ - O
( PUNCT - O
LAI NNP - B-ORG
) PUNCT - O
formulations NOUN - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
concentrations NOUN - O
and CCONJ - O
doses NOUN - O
from ADP - O
8,288 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
21,378 CD - B-QUANTITY
measurements NNS - I-QUANTITY
) PUNCT - O
were VERB - O
included VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic NOUN - O
widely ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
schizophrenia NOUN - O
and CCONJ - O
bipolar ADJ - O
disorder NOUN - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
significantly ADV - O
increased VERB - O
fasting NOUN - O
plasma NOUN - O
insulin NOUN - O
concentration NOUN - O
, PUNCT - O
the DET - O
index NOUN - O
of ADP - O
the DET - O
homeostasis NOUN - O
model NOUN - O
assessment NOUN - O
of ADP - O
insulin NOUN - O
resistance NOUN - O
( PUNCT - O
HOMA NNP - B-ORG
- HYPH - I-ORG
IR NNP - I-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
hepatic ADJ - O
triglyceride NOUN - O
and CCONJ - O
fatty ADJ - O
droplet NOUN - O
accumulation NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
Versus NNP - I-GPE
Placebo NNP - I-GPE
in ADP - O
Adult NNP - B-ORG
Outpatients NNS - I-ORG
With IN - I-ORG
Anorexia NNP - I-ORG
Nervosa NN - I-ORG
: PUNCT - O
A DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
( PUNCT - O
mean VERB - O
[ PUNCT - O
standard ADJ - O
deviation NOUN - O
] PUNCT - O
duration NOUN - O
â¯ SPACE - O
= PUNCT - O
â¯ SPACE - O
12.3 CD - B-CARDINAL
[ PUNCT - O
7.6 CD - B-DATE
] -RRB- - I-DATE
weeks NNS - I-DATE
) PUNCT - O
was VERB - O
associated VERB - O
with ADP - O
a DET - O
significant ADJ - O
decrease NOUN - O
in ADP - O
blood NOUN - O
ghrelin NOUN - O
levels NOUN - O
with ADP - O
a DET - O
medium ADJ - O
effect NOUN - O
size NOUN - O
( PUNCT - O
SMD PROPN - O
â¯ SPACE - O
= SYM - O
â¯ SPACE - O
-0.48 PUNCT - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
-0.88 PROPN - O
to ADP - O
-0.08 PRON - O
, PUNCT - O
p X - O
â¯ SPACE - O
= SYM - O
â¯ SPACE - O
0.018 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
drug NOUN - O
from ADP - O
the DET - O
thienobenzodiazepine NOUN - O
family NOUN - O
which ADJ - O
displays VERB - O
efficacy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
and CCONJ - O
related ADJ - O
psychoses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
and CCONJ - O
droperidol ADJ - O
lead NOUN - O
to ADP - O
lower ADJ - O
rates NOUN - O
of ADP - O
rescue NOUN - O
sedation NOUN - O
at ADP - O
1 CD - B-CARDINAL
Â  SPACE - O
h NOUN - O
and CCONJ - O
overall ADV - O
, PUNCT - O
compared VERB - O
with ADP - O
haloperidol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics PROPN - O
and CCONJ - O
Short ADJ - O
- PUNCT - O
term NOUN - O
Safety NNP - B-PRODUCT
of IN - I-PRODUCT
ALKS NNP - I-PRODUCT
3831 CD - I-PRODUCT
, PUNCT - O
a DET - O
Fixed NNP - B-ORG
- PUNCT - O
dose NOUN - O
Combination NNP - B-ORG
of IN - I-ORG
Olanzapine NNP - I-MEDICINE
and CCONJ - O
Samidorphan NNP - B-GPE
, PUNCT - O
in ADP - O
Adult NNP - B-LOC
Subjects NNPS - I-LOC
with ADP - O
Schizophrenia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Late ADJ - O
- PUNCT - O
Onset NOUN - O
Cholestatic PROPN - O
Liver PROPN - O
Injury PROPN - O
During ADP - O
Combination PROPN - O
Treatment PROPN - O
With ADP - O
Chlorpromazine PROPN - O
and CCONJ - O
Olanzapine NNP - B-MEDICINE

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
appears VERB - O
effective ADJ - O
and CCONJ - O
tolerable ADJ - O
as ADP - O
an DET - O
antiemetic NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
leucopaenia NOUN - O
and CCONJ - O
thrombocytopaenia NOUN - O
in ADP - O
an DET - O
elderly ADJ - O
patient NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
report NOUN - O
and CCONJ - O
review NOUN - O
of ADP - O
the DET - O
evidence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Agranulocytosis NOUN - O
- PUNCT - O
Protective ADJ - O
Olanzapine NN - B-MEDICINE
- PUNCT - O
Loaded VERB - O
Nanostructured PROPN - O
Lipid PROPN - O
Carriers PROPN - O
Engineered VERB - O
for ADP - O
CNS NNP - B-ORG
Delivery PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Resurgence NOUN - O
of ADP - O
Eating PROPN - O
Disorders PROPN - O
with ADP - O
Olanzapine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
, PUNCT - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
drug NOUN - O
, PUNCT - O
has VERB - O
therapeutic ADJ - O
effects NOUN - O
for ADP - O
schizophrenia NOUN - O
. PUNCT - O

CONCLUSION NOUN - O
: PUNCT - O
Olanzapine NNP - B-MEDICINE
may VERB - O
exacerbate VERB - O
atherosclerosis NOUN - O
by ADP - O
deregulating VERB - O
hepatic ADJ - O
lipid NOUN - O
metabolism NOUN - O
and CCONJ - O
worsening VERB - O
hyperlipidemia ADJ - O
and CCONJ - O
aortic ADJ - O
inflammation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
monotherapy NOUN - O
increased VERB - O
BMI NN - B-ORG
and CCONJ - O
circulating NOUN - O
insulin NOUN - O
, PUNCT - O
triglyceride NOUN - O
, PUNCT - O
and CCONJ - O
MIF NNP - B-ORG
concentrations NOUN - O
in ADP - O
drug NOUN - O
- PUNCT - O
naive ADJ - O
schizophrenic ADJ - O
patients NOUN - O
with ADP - O
normal ADJ - O
MIF NN - B-ORG
expression NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
in ADP - O
genotypic ADJ - O
low ADJ - O
MIF NNP - B-ORG
expressers NOUN - O
. PUNCT - O

Olanzapine JJ - B-MEDICINE
administration NOUN - O
to ADP - O
mice NOUN - O
increased VERB - O
their ADJ - O
food NOUN - O
intake NOUN - O
and CCONJ - O
hypothalamic ADJ - O
MIF NN - B-ORG
expression NOUN - O
, PUNCT - O
which ADJ - O
led VERB - O
to ADP - O
activation NOUN - O
of ADP - O
the DET - O
appetite NOUN - O
- PUNCT - O
related VERB - O
AMP PROPN - O
- PUNCT - O
activated VERB - O
protein NOUN - O
kinase NOUN - O
and CCONJ - O
Agouti NNP - B-ORG
- PUNCT - O
related VERB - O
protein NOUN - O
pathway NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
also ADV - O
upregulated VERB - O
MIF NNP - B-ORG
expression NOUN - O
in ADP - O
adipose NOUN - O
tissue NOUN - O
, PUNCT - O
which ADJ - O
reduced VERB - O
lipolysis NOUN - O
and CCONJ - O
increased VERB - O
lipogenic NOUN - O
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
as ADP - O
an DET - O
antiemetic ADJ - O
represents VERB - O
a DET - O
new ADJ - O
use NOUN - O
of ADP - O
an DET - O
antipsychotic ADJ - O
drug NOUN - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
versus ADP - O
placebo NOUN - O
/ SYM - O
no INTJ - O
treatmentPrimary PROPN - O
outcomesOlanzapine NOUN - O
probably ADV - O
doubles VERB - O
the DET - O
likelihood NOUN - O
of ADP - O
no DET - O
nausea NOUN - O
or CCONJ - O
vomiting NOUN - O
during ADP - O
chemotherapy NOUN - O
from ADP - O
25 CD - B-PERCENT
% NN - I-PERCENT
to IN - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
( PUNCT - O
risk NOUN - O
ratio NOUN - O
( PUNCT - O
RR NNP - B-ORG
) PUNCT - O
1.98 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
1.59 CD - B-CARDINAL
to ADP - O
2.47 CD - B-CARDINAL
; PUNCT - O
561 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
3 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
solid ADJ - O
tumours NOUN - O
; PUNCT - O
HEC PROPN - O
or CCONJ - O
MEC NNP - B-ORG
therapy NOUN - O
; PUNCT - O
moderate ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
when ADV - O
added VERB - O
to ADP - O
standard ADJ - O
therapy NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
may VERB - O
increase VERB - O
other ADJ - O
adverse ADJ - O
events NOUN - O
( PUNCT - O
RR NOUN - O
1.71 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.99 CD - B-CARDINAL
to ADP - O
2.96 CD - B-CARDINAL
; PUNCT - O
332 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
4 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
and CCONJ - O
probably ADV - O
increases VERB - O
somnolence NOUN - O
and CCONJ - O
fatigue NOUN - O
compared VERB - O
to ADP - O
no DET - O
treatment NOUN - O
or CCONJ - O
placebo NOUN - O
( PUNCT - O
RR PROPN - O
2.33 CD - B-MONEY
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.30 CD - B-CARDINAL
to ADP - O
4.18 CD - B-CARDINAL
; PUNCT - O
anticipated VERB - O
absolute ADJ - O
risk NOUN - O
8.2 CD - B-PERCENT
% NN - I-PERCENT
more ADJ - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.9 NUM - O
to ADP - O
18.8 CD - B-CARDINAL
; PUNCT - O
464 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
5 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
moderate ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
probably ADV - O
does VERB - O
not ADV - O
affect VERB - O
all DET - O
- PUNCT - O
cause NOUN - O
attrition NOUN - O
( PUNCT - O
RR NOUN - O
0.99 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.57 CD - B-CARDINAL
to ADP - O
1.73 CD - B-CARDINAL
; PUNCT - O
943 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
8 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
IÂ² NOUN - O
= SYM - O
0 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
probably ADV - O
reduces VERB - O
delayed VERB - O
nausea NOUN - O
( PUNCT - O
RR NOUN - O
1.71 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.40 NUM - O
to ADP - O
2.09 CD - B-CARDINAL
; PUNCT - O
585 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
3 CD - B-CARDINAL
studies NOUN - O
) PUNCT - O
and CCONJ - O
vomiting VERB - O
( PUNCT - O
RR PROPN - O
1.28 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.14 CD - B-CARDINAL
to ADP - O
1.42 CD - B-CARDINAL
; PUNCT - O
702 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
5 CD - B-CARDINAL
studies).Subgroup NUM - O
analysis NOUN - O
: PUNCT - O
5 CD - B-CARDINAL
mg X - O
versus ADP - O
10 CD - B-CARDINAL
mgPlanned VERB - O
subgroup NOUN - O
analyses NOUN - O
found VERB - O
that ADP - O
it PRON - O
is VERB - O
unclear ADJ - O
if ADP - O
5 CD - B-CARDINAL
mg PRON - O
is VERB - O
as ADV - O
effective ADJ - O
an DET - O
antiemetic ADJ - O
as ADP - O
10 CD - B-QUANTITY
mg NN - I-QUANTITY
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Fatal PROPN - O
Ketoacidosis PROPN - O
with ADP - O
Pneumomediastinum NNP - B-GPE
and CCONJ - O
Subcutaneous PROPN - O
Emphysema PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
can VERB - O
lower VERB - O
seizure NOUN - O
threshold NOUN - O
and CCONJ - O
induce VERB - O
epileptiform NOUN - O
discharges NOUN - O
. PUNCT - O

However ADV - O
in ADP - O
patients NOUN - O
on ADP - O
Olanzapine NNP - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
a DET - O
primary ADJ - O
psychiatric ADJ - O
disorder NOUN - O
, PUNCT - O
clinical ADJ - O
seizure NOUN - O
is VERB - O
a DET - O
rare ADJ - O
occurrence NOUN - O
. PUNCT - O

We PRON - O
report VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
23-year CD - B-CARDINAL
- PUNCT - O
old ADJ - O
female NOUN - O
with ADP - O
mild ADJ - O
mental ADJ - O
retardation NOUN - O
with ADP - O
schizophrenia NOUN - O
with ADP - O
obsessive ADJ - O
compulsive ADJ - O
disorder NOUN - O
who NOUN - O
developed VERB - O
new ADJ - O
- PUNCT - O
onset NOUN - O
generalized VERB - O
tonic NOUN - O
- PUNCT - O
clonic NOUN - O
seizure NOUN - O
probably ADV - O
due ADP - O
to ADP - O
Olanzapine NNP - B-MEDICINE
. PUNCT - O

The DET - O
seizure NOUN - O
risk NOUN - O
associated VERB - O
with ADP - O
Olanzapine NNP - B-MEDICINE
was VERB - O
reviewed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
drug NOUN - O
most ADV - O
commonly ADV - O
used VERB - O
to PART - O
manage VERB - O
psychoses NOUN - O
and CCONJ - O
symptoms NOUN - O
of ADP - O
irritability NOUN - O
and CCONJ - O
aggressive ADJ - O
behavior NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
Acute ADJ - O
Voluntary PROPN - O
Poisoning PROPN - O
With ADP - O
a DET - O
Huge PROPN - O
Dose PROPN - O
of ADP - O
Oxcarbazepine PROPN - O
and CCONJ - O
Olanzapine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
: PUNCT - O
a DET - O
full ADJ - O
and CCONJ - O
potent ADJ - O
agonist NOUN - O
at ADP - O
the DET - O
hM4D(Gi NOUN - O
) PUNCT - O
DREADD VERB - O
amenable ADJ - O
to ADP - O
clinical ADJ - O
translation NOUN - O
of ADP - O
chemogenetics NOUN - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
with ADP - O
ondansetron NOUN - O
and CCONJ - O
dexamethasone NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
cisplatin NOUN - O
- PUNCT - O
based VERB - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
lung NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Brain NOUN - O
Sub PROPN - O
/ SYM - O
Region PROPN - O
- PUNCT - O
Specific PROPN - O
Effects PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
on ADP - O
c PROPN - O
- PUNCT - O
Fos PROPN - O
Expression PROPN - O
of ADP - O
Chronically PROPN - O
Socially PROPN - O
Isolated PROPN - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
OLZ PROPN - O
) PUNCT - O
, PUNCT - O
a DET - O
drug NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
schizophrenia NOUN - O
, PUNCT - O
presents VERB - O
in ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
60 CD - I-CARDINAL
crystal NOUN - O
forms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bioequivalence NOUN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
Given VERB - O
in ADP - O
Combination NNP - B-ORG
With ADP - O
Samidorphan PROPN - O
as ADP - O
a DET - O
Bilayer PROPN - O
Tablet PROPN - O
( PUNCT - O
ALKS NNP - B-PRODUCT
3831 CD - I-PRODUCT
) PUNCT - O

Compared VERB - O
With ADP - O
Olanzapine NN - B-MEDICINE
- PUNCT - O
Alone ADJ - O
Tablets NOUN - O
: PUNCT - O
Results NOUN - O
From ADP - O
a DET - O
Randomized VERB - O
, PUNCT - O
Crossover PROPN - O
Relative PROPN - O
Bioavailability PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DET - O
Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
for ADP - O
Anorexia NNP - B-PERSON
Nervosa NNP - I-PERSON
in ADP - O
Children NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Adolescents NNPS - B-PERSON
; PUNCT - O
http://clinicaltrials.gov X - O
; PUNCT - O
NCT01184443 NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DET - O
Effectiveness PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Olanzapine NNP - B-MEDICINE
as ADP - O
an DET - O
Adjunctive PROPN - O
Treatment PROPN - O
for ADP - O
Anorexia PROPN - O
Nervosa PROPN - O
in ADP - O
Adolescents NNS - B-GPE
: PUNCT - O
An DET - O
Open PROPN - O
- PUNCT - O
Label PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Craving PROPN - O
Behavior NNP - B-PERSON
from ADP - O
Opioid PROPN - O
Addiction PROPN - O
Controlled VERB - O
with ADP - O
Olanzapine NNP - B-MEDICINE
in ADP - O
an DET - O
Advanced PROPN - O
Cancer PROPN - O
Patient PROPN - O
: PUNCT - O
A DT - B-WORK_OF_ART
Case NNP - I-WORK_OF_ART
Report NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
and CCONJ - O
acts NOUN - O
on ADP - O
multiple ADJ - O
receptors NOUN - O
and CCONJ - O
may VERB - O
help VERB - O
in ADP - O
treating VERB - O
vomiting VERB - O
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
advanced ADJ - O
malignancy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Refractory NNP - I-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NNP - I-ORG
in ADP - O
Palliative PROPN - O
Care PROPN - O
Settings PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
1)Olanzapine CD - B-CARDINAL
group NOUN - O
had VERB - O
higher ADJ - O
incidence NOUN - O
of ADP - O
somnolence NOUN - O
than ADP - O
risperidone NOUN - O
group NOUN - O
( PUNCT - O
OR=1.49 PROPN - O
, PUNCT - O

( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
Olanzapine NNP - B-MEDICINE
group NOUN - O
had VERB - O
higher ADJ - O
incidence NOUN - O
of ADP - O
extrapyramidal ADJ - O
symptoms NOUN - O
than ADP - O
quetiapine NOUN - O
group NOUN - O
( PUNCT - O
OR=11.10 NNP - B-ORG
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
[ PUNCT - O
3.35 CD - B-CARDINAL
- SYM - O
36.75 NUM - O
] PUNCT - O
, PUNCT - O
P<0.000 PROPN - O
1 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
while ADP - O
for ADP - O
somnolence NOUN - O
, PUNCT - O
sleep NOUN - O
disturbances NOUN - O
, PUNCT - O
constipation NOUN - O
, PUNCT - O
agitation NOUN - O
, PUNCT - O
weight NOUN - O
gain NOUN - O
, PUNCT - O
dizziness NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
significant ADJ - O
difference NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
treatment NOUN - O
increased VERB - O
the DET - O
food NOUN - O
intake NOUN - O
of ADP - O
the DET - O
mice NOUN - O
as ADV - O
well ADV - O
as ADP - O
their ADJ - O
body NOUN - O
weight NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine RB - B-MEDICINE
long ADV - O
- PUNCT - O
acting VERB - O
injection NOUN - O
( PUNCT - O
LAI NNP - B-ORG
; PUNCT - O
adjusted VERB - O
hazard NOUN - O
ratio NOUN - O
= SYM - O
0.46 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
= SYM - O
0.36 CD - B-CARDINAL
- SYM - O
0.61 NUM - O
) PUNCT - O
, PUNCT - O
clozapine NOUN - O
( PUNCT - O
0.51 CD - B-CARDINAL
, PUNCT - O
0.49 CD - B-CARDINAL
- SYM - O
0.53 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
paliperidone ADJ - O
LAI NNP - B-ORG
( PUNCT - O
0.51 CD - B-CARDINAL
, PUNCT - O
0.40 CD - B-CARDINAL
- SYM - O
0.66 NUM - O
) PUNCT - O
were VERB - O
associated VERB - O
with ADP - O
the DET - O
lowest ADJ - O
risk NOUN - O
of ADP - O
psychiatric ADJ - O
rehospitalization NOUN - O
in ADP - O
the DET - O
prevalent ADJ - O
cohort NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine RB - B-MEDICINE
, PUNCT - O
quetiapine NOUN - O
, PUNCT - O
risperidone NOUN - O
, PUNCT - O
aripiprazole NOUN - O
, PUNCT - O
and CCONJ - O
ziprasidone NOUN - O
are VERB - O
the DET - O
only ADJ - O
AAs NOUN - O
with ADP - O
published VERB - O
studies NOUN - O
in ADP - O
pain NOUN - O
management NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
shows VERB - O
preliminary ADJ - O
and CCONJ - O
consistent ADJ - O
efficacy NOUN - O
in ADP - O
fibromyalgia NOUN - O
and CCONJ - O
headache NOUN - O
/ SYM - O
migraine NOUN - O
, PUNCT - O
although ADP - O
only RB - B-CARDINAL
1 CD - I-CARDINAL
study NOUN - O
was VERB - O
a DET - O
randomized VERB - O
controlled VERB - O
trial NOUN - O
with ADP - O
level NOUN - O

-DOCSTART- -X- - O

A DET - O
Systematic PROPN - O
Review PROPN - O
of ADP - O
Atypical PROPN - O
Antipsychotics PROPN - O
in ADP - O
Chronic PROPN - O
Pain PROPN - O
Management NOUN - O
: PUNCT - O
Olanzapine NN - B-MEDICINE
Demonstrates VERB - O
Potential PROPN - O
in ADP - O
Central PROPN - O
Sensitization PROPN - O
, PUNCT - O
Fibromyalgia NNP - B-ORG
, PUNCT - O
and CCONJ - O
Headache NNP - B-ORG
/ SYM - I-ORG
Migraine NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
as ADP - O
antiemetic ADJ - O
drug NOUN - O
in ADP - O
oncology NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
study NOUN - O
in ADP - O
non ADJ - O
- NOUN - O
responders NOUN - O
to ADP - O
standard ADJ - O
antiemetic ADJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
long ADV - O
- PUNCT - O
acting VERB - O
injections NOUN - O
( PUNCT - O
OLAIs NOUN - O
) PUNCT - O
are VERB - O
often ADV - O
prescribed VERB - O
to ADP - O
patients NOUN - O
with ADP - O
severe ADJ - O
schizophrenia NOUN - O
who NOUN - O
are VERB - O
typically ADV - O
excluded VERB - O
from ADP - O
randomized VERB - O
clinical ADJ - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
was VERB - O
administered VERB - O
daily RB - B-DATE
by ADP - O
intraperitoneal ADJ - O
route NOUN - O
, PUNCT - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
CART NNP - B-ORG
( PUNCT - O
intracerebroventricular ADJ - O
) PUNCT - O
for ADP - O
a DT - B-DATE
period NN - I-DATE
of IN - I-DATE
two CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Olanzapine NN - B-MEDICINE
administration NOUN - O
resulted VERB - O
in ADP - O
a DET - O
significant ADJ - O
reduction NOUN - O
in ADP - O
CART NNP - B-ORG
immunoreactivity NOUN - O
in ADP - O
the DET - O
hypothalamic ADJ - O
arcuate NOUN - O
, PUNCT - O
paraventricular ADJ - O
, PUNCT - O
dorsomedial ADJ - O
and CCONJ - O
ventromedial ADJ - O
nuclei NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Development PROPN - O
of ADP - O
Quasi PROPN - O
- PUNCT - O
isothermal PROPN - O
Calorimetry PROPN - O
for ADP - O
the DET - O
Measurement PROPN - O
of ADP - O
Drug PROPN - O
- PUNCT - O
Polymer PROPN - O
Miscibility PROPN - O
and CCONJ - O
Crystallization PROPN - O
Kinetics PROPN - O
: PUNCT - O
Olanzapine NN - B-MEDICINE
- PUNCT - O
Loaded VERB - O
PLGA NOUN - O
Microparticles PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
administration NOUN - O
largely ADV - O
prevented VERB - O
these DET - O
changes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
used VERB - O
atypical ADJ - O
antipsychotic ADJ - O
medication NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
schizophrenia NOUN - O
and CCONJ - O
is VERB - O
often ADV - O
associated VERB - O
with ADP - O
serious ADJ - O
metabolic NOUN - O
abnormalities NOUN - O
including VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
impaired VERB - O
glucose NOUN - O
tolerance NOUN - O
. PUNCT - O

Olanzapine NN - B-MEDICINE
challenge NOUN - O
induced VERB - O
remarkably ADV - O
increased VERB - O
body NOUN - O
weight NOUN - O
, PUNCT - O
fasting VERB - O
insulin NOUN - O
, PUNCT - O
homeostasis NOUN - O
model NOUN - O
assessment NOUN - O
- PUNCT - O
insulin NOUN - O
resistance NOUN - O
index NOUN - O
, PUNCT - O
and CCONJ - O
TCF7L2 JJ - B-NORP
protein NOUN - O
expression NOUN - O
in ADP - O
liver NOUN - O
, PUNCT - O
skeletal ADJ - O
muscle NOUN - O
, PUNCT - O
and CCONJ - O
adipose NOUN - O
tissues NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Wnt PROPN - O
Signaling PROPN - O
Pathway PROPN - O
Effector PROPN - O
TCF7L2 VERB - O
Mediates PROPN - O
Olanzapine NNP - B-MEDICINE
- PUNCT - O
Induced VERB - O
Weight PROPN - O
Gain PROPN - O
and CCONJ - O
Insulin NNP - B-ORG
Resistance NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
had VERB - O
the DET - O
highest ADJ - O
reported VERB - O
proportion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Economic PROPN - O
Evaluation PROPN - O
of ADP - O
Midazolam NNP - B-ORG
- HYPH - I-ORG
Droperidol NNP - I-ORG
Combination NNP - I-ORG
, PUNCT - O
Versus NNP - B-PERSON
Droperidol NNP - I-PERSON
or CCONJ - O
Olanzapine NNP - B-MEDICINE
for ADP - O
the DET - O
Management PROPN - O
of ADP - O
Acute PROPN - O
Agitation PROPN - O
in ADP - O
the DET - O
Emergency PROPN - O
Department PROPN - O
: PUNCT - O
A NNP - B-ORG
Within NNP - I-ORG
- HYPH - I-ORG
Trial NNP - I-ORG
Analysis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
an DET - O
effective ADJ - O
antipsychotic ADJ - O
drug NOUN - O
but CCONJ - O
since ADP - O
it PRON - O
causes VERB - O
significant ADJ - O
weight NOUN - O
gain NOUN - O
, PUNCT - O
it PRON - O
is VERB - O
not ADV - O
well ADV - O
tolerated VERB - O
by ADP - O
psychosis NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
may VERB - O
be VERB - O
cataractogenic ADJ - O
via ADP - O
its ADJ - O
action NOUN - O
as ADP - O
a DET - O
serotonin ADJ - O
antagonist NOUN - O
, PUNCT - O
which ADJ - O
results VERB - O
in ADP - O
reduced ADJ - O
glucose NOUN - O
responsiveness NOUN - O
of ADP - O
the DET - O
pancreatic ADJ - O
beta NOUN - O
- PUNCT - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
case NOUN - O
of ADP - O
typical ADJ - O
antipsychotics NOUN - O
such ADJ - O
as ADP - O
Haloperidol NNP - B-PRODUCT
, PUNCT - O
the DET - O
c NOUN - O
- PUNCT - O
fos NOUN - O
active ADJ - O
cells NOUN - O
were VERB - O
predominantly ADV - O
found VERB - O
in ADP - O
the DET - O
striatum NOUN - O
, PUNCT - O
whereas ADP - O
in ADP - O
case NOUN - O
of ADP - O
the DET - O
atypical ADJ - O
antipsychotics NOUN - O
( PUNCT - O
Clozapine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Olanzapine NNP - I-MEDICINE
) PUNCT - O
, PUNCT - O
c NOUN - O
- PUNCT - O
fos NOUN - O
- PUNCT - O
induced VERB - O
cells NOUN - O
were VERB - O
more ADV - O
numerous ADJ - O
in ADP - O
the DET - O
cortical ADJ - O
regions NOUN - O
, PUNCT - O
e.g. ADJ - O
, PUNCT - O
orbital ADJ - O
cortex NOUN - O
, PUNCT - O
piriform NOUN - O
cortex NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
combined VERB - O
with ADP - O
palonosetron NOUN - O
and CCONJ - O
dexamethasone NOUN - O
significantly ADV - O
improved VERB - O
QOL NNP - B-ORG
and CCONJ - O
vomiting NOUN - O
control NOUN - O
among ADP - O
previously ADV - O
untreated ADJ - O
patients NOUN - O
receiving VERB - O
MEC NNP - B-ORG
, PUNCT - O
although ADP - O
the DET - O
efficacy NOUN - O
was VERB - O
limited VERB - O
to ADP - O
the DET - O
reduction NOUN - O
of ADP - O
the DET - O
frequency NOUN - O
of ADP - O
CINV NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
uM NOUN - O
) PUNCT - O
treatment NOUN - O
caused VERB - O
a DET - O
significant ADJ - O
increase NOUN - O
in ADP - O
IL-6 PROPN - O
while ADP - O
aripiprazole NOUN - O
( PUNCT - O
20 CD - B-CARDINAL
uM INTJ - O
) PUNCT - O
significantly ADV - O
decreased VERB - O
IL-10 PROPN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
uM INTJ - O
) PUNCT - O
and CCONJ - O
aripiprazole NOUN - O
( PUNCT - O
20 CD - B-CARDINAL
uM INTJ - O
) PUNCT - O
increased VERB - O
BDNF ADJ - O
expression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cyclosporine NNP - B-ORG
- HYPH - I-ORG
Olanzapine NNP - I-MEDICINE
Drug NNP - I-ORG
- HYPH - I-ORG
Drug NNP - I-ORG
Interaction NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
Treatment PROPN - O
with ADP - O
Olanzapine NNP - B-MEDICINE
of ADP - O
Psychosis PROPN - O
in ADP - O
Dentatorubral PROPN - O
- PUNCT - O
pallidoluysian PROPN - O
Atrophy PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
prescribed VERB - O
antipsychotic ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
clozapine ADJ - O
, PUNCT - O
reduced VERB - O
correct ADJ - O
entries NOUN - O
in ADP - O
the DET - O
T PROPN - O
- PUNCT - O
Maze PROPN - O
test NOUN - O
( PUNCT - O
p VERB - O
< X - O
0.05 CD - B-CARDINAL
versus ADP - O
Control NNP - B-ORG
) PUNCT - O
while ADP - O
liraglutide NOUN - O
prevented VERB - O
this DET - O
deficit NOUN - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
significantly ADV - O
decreased VERB - O
voluntary ADJ - O
locomotor NOUN - O
activity NOUN - O
and CCONJ - O
liraglutide NOUN - O
co NOUN - O
- NOUN - O
treatment NOUN - O
partially ADV - O
reversed VERB - O
this DET - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
describe VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
70-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
Alzheimer PROPN - O
patient NOUN - O
who NOUN - O
was VERB - O
taking VERB - O
olanzapine NN - B-MEDICINE
for ADP - O
2 CD - B-DATE
months NNS - I-DATE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
depression NOUN - O
, PUNCT - O
and CCONJ - O
developed VERB - O
peripheral ADJ - O
eosinophilia NOUN - O
and CCONJ - O
bilateral ADJ - O
EPE.Olanzapine PROPN - O
- PUNCT - O
induced VERB - O
peripheral ADJ - O
eosinophilia NOUN - O
and CCONJ - O
eosinophilic ADJ - O
pleural ADJ - O
effusion NOUN - O
was VERB - O
diagnosed VERB - O
. PUNCT - O

Olanzapine NNP - B-MEDICINE
was VERB - O
discontinued VERB - O
, PUNCT - O
and CCONJ - O
repeated VERB - O
drainage NOUN - O
of ADP - O
fluid NOUN - O
from ADP - O
the DET - O
pleural ADJ - O
cavity NOUN - O
was VERB - O
performed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
peripheral ADJ - O
eosinophilia NOUN - O
and CCONJ - O
eosinophilic ADJ - O
pleural ADJ - O
effusion NOUN - O
: PUNCT - O
A DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Olanzapine NNP - B-MEDICINE
associated VERB - O
palpebral ADJ - O
edema NOUN - O
: PUNCT - O
An DET - O
uncommon ADJ - O
adverse ADJ - O
effect NOUN - O
of ADP - O
a DET - O
commonly ADV - O
prescribed VERB - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Within ADP - O
this DET - O
paper NOUN - O
, PUNCT - O
OTF PROPN - O
strips VERB - O
containing VERB - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
were VERB - O
prepared VERB - O
using VERB - O
the DET - O
solvent NOUN - O
casting NOUN - O
method NOUN - O
and CCONJ - O
then ADV - O
characterised VERB - O
to PART - O
ensure VERB - O
the DET - O
method NOUN - O
could VERB - O
conform VERB - O
to ADP - O
acceptable ADJ - O
levels NOUN - O
of ADP - O
uniformity NOUN - O
, PUNCT - O
the DET - O
mean ADJ - O
( PUNCT - O
SD NNP - B-ORG
) PUNCT - O
diclofenac NN - B-MEDICINE
sodium NN - I-MEDICINE
content NOUN - O
was VERB - O
25.43(1.39 NUM - O
) PUNCT - O
mg VERB - O
, PUNCT - O
range VERB - O
22.84 CD - B-CARDINAL
- SYM - O
27.44 NUM - O
mg PRON - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
an DET - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
Method PROPN - O
for ADP - O
the DT - B-ORG
Quantification NNP - I-ORG
of IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
in ADP - O
Dairy NNP - B-GPE
Cow NNP - B-PERSON
Plasma NNP - I-PERSON
and CCONJ - O
its ADJ - O
Application NNP - B-ORG
in IN - I-ORG
Pharmacokinetics NNP - I-ORG
Studies NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Assessment NOUN - O
of ADP - O
the DET - O
Effect PROPN - O
of ADP - O
3 NUM - O
% NOUN - O
Diclofenac NN - B-MEDICINE
Sodium NNP - I-MEDICINE
on ADP - O
Photodamaged PROPN - O
Skin PROPN - O
by ADP - O
Means PROPN - O
of ADP - O
Reflectance PROPN - O
Confocal PROPN - O
Microscopy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
Treatment NNP - I-ORG
Ameliorates NNP - I-ORG
Extrapancreatic NNP - I-ORG
Organ NNP - I-ORG
Injuries NNPS - I-ORG
in ADP - O
a DET - O
Murine NNP - B-NORP
Model NNP - B-NORP
of ADP - O
Acute NNP - B-ORG
Pancreatitis NNP - I-ORG
Induced VBN - I-ORG
by ADP - O
Caerulein NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Lycopene NNP - B-PERSON
Attenuates VBZ - I-PERSON
Tulathromycin NNP - I-PERSON
and CCONJ - O
Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Cardiotoxicity NNP - I-ORG
in ADP - O
Mice NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Investigation PROPN - O
an DET - O
Antifungal PROPN - O
Activity PROPN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
against ADP - O
Hyphae NNP - B-ORG
Formation NNP - I-ORG
in ADP - O
Aspergillus PROPN - O
Fumigatus PROPN - O
with ADP - O
Attention PROPN - O
to ADP - O
the DET - O
Expression PROPN - O
of ADP - O
Ef-1 PROPN - O
Gene PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
on ADP - O
Tilmicosin NNP - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Acute NNP - I-ORG
Cardiotoxicity NNP - I-ORG
in ADP - O
Rats PROPN - O
( PUNCT - O
Tilmicosin PROPN - O
and CCONJ - O
Diclofenac PROPN - O
Cardiotoxicity PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
on ADP - O
the DT - B-ORG
Visible JJ - I-ORG
- HYPH - I-ORG
Light NN - I-ORG
Photocatalytic NNP - I-ORG
Performance NNP - I-ORG
and CC - I-ORG
Degradation NNP - I-ORG
Mechanism NNP - I-ORG
of IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
under ADP - O
the DET - O
System PROPN - O
of ADP - O
Hetero PROPN - O
- PUNCT - O
Structural PROPN - O
CuBiâOâ/AgâPOâ PROPN - O
with ADP - O
HâOâ. NOUN - O

-DOCSTART- -X- - O

Application PROPN - O
of ADP - O
Quality PROPN - O
by ADP - O
Design PROPN - O
: PUNCT - O
Development NOUN - O
to ADP - O
Manufacturing NN - B-ORG
of IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
Topical PROPN - O
Gel PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Corrigendum VERB - O
to ADP - O
" PUNCT - O
Topical NNP - B-WORK_OF_ART
Colchicine NNP - I-WORK_OF_ART
Gel NNP - I-WORK_OF_ART
versus IN - I-WORK_OF_ART
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Gel PROPN - O
for ADP - O
the DT - B-WORK_OF_ART
Treatment NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Actinic NNP - I-WORK_OF_ART
Keratoses NNPS - I-WORK_OF_ART
: PUNCT - O
A DET - O
Randomized VERB - O
, PUNCT - O
Double ADJ - O
- PUNCT - O
Blind ADJ - O
Study PROPN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Low ADJ - O
- PUNCT - O
Dose NOUN - O
Intramuscular PROPN - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
for ADP - O
Fever NNP - B-ORG
Control NNP - I-ORG
in ADP - O
Acute PROPN - O
Brain PROPN - O
Injury PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Effectiveness NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Diclofenac NNP - I-WORK_OF_ART
Sodium NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Treatment NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Mondor NNP - I-WORK_OF_ART
's POS - I-WORK_OF_ART
Disease NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Breast NNP - I-WORK_OF_ART
: : - I-WORK_OF_ART
The DT - I-WORK_OF_ART
Topical NNP - I-WORK_OF_ART
Patch NNP - I-WORK_OF_ART

-DOCSTART- -X- - O

Design PROPN - O
and CCONJ - O
Evaluation PROPN - O
of ADP - O
Topical PROPN - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Gel PROPN - O
Using VERB - O
Hot PROPN - O
Melt PROPN - O
Extrusion PROPN - O
Technology PROPN - O
as ADP - O
a DET - O
Continuous PROPN - O
Manufacturing PROPN - O
Process PROPN - O
with ADP - O
Kolliphor PROPN - O
Â® PUNCT - O
P407 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Bromelain NNP - B-GPE
along ADV - O
with ADP - O
Trypsin NNP - B-GPE
, PUNCT - O
Rutoside NNP - B-ORG
Trihydrate NNP - I-ORG
Enzymes NNP - I-ORG
and CCONJ - O
Diclofenac NNP - B-ORG
Sodium NNP - I-ORG
Combination NNP - I-ORG
Therapy NNP - I-ORG
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
TMJ NNP - B-ORG
Osteoarthritis PROPN - O
- PUNCT - O
A PROPN - O
Randomised VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Topical ADJ - O
Fluorometholone NOUN - O
Versus PROPN - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
in ADP - O
Cases NNP - B-ORG
With IN - I-ORG
Perennial NNP - I-ORG
Allergic NNP - I-ORG
Conjunctivitis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pre ADJ - O
- ADJ - O
Emptive ADJ - O
Effect PROPN - O
of ADP - O
Dexamethasone PROPN - O
and CCONJ - O
Diclofenac NNP - B-MEDICINE
Sodium NN - I-MEDICINE

-DOCSTART- -X- - O

Composition NN - B-ORG
and CC - I-ORG
Concentration NN - I-ORG
Gradient NNP - I-ORG
Induced VBN - I-ORG
Structural NNP - I-ORG
Transition NNP - I-ORG
from ADP - O
Micelles NOUN - O
to ADP - O
Vesicles NNP - B-GPE
in ADP - O
the DET - O
Mixed PROPN - O
System PROPN - O
of ADP - O
Ionic PROPN - O
Liquid PROPN - O
- PUNCT - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
on ADP - O
BMP NNP - B-ORG
- HYPH - I-ORG
induced VBN - I-ORG
Inflammation NNP - I-ORG
in ADP - O
a DET - O
Rodent PROPN - O
Model NNP - B-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Design PROPN - O
and CCONJ - O
Evaluation PROPN - O
of ADP - O
Ocular PROPN - O
Controlled PROPN - O
Delivery PROPN - O
System PROPN - O
for ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Stability PROPN - O
of ADP - O
Atenolol PROPN - O
, PUNCT - O
Clonazepam PROPN - O
, PUNCT - O
Dexamethasone NNP - B-ORG
, , - I-ORG
Diclofenac NNP - B-PERSON
Sodium NNP - I-PERSON
, PUNCT - O
Diltiazem NNP - B-PERSON
, PUNCT - O
Enalapril NNP - B-PERSON
Maleate NNP - I-PERSON
, PUNCT - O
Ketoprofen NNP - B-PERSON
, PUNCT - O
Lamotrigine PROPN - O
, PUNCT - O
Penicillamine PROPN - O
- PUNCT - O
D PROPN - O
, PUNCT - O
and CCONJ - O
Thiamine NNP - B-NORP
in ADP - O
SyrSpend PROPN - O
SF PROPN - O
PH4 PROPN - O
Oral PROPN - O
Suspensions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetic ADJ - O
Study PROPN - O
of ADP - O
a DET - O
Diclofenac NN - B-MEDICINE
Sodium NNP - I-MEDICINE
Capsule PROPN - O
Filled VERB - O
with ADP - O
Enteric PROPN - O
- PUNCT - O
coated VERB - O
Pellets PROPN - O
in ADP - O
Healthy PROPN - O
Chinese ADJ - O
Volunteers PROPN - O
by ADP - O
Liquid JJ - B-PERSON
Chromatography NNP - I-PERSON
- HYPH - I-PERSON
electrospray NN - I-PERSON
Ionization NNP - B-ORG
- PUNCT - O
tandem PROPN - O
Mass NNP - B-ORG
Spectrometry NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Preparation PROPN - O
and CCONJ - O
Evaluation PROPN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Tablet PROPN - O
Coated VERB - O
with ADP - O
Polyelectrolyte PROPN - O
Multilayer PROPN - O
Film PROPN - O
Using VERB - O
Hypromellose PROPN - O
Acetate PROPN - O
Succinate PROPN - O
and CCONJ - O
Polymethacrylates NNPS - B-LOC
for ADP - O
pH PROPN - O
- PUNCT - O
Dependent PROPN - O
, PUNCT - O
Modified NNP - B-ORG
Release NNP - I-ORG
Drug NNP - I-ORG
Delivery NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial NNP - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
on ADP - O
Enterococcus NNP - B-ORG
faecalis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Evaluation PROPN - O
of ADP - O
Diclofenac NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Loaded ADJ - O
- PUNCT - O
N PROPN - O
- PUNCT - O
Trimethyl NOUN - O
Chitosan PROPN - O
Nanoparticles PROPN - O
for ADP - O
Ophthalmic PROPN - O
Use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bioavailability PROPN - O
and CCONJ - O
Tolerability NNP - B-ORG
of IN - I-ORG
Topical NNP - I-ORG
and CC - I-ORG
Oral NNP - I-ORG
Diclofenac NNP - I-ORG
Sodium NNP - I-ORG
Administration NNP - I-ORG
in ADP - O
Healthy PROPN - O
Ponies NOUN - O

-DOCSTART- -X- - O

THE DET - O
ADJUNCTIVE PROPN - O
LAMICTAL NNP - B-MEDICINE
( PUNCT - O
LAMOTRIGINE PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Antimicrobial PROPN - O
Efficacy NOUN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
- PUNCT - O
eluting VERB - O
Polymer NNP - B-ORG
Nanofibers NNPS - I-ORG
against ADP - O
Multispecies NNP - B-ORG
Biofilm NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Clindamycin PROPN - O
- PUNCT - O
modified VERB - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Nanofibers PROPN - O
: PUNCT - O
A DET - O
Stain NOUN - O
- PUNCT - O
free ADJ - O
Antimicrobial NNP - B-ORG
Intracanal NNP - I-ORG
Drug NNP - I-ORG
Delivery NNP - I-ORG
System NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Mineral NOUN - O
Trioxide NOUN - O
Aggregate PROPN - O
, PUNCT - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
, PUNCT - O
and CCONJ - O
Abscess NOUN - O
Remedy PROPN - O
on ADP - O
Apical PROPN - O
Development PROPN - O
of ADP - O
Vital PROPN - O
Young ADJ - O
Permanent PROPN - O
Teeth PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NN - B-ORG
of IN - I-ORG
Residual NNP - I-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
, PUNCT - O
Propolis NNP - B-GPE
and CCONJ - O
Calcium NNP - B-ORG
Hydroxide NNP - I-ORG
on IN - I-ORG
Root PROPN - O
Canal PROPN - O
Walls PROPN - O
in ADP - O
Natural PROPN - O
Open PROPN - O
Apex PROPN - O
Teeth NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
XP NNP - B-PERSON
- HYPH - I-PERSON
Endo NNP - I-PERSON
Finisher NNP - I-PERSON
in ADP - O
the DET - O
Removal PROPN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
from ADP - O
Immature NNP - B-ORG
Root NNP - I-ORG
Canals NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparative PROPN - O
Evaluation NOUN - O
of ADP - O
Anti PROPN - O
Microbial ADJ - O
effects NOUN - O
of ADP - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
and CCONJ - O
Amox NNP - B-PERSON
and CCONJ - O
its ADJ - O
derivatives NOUN - O
against ADP - O
E. NNP - B-PERSON
Faecalis NNP - I-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Calcium NOUN - O
hydroxide NOUN - O
Ca(OH)2 PROPN - O
, PUNCT - O
Group PROPN - O
3 CD - B-CARDINAL
: SYM - O
2 CD - B-PERCENT
% NN - I-PERCENT
CHX NOUN - O
gel NOUN - O
, PUNCT - O
Group NOUN - O
4 CD - B-CARDINAL
: PUNCT - O
Triple JJ - B-MEDICINE
Antibiotic JJ - I-MEDICINE
Paste PROPN - O
( PUNCT - O
TAP NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
, PUNCT - O
Moxifloxacin NNP - B-ORG
, PUNCT - O
Calcium NNP - B-PERSON
Hydroxide NNP - I-PERSON
And CCONJ - O
2 CD - B-PERCENT
% NN - I-PERCENT
Chlorhexidine PROPN - O
Gel PROPN - O

-DOCSTART- -X- - O

Minimum PROPN - O
Intracanal PROPN - O
Dressing PROPN - O
Time PROPN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
to PART - O
Eliminate VB - B-ORG
Enterococcus NNP - I-ORG
Faecalis NNPS - I-ORG
( PUNCT - O
ATCC PROPN - O
29212 CD - B-DATE
) PUNCT - O
and CCONJ - O
Determination NNP - B-ORG
of IN - I-ORG
Minimum NNP - I-ORG
Inhibitory NNP - I-ORG
Concentration NNP - I-ORG
and CCONJ - O
Minimum PROPN - O
Bactericidal PROPN - O
Concentration PROPN - O
: PUNCT - O
An PROPN - O
Ex PROPN - O
Vivo PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial PROPN - O
and CCONJ - O
Cytotoxic PROPN - O
Activity PROPN - O
of ADP - O
Cinnamomum NNP - B-ORG
zeylanicum NOUN - O
, PUNCT - O
Calcium NNP - B-PERSON
Hydroxide NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
as IN - I-ORG
Root PROPN - O
Canal PROPN - O
Dressing PROPN - O
Materials PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
Antimicrobial PROPN - O
Effects NOUN - O
of ADP - O
Different PROPN - O
Concentrations PROPN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
on ADP - O
Mature PROPN - O
Biofilm PROPN - O
of ADP - O
Enterococcus PROPN - O
faecalis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Comparison NN - B-ORG
between ADP - O
the DET - O
Antimicrobial PROPN - O
Effects PROPN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
and CCONJ - O
Calcium NNP - B-PERSON
Hydroxide NNP - I-PERSON
Against PROPN - O
Entrococcus NNP - B-PERSON
Faecalis NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Use PROPN - O
of ADP - O
Antidotes PROPN - O
for ADP - O
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
Extravasation PROPN - O
: PUNCT - O
An DET - O
Experimental ADJ - O
Study PROPN - O
in ADP - O
Mice NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Calcium NNP - B-ORG
Chloride NNP - I-ORG
and CCONJ - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
in ADP - O
Neonatal NNP - B-ORG
Parenteral NNP - I-ORG
Nutrition NNP - I-ORG
Solutions NNPS - I-ORG
with ADP - O
Added NNP - B-ORG
Cysteine NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Calcium NNP - B-ORG
Chloride NNP - I-ORG
and CCONJ - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
in ADP - O
Neonatal NNP - B-ORG
Parenteral NNP - I-ORG
Nutrition NNP - I-ORG
Solutions NNPS - I-ORG
without ADP - O
Cysteine NNP - B-ORG
: : - I-ORG
Compatibility NNP - I-ORG
Studies NNPS - I-ORG

-DOCSTART- -X- - O

Aluminum NNP - B-ORG
and CCONJ - O
Phthalates NNPS - B-ORG
in IN - I-ORG
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
: PUNCT - O
Contribution NOUN - O
From ADP - O
Glass NNP - B-PERSON
and CCONJ - O
Plastic PROPN - O
Packaging PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Injectable NNP - B-ORG
Alginate NNP - I-ORG
Hydrogel NNP - I-ORG
Cross NNP - I-ORG
- HYPH - I-ORG
Linked VBN - I-ORG
by ADP - O
Calcium NNP - B-PERSON
Gluconate NNP - I-PERSON
- HYPH - I-PERSON
Loaded JJ - I-PERSON
Porous ADJ - O
Microspheres NOUN - O
for ADP - O
Cartilage PROPN - O
Tissue PROPN - O
Engineering PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Managed VBN - B-NORP
With ADP - O
Hyperinsulinemia NNP - B-ORG
/ SYM - I-ORG
Euglycemia NNP - I-ORG
Therapy NNP - I-ORG
Supplemented VBN - I-ORG
With IN - I-ORG
Calcium NNP - I-ORG
Gluconate NNP - I-ORG
, PUNCT - O
Intravenous PROPN - O
Glucagon PROPN - O
and CCONJ - O
Other PROPN - O
Vasopressor PROPN - O
Support PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
Double PROPN - O
- PUNCT - O
Blind PROPN - O
, PUNCT - O
Active NNP - B-ORG
- HYPH - I-ORG
Controlled VBN - I-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
of IN - I-ORG
Sodium NNP - I-ORG
Bicarbonate NNP - I-ORG
and CC - I-ORG
Calcium NNP - B-MEDICINE
Gluconate NNP - I-MEDICINE
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Bilateral NNP - I-ORG
Osteoarthritis NNP - I-ORG
of IN - I-ORG
the DT - I-ORG
Knee NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Topical PROPN - O
Application PROPN - O
of ADP - O
Polycal PROPN - O
( PUNCT - O
a DET - O
2:98 NUM - O
( PUNCT - O
g NOUN - O
/ SYM - O
g NOUN - O
) PUNCT - O
Mixture NOUN - O
of ADP - O
Polycan PROPN - O
and CCONJ - O
Calcium NNP - B-PERSON
Gluconate NNP - I-PERSON
) PUNCT - O
on ADP - O
Experimental NNP - B-ORG
Periodontitis NNP - I-ORG
and CCONJ - O
Alveolar PROPN - O
Bone PROPN - O
Loss PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Physical NNP - B-ORG
Compatibility NNP - I-ORG
of IN - I-ORG
Sodium NNP - I-ORG
Glycerophosphate NNP - I-ORG
and CC - I-ORG
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
in IN - I-ORG
Pediatric NNP - I-ORG
Parenteral NNP - I-ORG
Nutrition NNP - I-ORG
Solutions NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
objective NOUN - O
was VERB - O
to PART - O
reduce VERB - O
aluminum NOUN - O
( PUNCT - O
Al NNP - B-PERSON
) PUNCT - O
in ADP - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
US NNP - B-ORG
Pharmacopeia NNP - I-ORG
( PUNCT - O
USP NNP - B-ORG
) PUNCT - O
used VERB - O
in ADP - O
the DET - O
preparation NOUN - O
of ADP - O
parenteral ADJ - O
nutrition NOUN - O
( PUNCT - O
PN PROPN - O
) PUNCT - O
solutions NOUN - O
. PUNCT - O

A DET - O
flow NOUN - O
- PUNCT - O
through PART - O
filter NOUN - O
containing VERB - O
an DET - O
immobilized ADJ - O
chelator NOUN - O
that ADJ - O
complexes VERB - O
Al NNP - B-ORG
from IN - I-ORG
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
USP NNP - B-ORG
as ADP - O
it PRON - O
flows VERB - O
through ADP - O
the DET - O
filter NOUN - O
was VERB - O
designed VERB - O
, PUNCT - O
refined VERB - O
by ADP - O
design NOUN - O
modifications NOUN - O
, PUNCT - O
and CCONJ - O
extensively ADV - O
tested VERB - O
. PUNCT - O

When ADV - O
a DET - O
small ADJ - O
- PUNCT - O
volume NOUN - O
parenteral ADJ - O
vial NOUN - O
containing VERB - O
100 CD - B-CARDINAL
mL NOUN - O
of ADP - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
USP NNP - B-ORG
is VERB - O
connected VERB - O
on ADP - O
the DET - O
inlet NOUN - O
side NOUN - O
of ADP - O
the DET - O
filter NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
outlet ADJ - O
side NOUN - O
is VERB - O
connected VERB - O
to ADP - O
an DET - O
evacuated VERB - O
receiving VERB - O
vial NOUN - O
, PUNCT - O
the DET - O
filtered ADJ - O
solution NOUN - O
is VERB - O
drawn VERB - O
into ADP - O
the DET - O
receiving VERB - O
vial NOUN - O
. PUNCT - O

This DET - O
constitutes VERB - O
a DET - O
complete ADJ - O
system NOUN - O
to PART - O
remove VERB - O
Al NNP - B-ORG
from IN - I-ORG
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
USP.The PROPN - O
extent NOUN - O
of ADP - O
Al NNP - B-PERSON
removal NOUN - O
is VERB - O
flow NOUN - O
rate NOUN - O
dependent ADJ - O
. PUNCT - O

Given VERB - O
that ADP - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O
USP NNP - B-ORG
provides VERB - O
85 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
Al PROPN - O
in ADP - O
neonatal ADJ - O
PN PROPN - O
solutions NOUN - O
, PUNCT - O
removal NOUN - O
of ADP - O
85 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
Al PROPN - O
from ADP - O
this DET - O
source NOUN - O
was VERB - O
calculated VERB - O
to PART - O
reduce VERB - O
Al NNP - B-PERSON
delivered VERB - O
to ADP - O
most ADJ - O
neonates NOUN - O
to PART - O
< X - O
5 CD - B-TIME
mcg NN - I-TIME
/ SYM - I-TIME
kg NN - I-TIME
/ SYM - O
day NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Filtration PROPN - O
System PROPN - O
That ADJ - O
Greatly ADV - O
Reduces VERB - O
Aluminum PROPN - O
in ADP - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
Injection NNP - I-ORG
, PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Calcium NNP - B-ORG
Gluconate NNP - I-ORG
, PUNCT - O
a DET - O
Water PROPN - O
Soluble PROPN - O
Calcium PROPN - O
Salt PROPN - O
on ADP - O
the DET - O
Collagen PROPN - O
- PUNCT - O
Induced VERB - O
DBA/1J PROPN - O
Mice NOUN - O
Rheumatoid PROPN - O
Arthritis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
could VERB - O
also ADV - O
significantly ADV - O
reduce VERB - O
the DET - O
frequency NOUN - O
requirement NOUN - O
of ADP - O
fentanyl NOUN - O
at ADP - O
20 CD - B-QUANTITY
min NN - I-QUANTITY
( PUNCT - O
Dose NN - B-PERSON
3 CD - B-CARDINAL
) PUNCT - O
in ADP - O
general ADJ - O
anesthesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
no DET - O
RCT PROPN - O
had VERB - O
ever ADV - O
compared VERB - O
the DET - O
use NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
alone ADJ - O
with ADP - O
combined ADJ - O
vasoconstrictors NOUN - O
and CCONJ - O
fluid NOUN - O
preload NOUN - O
, PUNCT - O
so CCONJ - O
, PUNCT - O
this DET - O
randomised VERB - O
controlled VERB - O
trial NOUN - O
has VERB - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
the DET - O
use NOUN - O
of ADP - O
ondansetron NN - B-MEDICINE
alone ADV - O
compared VERB - O
to ADP - O
the DET - O
combined VERB - O
use NOUN - O
of ADP - O
fluid ADJ - O
preload NOUN - O
and CCONJ - O
vasoconstrictors NOUN - O
to PART - O
decrease VERB - O
the DET - O
incidence NOUN - O
of ADP - O
spinal ADJ - O
hypotension NOUN - O
. PUNCT - O

The DET - O
preemptive ADJ - O
use NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
alone ADV - O
versus ADP - O
combined VERB - O
vasoconstrictors NOUN - O
with ADP - O
fluid ADJ - O
preload NOUN - O
significantly ADV - O
reduces VERB - O
the DET - O
incidence NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
spinal ADJ - O
hypotension NOUN - O
( PUNCT - O
PSH NOUN - O
) PUNCT - O
with ADP - O
no DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
both DET - O
regimens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

BACKGROUND::Ondansetron NN - B-CARDINAL
is VERB - O
a DET - O
serotonin ADJ - O
3 CD - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
widely ADV - O
used VERB - O
to PART - O
prevent VERB - O
nausea NOUN - O
and CCONJ - O
vomiting VERB - O
in ADP - O
pregnancy NOUN - O
and CCONJ - O
in ADP - O
patients NOUN - O
receiving VERB - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
- PUNCT - O
a DET - O
promising ADJ - O
adjunctive ADJ - O
treatment NOUN - O
for ADP - O
persistent ADJ - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
with ADP - O
dexamethasone ADJ - O
premedication NOUN - O
was VERB - O
more ADV - O
effective ADJ - O
in ADP - O
controlling VERB - O
PONV PROPN - O
after ADP - O
orthognathic ADJ - O
surgery NOUN - O
compared VERB - O
to PART - O
clonidine VERB - O
with ADP - O
dexamethasone NOUN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gaining VERB - O
Insight PROPN - O
Into ADP - O
Ondansetron NNP - B-MEDICINE
Safety PROPN - O
in ADP - O
Early ADJ - O
Pregnancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aromatherapy NN - B-ORG
Versus NNP - I-ORG
Oral NNP - I-ORG
Ondansetron NNP - I-MEDICINE
for ADP - O
Antiemetic PROPN - O
Therapy PROPN - O

-DOCSTART- -X- - O

PharmGKB NOUN - O
summary NOUN - O
: PUNCT - O
Ondansetron NN - B-MEDICINE
and CCONJ - O
tropisetron ADJ - O
pathways NOUN - O
, PUNCT - O
pharmacokinetics NOUN - O
and CCONJ - O
pharmacodynamics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Comparison NNP - B-ORG
of IN - I-ORG
Metoclopramide NNP - I-ORG
and CCONJ - O
Ondansetron NNP - B-MEDICINE
Efficacy NNP - I-PERSON
for ADP - O
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NN - I-ORG

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
alone ADV - O
did VERB - O
not ADV - O
affect VERB - O
hippocampal ADJ - O
network NOUN - O
oscillations NOUN - O
. PUNCT - O

Ondansetron NNP - B-MEDICINE
( PUNCT - O
0.3 CD - B-MONEY
â¯ _SP - I-MONEY
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
i.v PROPN - O
. PUNCT - O
) PUNCT - O
potentiated VERB - O
theta NOUN - O
and CCONJ - O
gamma NOUN - O
responses NOUN - O
to ADP - O
0.2 CD - B-CARDINAL
â¯ SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
donepezil VERB - O
and CCONJ - O
prolonged VERB - O
theta NOUN - O
and CCONJ - O
gamma NOUN - O
responses NOUN - O
to ADP - O
0.3 CD - B-CARDINAL
â¯ SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
donepezil NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Assessment NOUN - O
and CCONJ - O
comparison NOUN - O
of ADP - O
the DET - O
effectiveness NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
and CCONJ - O
Promethazine NNP - B-GPE
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
acute ADJ - O
peripheral ADJ - O
vertigo NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
170 CD - B-CARDINAL
eligible ADJ - O
patients NOUN - O
were VERB - O
randomly ADV - O
allocated VERB - O
to ADP - O
groups NOUN - O
A NOUN - O
: PUNCT - O
received VERB - O
intramuscular ADJ - O
( PUNCT - O
IM NNP - B-ORG
) PUNCT - O
promethazine NOUN - O
; PUNCT - O
and CCONJ - O
B NOUN - O
: PUNCT - O
received VERB - O
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
Ondansetron NNP - B-MEDICINE
, PUNCT - O
using VERB - O
quadripartite ADJ - O
blocks NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
or CCONJ - O
promethazine NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
caused VERB - O
concentration NOUN - O
dependent ADJ - O
bradycardia NOUN - O
and CCONJ - O
arrhythmia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
and CCONJ - O
teratogenicity NOUN - O
in ADP - O
rats NOUN - O

-DOCSTART- -X- - O

Oral PROPN - O
Ondansetron NNP - B-MEDICINE
Offers VERB - O
Effective PROPN - O
Antidiarrheal PROPN - O
Activity PROPN - O
for ADP - O
Carcinoid PROPN - O
Syndrome PROPN - O
Refractory PROPN - O
to ADP - O
Somatostatin NNP - B-PERSON
Analogs NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

CONCLUSIONS NOUN - O
: PUNCT - O
Ondansetron NNP - B-MEDICINE
0.05 NUM - O
Â  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
or CCONJ - O
0.1 CD - B-MONEY
Â  _SP - I-MONEY
mg NOUN - O
/ SYM - O
kg NOUN - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
use NOUN - O
was VERB - O
not ADV - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
for ADP - O
most ADJ - O
of ADP - O
the DET - O
51 CD - B-CARDINAL
defect NOUN - O
groups NOUN - O
analyzed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
for ADP - O
Treatment PROPN - O
of ADP - O
Nausea PROPN - O
and CCONJ - O
Vomiting PROPN - O
of ADP - O
Pregnancy PROPN - O
and CCONJ - O
the DT - B-ORG
Risk NNP - I-ORG
of IN - I-ORG
Specific NNP - I-ORG
Birth NNP - I-ORG
Defects NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Assessing VERB - O
the DET - O
Efficacy PROPN - O
of ADP - O
Maropitant NNP - B-GPE
Versus NNP - I-GPE
Ondansetron NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Dogs NNP - I-ORG
with IN - I-ORG
Parvoviral NNP - I-ORG
Enteritis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
appears VERB - O
to PART - O
have VERB - O
benefit NOUN - O
in ADP - O
improving VERB - O
positive ADJ - O
symptoms NOUN - O
of ADP - O
psychosis NOUN - O
in ADP - O
individuals NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
, PUNCT - O
but CCONJ - O
RCTs NOUN - O
are VERB - O
needed VERB - O
before ADP - O
routine ADJ - O
use NOUN - O
is VERB - O
recommended VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Oral PROPN - O
Ondansetron NNP - B-MEDICINE
to ADP - O
Reduce VERB - O
Intravenous PROPN - O
Fluid PROPN - O
Rehydration PROPN - O
: PUNCT - O
Context NNP - B-PERSON
Matters NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
and CCONJ - O
dexamethasone NOUN - O
were VERB - O
continued VERB - O
for ADP - O
48 CD - B-TIME
hours NNS - I-TIME
after ADP - O
completion NOUN - O
of ADP - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
( PUNCT - O
0.01 CD - B-CARDINAL
â¯ SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
0.1 CD - B-CARDINAL
â¯ SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
or CCONJ - O
vehicle NOUN - O
) PUNCT - O
was VERB - O
administered VERB - O
before ADP - O
the DT - B-TIME
hour NN - I-TIME
of ADP - O
consumption NOUN - O
in ADP - O
the DET - O
initial ADJ - O
phase NOUN - O
( PUNCT - O
days NOUN - O
1 NUM - O
, PUNCT - O
2 CD - B-CARDINAL
, PUNCT - O
3 CD - B-DATE
) PUNCT - O
of ADP - O
the DET - O
procedure NOUN - O
, PUNCT - O
and CCONJ - O
after ADP - O
prolonged ADJ - O
alcohol NOUN - O
intake NOUN - O
( PUNCT - O
days NOUN - O
11 CD - B-DATE
, PUNCT - O
12 CD - B-DATE
, PUNCT - O
13 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
8 CD - B-CARDINAL
mg NOUN - O
and CCONJ - O
4 CD - B-CARDINAL
mg PRON - O
with ADP - O
normal ADJ - O
saline NOUN - O
against ADP - O
post ADJ - O
- ADJ - O
operative ADJ - O
headache NOUN - O
and CCONJ - O
nausea NOUN - O
/ SYM - O
vomiting NOUN - O
after ADP - O
spinal ADJ - O
anesthesia NOUN - O
: PUNCT - O
a DET - O
randomized VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
emetic ADJ - O
efficacy NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
with ADP - O
18792A PROPN - O
> X - O
G NOUN - O
polymorphism NOUN - O
in ADP - O
a DET - O
drug NOUN - O
target NOUN - O
gene NOUN - O
5-HT3B NUM - O
in ADP - O
Pakistani JJ - B-NORP
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
hydrochloride NOUN - O
( PUNCT - O
OND NNP - B-ORG
) PUNCT - O
is VERB - O
commonly ADV - O
used VERB - O
for ADP - O
management NOUN - O
of ADP - O
postoperative NOUN - O
and CCONJ - O
chemotherapeutic NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal JJ - B-ORG
Delivery NN - I-ORG
of ADP - O
Ondansetron NNP - B-MEDICINE
Hydrochloride NNP - I-ORG
via IN - I-ORG
Bilosomal NNP - I-ORG
Systems NNPS - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Ondansetron NN - B-MEDICINE
at ADP - O
nanomolar ADJ - O
concentrations NOUN - O
inhibited VERB - O
WT NNP - B-ORG
and CCONJ - O
p NOUN - O
. PUNCT - O

Ondansetron RB - B-MEDICINE
- PUNCT - O
induced VERB - O
IKAS PROPN - O
inhibition NOUN - O
was VERB - O
also ADV - O
demonstrated VERB - O
in ADP - O
Langendorff NNP - B-GPE
- PUNCT - O
perfused VERB - O
murine NOUN - O
hearts NOUN - O
. PUNCT - O

Ondansetron NN - B-MEDICINE
at ADP - O
therapeutic ADJ - O
( PUNCT - O
i.e. X - O
, PUNCT - O
nanomolar ADJ - O
) PUNCT - O
concentrations NOUN - O
is VERB - O
a DET - O
potent ADJ - O
IKAS PROPN - O
blocker NOUN - O
. PUNCT - O

Ondansetron NNP - B-MEDICINE
may VERB - O
be VERB - O
useful ADJ - O
in ADP - O
controlling VERB - O
arrhythmias NOUN - O
in ADP - O
which ADJ - O
increased VERB - O
SK NNP - B-GPE
current NOUN - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
was VERB - O
discontinued VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
improves VERB - O
the DET - O
success NOUN - O
of ADP - O
oral ADJ - O
rehydration NOUN - O
in ADP - O
children NOUN - O
with ADP - O
gastroenteritis NOUN - O
. PUNCT - O

Ondansetron NNP - B-MEDICINE
does VERB - O
not ADV - O
affect VERB - O
the DET - O
QTc NOUN - O
of ADP - O
pediatric ADJ - O
patients NOUN - O
receiving VERB - O
the DET - O
medication NOUN - O
for ADP - O
nausea NOUN - O
, PUNCT - O
vomiting NOUN - O
, PUNCT - O
or CCONJ - O
inability NOUN - O
to PART - O
take VERB - O
fluids NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Intravenous PROPN - O
Ondansetron NNP - B-MEDICINE
on ADP - O
the DT - B-ORG
QT NNP - I-ORG
Interval NNP - I-ORG
of IN - I-ORG
Patients NNPS - I-ORG
' POS - I-ORG
Electrocardiograms NNS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
hydrochloride NOUN - O
OR=7.12 PROPN - O
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
, PUNCT - O
1.59 CD - B-CARDINAL
â NOUN - O
31.9 CD - B-CARDINAL
) PUNCT - O
resulted VERB - O
in ADP - O
the DET - O
highest ADJ - O
odds NOUN - O
of ADP - O
pneumothorax NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
may VERB - O
be VERB - O
prescribed VERB - O
if ADP - O
needed VERB - O
to PART - O
prevent VERB - O
vomiting NOUN - O
and CCONJ - O
improve VERB - O
tolerance NOUN - O
of ADP - O
oral ADJ - O
rehydration NOUN - O
solutions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sodium NOUN - O
Dodecyl PROPN - O
Sulphate PROPN - O
- PUNCT - O
Supported PROPN - O
Nanocomposite PROPN - O
as ADP - O
Drug PROPN - O
Carrier PROPN - O
System PROPN - O
for ADP - O
Controlled PROPN - O
Delivery PROPN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
minskar ADJ - O
krÃ¤kningar NOUN - O
hos PRON - O
barn NOUN - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
formulate VERB - O
suitable ADJ - O
nanovesicles NOUN - O
( PUNCT - O
NVs NOUN - O
) PUNCT - O
for ADP - O
transdermal ADJ - O
delivery NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
. PUNCT - O

A DET - O
23 CD - B-CARDINAL
full ADJ - O
factorial ADJ - O
design NOUN - O
was VERB - O
used VERB - O
to PART - O
enable VERB - O
testing VERB - O
transfersomes NOUN - O
, PUNCT - O
ethosomes NOUN - O
, PUNCT - O
and CCONJ - O
transethosomes VERB - O
of ADP - O
Ondansetron NNP - B-MEDICINE
simultaneously ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
decrease VERB - O
admission NOUN - O
rates NOUN - O
and CCONJ - O
the DET - O
need NOUN - O
for ADP - O
intravenous ADJ - O
fluids NOUN - O
among ADP - O
pediatric ADJ - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
patients NOUN - O
with ADP - O
acute ADJ - O
gastroenteritis NOUN - O
, PUNCT - O
but CCONJ - O
there ADV - O
is VERB - O
limited ADJ - O
evidence NOUN - O
regarding VERB - O
its ADJ - O
use NOUN - O
after ADP - O
ED NNP - B-ORG
discharge NOUN - O
. PUNCT - O

The DT - B-ORG
All NNP - I-ORG
Ondansetron NNP - I-MEDICINE
Group NNP - I-ORG
included VERB - O
any DET - O
child NOUN - O
prescribed VERB - O
ondansetron NN - B-MEDICINE
at ADP - O
discharge NOUN - O
. PUNCT - O

Discharge ADJ - O
diagnosis NOUN - O
was VERB - O
evaluated VERB - O
for ADP - O
the DET - O
any DET - O
Ondansetron NNP - B-MEDICINE
Group NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
Prescription NNP - I-ORG
for IN - I-ORG
Home NNP - I-ORG
Use NNP - I-ORG
in ADP - O
a DT - B-ORG
Pediatric NNP - I-ORG
Emergency NNP - I-ORG
Department NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
has VERB - O
been VERB - O
reported VERB - O
to PART - O
reduce VERB - O
the DET - O
incidence NOUN - O
of ADP - O
SAIH PROPN - O
in ADP - O
patients NOUN - O
undergoing VERB - O
cesarean ADJ - O
section NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron JJ - B-MEDICINE
treatment NOUN - O
reduces VERB - O
rotavirus NOUN - O
symptoms NOUN - O
- PUNCT - O
A NOUN - O
randomized VERB - O
double ADJ - O
- PUNCT - O
blinded ADJ - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Severe ADJ - O
Proarrhythmic PROPN - O
Potential PROPN - O
of ADP - O
the DET - O
Antiemetic PROPN - O
Agents PROPN - O
Ondansetron NNP - B-MEDICINE
and CCONJ - O
Domperidone NN - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron RB - B-MEDICINE
, PUNCT - O
a DET - O
5-hydroxytryptamine NUM - O
type NOUN - O
3 CD - B-CARDINAL
receptor NOUN - O
antagonist NOUN - O
antiemetic NOUN - O
, PUNCT - O
is VERB - O
one CD - B-CARDINAL
such ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
is VERB - O
the DET - O
agent NOUN - O
typically ADV - O
administered VERB - O
to PART - O
prevent VERB - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methamphetamine NOUN - O
- PUNCT - O
Induced VERB - O
Neurotoxicity PROPN - O
: PUNCT - O
Neuroprotective PROPN - O
Effects PROPN - O
of ADP - O
Nanowired PROPN - O
Delivery PROPN - O
of ADP - O
5-HT3-Receptor NUM - O
Antagonist PROPN - O
Ondansetron NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
respectively]. NOUN - O
Conclusion NNP - B-PERSON
Ondansetron NNP - I-MEDICINE
effectively ADV - O
reduces VERB - O
the DET - O
incidences NOUN - O
of ADP - O
nausea NOUN - O
/ SYM - O
vomiting NOUN - O
and CCONJ - O
bradycardia NOUN - O
under ADP - O
spinal ADJ - O
anesthesia NOUN - O
during ADP - O
cesarean ADJ - O
section NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
randomized VERB - O
controlled VERB - O
study NOUN - O
, PUNCT - O
120 CD - B-CARDINAL
patients NOUN - O
aged VERB - O
18 CD - B-DATE
- SYM - I-DATE
65 CD - I-DATE
years NNS - I-DATE
of ADP - O
American NNP - B-ORG
Society NNP - I-ORG
of IN - I-ORG
Anesthesiologist NNP - I-ORG
( PUNCT - O
ASA NNP - B-ORG
) PUNCT - O
physical ADJ - O
status NOUN - O
I PRON - O
and CCONJ - O
II NNP - B-ORG
undergoing VERB - O
various ADJ - O
surgical ADJ - O
procedures NOUN - O
were VERB - O
included VERB - O
and CCONJ - O
allocated VERB - O
alternately ADV - O
to ADP - O
one CD - B-CARDINAL
of ADP - O
the DET - O
4 CD - B-CARDINAL
groups NOUN - O
; PUNCT - O
Normal JJ - B-ORG
saline NOUN - O
( PUNCT - O
Group1 NNP - B-PERSON
) PUNCT - O
, PUNCT - O
Ondansetron NN - B-MEDICINE
4 CD - B-QUANTITY
mg MD - I-QUANTITY
( PUNCT - O
Group2 PROPN - O
) PUNCT - O
, PUNCT - O
Ketamine NNP - B-PERSON
0.25mg CD - I-PERSON
/ SYM - O
kg NOUN - O
( PUNCT - O
Group3 NNP - B-ORG
) PUNCT - O
and CCONJ - O
Tramadol NNP - B-PRODUCT
0.5mg NNP - I-PRODUCT
/ SYM - I-PRODUCT
kg NNS - I-PRODUCT
( PUNCT - O
Group4 NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
was VERB - O
administered VERB - O
subcutaneously ADV - O
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
3 CD - B-CARDINAL
Â  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
Does VERB - O
Not ADV - O
Reduce VERB - O
Withdrawal PROPN - O
in ADP - O
Patients NNP - B-ORG
With IN - I-ORG
Physical NNP - I-ORG
Dependence NNP - I-ORG
on ADP - O
Chronic PROPN - O
Opioid PROPN - O
Therapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
fluid NOUN - O
intake NOUN - O
after ADP - O
receiving VERB - O
medication NOUN - O
was VERB - O
statistically ADV - O
better ADJ - O
with ADP - O
Ondansetronwhile NNP - B-PERSON
also ADV - O
having VERB - O
less ADJ - O
side NOUN - O
effects NOUN - O
compared VERB - O
to ADP - O
the DET - O
other ADJ - O
two CD - B-CARDINAL
agents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
, PUNCT - O
an DET - O
Htr3 NNP - B-GPE
antagonist NOUN - O
, PUNCT - O
decreased VERB - O
Kv NNP - B-PERSON
currents NOUN - O
in ADP - O
WT NNP - B-ORG
- HYPH - I-ORG
LP NNP - I-ORG
mice NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
in ADP - O
WT NNP - B-ORG
- HYPH - I-ORG
NP NNP - I-ORG
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
has VERB - O
proven VERB - O
to PART - O
be VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
adjunct NOUN - O
in ADP - O
children NOUN - O
with ADP - O
vomiting VERB - O
. PUNCT - O

-DOCSTART- -X- - O

574 CD - B-CARDINAL
] PUNCT - O
mg PRON - O
in ADP - O
the DET - O
placebo NOUN - O
group NOUN - O
, PUNCT - O
P=0.95.Ondansetron PROPN - O
significantly ADV - O
decreased VERB - O
the DET - O
analgesic ADJ - O
effect NOUN - O
of ADP - O
acetaminophen NOUN - O
during ADP - O
the DET - O
initial ADJ - O
postoperative ADJ - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
is VERB - O
a DET - O
reliable ADJ - O
and CCONJ - O
safe ADJ - O
drug NOUN - O
and CCONJ - O
it PRON - O
is VERB - O
currently ADV - O
used VERB - O
in ADP - O
the DET - O
prevention NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
and CCONJ - O
has VERB - O
no DET - O
side NOUN - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Ondansetron NNP - B-MEDICINE
on ADP - O
Prevention PROPN - O
of ADP - O
Ventilator PROPN - O
Associated PROPN - O
Pneumonia PROPN - O
in ADP - O
Intensive NNP - B-ORG
Care NNP - I-ORG
Unit NNP - I-ORG
Patients NNPS - I-ORG
in ADP - O
Kashani NNP - B-ORG
Hospital NNP - I-ORG
in ADP - O
2013 CD - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Ondansetron NNP - B-MEDICINE
has VERB - O
been VERB - O
used VERB - O
to PART - O
deal VERB - O
with ADP - O
the DET - O
problem NOUN - O
of ADP - O
neuraxial ADJ - O
morphine NOUN - O
- PUNCT - O
induced VERB - O
pruritus NOUN - O
( PUNCT - O
NMIP NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Thirty CD - B-CARDINAL
drugs NOUN - O
were VERB - O
involved VERB - O
in ADP - O
the DET - O
pharmaceutical ADJ - O
interventions NOUN - O
, PUNCT - O
Carboplatin NNP - B-GPE
and CCONJ - O
Ondansetron NNP - B-MEDICINE
being VERB - O
the DET - O
most ADV - O
frequent ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Heparin NNP - B-MEDICINE
Sodium NN - I-MEDICINE
Combined VERB - O
with ADP - O
Magnesium PROPN - O
Sulfate PROPN - O
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Patients NNPS - I-ORG
with ADP - O
Severe PROPN - O
Preeclampsia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Biopolymer PROPN - O
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Interlayer PROPN - O
Anchoring PROPN - O
TiO2 PROPN - O
and CCONJ - O
MAPbI3 PROPN - O
Enhances PROPN - O
Trap PROPN - O
Passivation PROPN - O
and CCONJ - O
Device PROPN - O
Stability PROPN - O
in ADP - O
Perovskite PROPN - O
Solar PROPN - O
Cells PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Emodin PROPN - O
- PUNCT - O
Loaded ADJ - O
PLGA NOUN - O
- PUNCT - O
TPGS NOUN - O
Nanoparticles NOUN - O
Combined VERB - O
with ADP - O
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
- PUNCT - O
Loaded PROPN - O
PLGA NOUN - O
- PUNCT - O
TPGS VERB - O
Nanoparticles NOUN - O
to ADP - O
Enhance VERB - O
Chemotherapeutic PROPN - O
Efficacy PROPN - O
Against PROPN - O
Liver PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
discloses VERB - O
a DET - O
process NOUN - O
for ADP - O
the DET - O
coproduction NOUN - O
of ADP - O
Aprotinin NNP - B-PERSON
and CCONJ - O
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
through ADP - O
extracting VERB - O
from ADP - O
cow NOUN - O
's PART - O
lungs NOUN - O
, PUNCT - O
the DET - O
Aprotinin NNP - B-PERSON
activity NOUN - O
can VERB - O
reach VERB - O
5400 CD - B-CARDINAL
KIU PROPN - O
/ SYM - O
mg PROPN - O
, PUNCT - O
the DET - O
Heparin NNP - B-ORG
Sodium NNP - I-ORG
potency NOUN - O
can VERB - O
reach VERB - O
70 CD - B-CARDINAL
IU NN - B-ORG
/ SYM - I-ORG
mg PRP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Porcine NOUN - O
samples NOUN - O
met VERB - O
the DET - O
current ADJ - O
criteria NOUN - O
as ADP - O
laid VERB - O
out PART - O
in ADP - O
the DET - O
USP NNP - B-ORG
Heparin NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
monograph NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CORRELATION NOUN - O
FACTORS NOUN - O
OF ADP - O
ABNORMAL NOUN - O
MENSES VERB - O
IN ADP - O
SCHIZOPHRENIA PROPN - O
TREATMENT NOUN - O
WITH ADP - O
RISPERIDONE NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

TRPA1 PROPN - O
Antagonists PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Practical ADJ - O
tips NOUN - O
for ADP - O
IUD NNP - B-ORG
Counselling NNP - I-ORG
, , - I-ORG
Insertion NNP - I-ORG
, PUNCT - O
and CCONJ - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Adolescents NOUN - O
: PUNCT - O
An DET - O
Update PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Endovascular PROPN - O
Denervation PROPN - O
: PUNCT - O
A DET - O
New PROPN - O
Approach PROPN - O
for ADP - O
Cancer PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
? PUNCT - O

-DOCSTART- -X- - O

Prehospital NNP - B-ORG
Analgesic NNP - I-ORG
Administration NNP - I-ORG
by ADP - O
Parents NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacological ADJ - O
and CCONJ - O
Non JJ - B-ORG
- JJ - I-ORG
Pharmacological JJ - I-ORG
Methods NNPS - I-ORG
of IN - I-ORG
Labour PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
- PUNCT - O
Establishment PROPN - O
of ADP - O
Effectiveness PROPN - O
and CCONJ - O
Comparison PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Solving VERB - O
the DET - O
Global PROPN - O
Crisis PROPN - O
in ADP - O
Access NOUN - O
to ADP - O
Pain NNP - B-MEDICINE
Relief NN - I-MEDICINE
: PUNCT - O
Lessons NOUN - O
From ADP - O
Country PROPN - O
Actions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Cancer PROPN - O
Pain NNP - B-MEDICINE
Relief NN - I-MEDICINE

-DOCSTART- -X- - O

Addressing VERB - O
the DT - B-ORG
Clinical NNP - I-ORG
Need NNP - I-ORG
for IN - I-ORG
Novel NNP - I-ORG
Nonopioid NNP - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
Therapies NNPS - I-ORG
for IN - I-ORG
Cancer NNP - I-ORG
Patients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tanezumab ADJ - O
: PUNCT - O
Finally ADV - O
a DET - O
Monoclonal PROPN - O
Antibody PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Optimal PROPN - O
Laser PROPN - O
Phototherapy PROPN - O
Parameters NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Brain NNP - B-ORG
Dynamics NNP - I-ORG
and CC - I-ORG
Temporal NNP - I-ORG
Summation NNP - I-ORG
of IN - I-ORG
Pain NNP - I-ORG
Predicts NNPS - I-ORG
Neuropathic NNP - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
from ADP - O
Ketamine NNP - B-ORG
Infusion NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Intraperitoneal NNP - B-ORG
Bupivacaine NNP - I-ORG
on IN - I-ORG
Pain NNP - B-MEDICINE
Relief NN - I-MEDICINE

-DOCSTART- -X- - O

Plant NNP - B-ORG
- HYPH - I-ORG
Chemical NNP - I-ORG
Shows NNPS - I-ORG
Promise NNP - I-ORG
for IN - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Acupuncture VERB - O
and CCONJ - O
Sham PROPN - O
Acupuncture PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Physical PROPN - O
- PUNCT - O
Agent PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
Modalities PROPN - O
for ADP - O
Fibromyalgia PROPN - O
Patients PROPN - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta NNP - B-ORG
- HYPH - I-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Randomized NNP - I-ORG
Controlled NNP - I-ORG
Trials NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Oral PROPN - O
Sucrose PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
During ADP - O
Clubfoot PROPN - O
Casting PROPN - O
: PUNCT - O
A DET - O
Double ADJ - O
- PUNCT - O
Blinded PROPN - O
Randomized PROPN - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Role NOUN - O
of ADP - O
Heparin NNP - B-ORG
Irrigation NNP - I-ORG
in ADP - O
the DET - O
Management PROPN - O
of ADP - O
Superficial PROPN - O
Burns PROPN - O
with ADP - O
Special PROPN - O
Reference PROPN - O
to ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Wound NNP - B-PERSON
Healing NNP - I-PERSON
: PUNCT - O
A NNP - B-WORK_OF_ART
Pilot NNP - I-WORK_OF_ART
Study NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Potential JJ - B-ORG
Uses NNS - I-ORG
of IN - I-ORG
Isolated NNP - I-ORG
Toxin NNP - I-ORG
Peptides NNP - I-ORG
in ADP - O
Neuropathic PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
: PUNCT - O
A PROPN - O
Literature PROPN - O
Review PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sustainability NOUN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE

-DOCSTART- -X- - O

Acupuncture VERB - O
and CCONJ - O
Sham PROPN - O
Acupuncture PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
- PUNCT - O
Reply PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Empathy PROPN - O
in ADP - O
the DET - O
Patient PROPN - O
- PUNCT - O
Doctor PROPN - O
Relationship PROPN - O
on ADP - O
Chronic PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Quality PROPN - O
of ADP - O
Life PROPN - O
: PUNCT - O
A DET - O
Prospective ADJ - O
Study PROPN - O
in ADP - O
Spanish NNP - B-NORP
Pain PROPN - O
Clinics PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
the DET - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
of ADP - O
Amitriptyline ADJ - O
Mouthwash PROPN - O
with ADP - O
Benzydamine PROPN - O
in ADP - O
Oral NNP - B-FAC
Mucositis NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Selective ADJ - O
L4 NOUN - O
Dorsal PROPN - O
Root PROPN - O
Ganglion PROPN - O
Stimulation PROPN - O
Evokes PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Changes PROPN - O
of ADP - O
Inflammatory PROPN - O
Markers PROPN - O
: PUNCT - O
Part NOUN - O
I NOUN - O
Profiling NOUN - O
of ADP - O
Saliva PROPN - O
and CCONJ - O
Serum PROPN - O
Molecular PROPN - O
Patterns PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Osteopathic PROPN - O
Manipulative PROPN - O
Treatment PROPN - O
Effect PROPN - O
on ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Quality PROPN - O
of ADP - O
Life PROPN - O
in ADP - O
Oncology PROPN - O

-DOCSTART- -X- - O

Autologous ADJ - O
Chondrocyte PROPN - O
Implantation PROPN - O
and CCONJ - O
Tibial PROPN - O
Tubercle PROPN - O
Osteotomy PROPN - O
for ADP - O
Patellofemoral PROPN - O
Chondral PROPN - O
Defects PROPN - O
: PUNCT - O
Improved PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Occupational PROPN - O
Outcomes PROPN - O
Among ADP - O
US PROPN - O
Army PROPN - O
Servicemembers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ring NNP - B-PERSON
Block NNP - I-PERSON
of ADP - O
the DET - O
Penis PROPN - O
: PUNCT - O
A PROPN - O
Proven VERB - O
Addition NOUN - O
to ADP - O
Multimodal PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
for ADP - O
Newborn PROPN - O
Circumcision PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Cold PROPN - O
Application PROPN - O
to ADP - O
the DET - O
Perineum PROPN - O
on ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE

-DOCSTART- -X- - O

Progress NOUN - O
on ADP - O
Botulinum PROPN - O
Toxin PROPN - O
Type PROPN - O
A PROPN - O
- PUNCT - O
Induced PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
the DET - O
Field PROPN - O
of ADP - O
Plastics PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Mindfulness NNP - B-ORG
or CC - I-ORG
Self NNP - I-ORG
- HYPH - I-ORG
Hypnosis NN - I-ORG
Provides VBZ - I-ORG
Immediate PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
to ADP - O
Hospitalized PROPN - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
and CCONJ - O
Radiographic ADJ - O
Results PROPN - O
of ADP - O
39 CD - B-CARDINAL
Retrospectives PROPN - O
Cases PROPN - O
- PUNCT - O
Is VERB - O
the DET - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
Enough PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Neural PROPN - O
Targeting PROPN - O
Shows VERB - O
Superior ADJ - O
Chronic PROPN - O
Axial NOUN - O
Low ADJ - O
Back PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE

-DOCSTART- -X- - O

Nerve PROPN - O
Decompression PROPN - O
Improves VERB - O
Spinal ADJ - O
Synaptic PROPN - O
Plasticity PROPN - O
of ADP - O
Opioid PROPN - O
Receptors PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Opiate JJ - B-ORG
- HYPH - I-ORG
Free JJ - I-ORG
Pain NNP - I-ORG
Therapy NNP - I-ORG
Using VBG - I-ORG
Carbamazepine PROPN - O
- PUNCT - O
Loaded VERB - O
Microparticles PROPN - O
Provides VERB - O
Up ADP - O
to ADP - O
2 NUM - O
Weeks NOUN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
a DET - O
Neuropathic NNP - B-PRODUCT
Pain NNP - I-PRODUCT
Model NNP - I-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Bilateral NNP - B-ORG
Transversus NNP - I-ORG
Abdominis NNP - I-ORG
Plane NNP - I-ORG
and CCONJ - O
Ilioinguinal NNP - B-ORG
- HYPH - I-ORG
Iliohypogastric NNP - I-ORG
Nerve NNP - I-ORG
Blocks NNS - I-ORG
for ADP - O
Postcaesarean ADJ - O
Delivery PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
under ADP - O
Spinal NNP - B-PERSON
Anesthesia NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Carbon NOUN - O
acquisition NOUN - O
and CCONJ - O
water NOUN - O
use NOUN - O
in ADP - O
a DET - O
Northern PROPN - O
Utah PROPN - O
Juniperus PROPN - O
osteosperma ADV - O
( PUNCT - O
Utah NNP - B-GPE
juniper NOUN - O
) PUNCT - O
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
- PUNCT - O
associated VERB - O
encephalopathy ADJ - O
with ADP - O
psychotic ADJ - O
features NOUN - O
is VERB - O
a DET - O
rare ADJ - O
adverse ADJ - O
event NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
associated VERB - O
Encephalopathy NNP - B-GPE
with ADP - O
Severe PROPN - O
Hyperventilation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
LVFX NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
antibacterial ADJ - O
agent NOUN - O
from ADP - O
the DET - O
fluoroquinolone ADJ - O
family NOUN - O
, PUNCT - O
is VERB - O
universally ADV - O
prescribed VERB - O
with ADP - O
antipyretics NOUN - O
, PUNCT - O
including VERB - O
paracetamol NOUN - O
( PUNCT - O
APAP NNP - B-ORG
) PUNCT - O
analogs VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Infectious ADJ - O
Outcomes PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
Prophylaxis PROPN - O
in ADP - O
Obese NNP - B-NORP
vs. ADP - O
Non JJ - B-PERSON
- JJ - I-PERSON
obese JJ - I-PERSON
Patients PROPN - O
with ADP - O
Hematologic PROPN - O
Malignancies PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
prophylaxis NOUN - O
was VERB - O
standard ADJ - O
of ADP - O
care NOUN - O
for ADP - O
patients NOUN - O
undergoing VERB - O
autologous ADJ - O
SCT NNP - B-ORG
or CCONJ - O
induction NOUN - O
chemotherapy NOUN - O
for ADP - O
acute ADJ - O
myeloid ADJ - O
leukemia NOUN - O
( PUNCT - O
AML NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
0.5 CD - B-MONEY
â _SP - I-MONEY
g NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
was VERB - O
used VERB - O
for ADP - O
20 CD - B-DATE
days NNS - I-DATE
; PUNCT - O
however ADV - O
, PUNCT - O
L. NNP - B-PERSON
lactis NOUN - O
subsp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
and CCONJ - O
amiodarone NOUN - O
are VERB - O
both DET - O
known VERB - O
to PART - O
prolong VERB - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
is VERB - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
and CCONJ - O
prevention NOUN - O
of ADP - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
in ADP - O
children NOUN - O
, PUNCT - O
but CCONJ - O
current ADJ - O
adult NOUN - O
formulations NOUN - O
are VERB - O
poorly ADV - O
palatable ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Acceptability NOUN - O
of ADP - O
a DET - O
Novel PROPN - O
Levofloxacin NNP - B-MEDICINE
Dispersible PROPN - O
Tablet PROPN - O
Formulation NOUN - O
in ADP - O
Young ADJ - O
Children NOUN - O
Exposed VERB - O
to ADP - O
Multidrug PROPN - O
- PUNCT - O
Resistant PROPN - O
Tuberculosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
versus ADP - O
placebo NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
tuberculosis NOUN - O
disease NOUN - O
in ADP - O
child NOUN - O
contacts NOUN - O
of ADP - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
: PUNCT - O
study VERB - O
protocol NOUN - O
for ADP - O
a DET - O
phase NOUN - O
III CD - B-ORG
cluster NOUN - O
randomised VERB - O
controlled VERB - O
trial NOUN - O
( PUNCT - O
TB PROPN - O
- PUNCT - O
CHAMP PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
is VERB - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
; PUNCT - O
however ADV - O
the DET - O
optimal NOUN - O
dose NOUN - O
is VERB - O
unknown ADJ - O
. PUNCT - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
underwent VERB - O
whole ADV - O
- PUNCT - O
genome ADJ - O
sequencing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
Pharmacokinetics NNP - I-ORG
/ SYM - I-ORG
Pharmacodynamics NNP - I-ORG
, PUNCT - O
Dosing NOUN - O
, PUNCT - O
Susceptibility PROPN - O
Breakpoints PROPN - O
, PUNCT - O
and CCONJ - O
Artificial NNP - B-ORG
Intelligence NNP - I-ORG
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Multidrug NNP - I-ORG
- PUNCT - O
resistant ADJ - O
Tuberculosis NN - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
67%)16 NUM - O
( PUNCT - O
10%)35 NUM - O
( PUNCT - O
23%)Levofloxacin114 CD - B-DATE
( PUNCT - O
74%)6 CD - B-CARDINAL
( PUNCT - O
4%)35 NUM - O
( PUNCT - O
23%)BMD JJ - B-CARDINAL
readings NOUN - O
were VERB - O
often ADV - O
complicated VERB - O
by ADP - O
noticeably ADV - O
poor ADJ - O
growth NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
is VERB - O
an DET - O
antituberculosis NOUN - O
drug NOUN - O
with ADP - O
substantial ADJ - O
interindividual ADJ - O
pharmacokinetic ADJ - O
variability NOUN - O
; PUNCT - O
therapeutic ADJ - O
drug NOUN - O
monitoring NOUN - O
( PUNCT - O
TDM NNP - B-ORG
) PUNCT - O
could VERB - O
therefore ADV - O
be VERB - O
helpful ADJ - O
to PART - O
improve VERB - O
treatment NOUN - O
results NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetic NNP - I-ORG
Model NNP - I-ORG
and CCONJ - O
Limited NNP - B-ORG
Sampling NNP - I-ORG
Strategies NNPS - I-ORG
for IN - I-ORG
Personalized NNP - I-ORG
Dosing NNP - I-ORG
of IN - I-ORG
Levofloxacin NNP - I-MEDICINE
in IN - I-ORG
Tuberculosis NNP - I-ORG
Patients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
and CCONJ - O
Cardiac PROPN - O
Safety PROPN - O
of ADP - O
Long ADJ - O
- PUNCT - O
term NOUN - O
Levofloxacin NNP - B-MEDICINE
in ADP - O
Children NNP - B-WORK_OF_ART
Treated VBN - I-WORK_OF_ART
for IN - I-WORK_OF_ART
Multidrug NNP - I-WORK_OF_ART
- PUNCT - O
resistant ADJ - O
Tuberculosis NN - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
a DET - O
third JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
fluoroquinolone NOUN - O
antibiotic NOUN - O
, PUNCT - O
is VERB - O
rarely ADV - O
associated VERB - O
with ADP - O
neurotoxicity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Colonization NOUN - O
With ADP - O
Levofloxacin NNP - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Extended ADJ - O
- PUNCT - O
spectrum PROPN - O
Î² ADJ - O
- PUNCT - O
Lactamase NOUN - O
- PUNCT - O
producing VERB - O
Enterobacteriaceae PROPN - O
and CCONJ - O
Risk PROPN - O
of ADP - O
Bacteremia PROPN - O
in ADP - O
Hematopoietic PROPN - O
Stem PROPN - O
Cell PROPN - O
Transplant NOUN - O
Recipients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
was VERB - O
discontinued VERB - O
and CCONJ - O
the DET - O
symptoms NOUN - O
resolved VERB - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Case PROPN - O
Report PROPN - O
of ADP - O
Anticoagulation PROPN - O
Management PROPN - O
in ADP - O
Acquired PROPN - O
Hemophilia PROPN - O
Associated VERB - O
With ADP - O
Levofloxacin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
USCAST PROPN - O
Proposed VERB - O
Breakpoint PROPN - O
Changes NOUN - O
to ADP - O
Aminoglycosides PROPN - O
, PUNCT - O
Cyclines PROPN - O
, PUNCT - O
and CCONJ - O
Levofloxacin NNP - B-MEDICINE
on ADP - O
Carbapenem NNP - B-ORG
- HYPH - I-ORG
Resistant NNP - I-ORG
Enterobacteriaceae NNP - I-ORG
at ADP - O
a DET - O
US NNP - B-GPE
Tertiary NNP - B-ORG
Referral NNP - I-ORG
Academic NNP - I-ORG
Medical NNP - I-ORG
Center NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
a DET - O
fluoroquinolone NOUN - O
, PUNCT - O
is VERB - O
an DET - O
isomer NOUN - O
of ADP - O
ofloxacin NOUN - O
with ADP - O
an DET - O
extensive ADJ - O
spectrum NOUN - O
of ADP - O
antimicrobial ADJ - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetics NNPS - I-ORG
and CC - I-ORG
Pharmacodynamics NNPS - B-ORG
Modeling NNP - I-ORG
of IN - I-ORG
Oral NNP - I-ORG
Levofloxacin NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
LVX NNP - B-ORG
) PUNCT - O
inhaled VERB - O
solution NOUN - O
is VERB - O
already ADV - O
an DET - O
effective ADJ - O
option NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
Prophylaxis NNP - I-ORG
on IN - I-ORG
Bacteremia PROPN - O
in ADP - O
Children PROPN - O
With ADP - O
Acute PROPN - O
Leukemia PROPN - O
or CCONJ - O
Undergoing PROPN - O
Hematopoietic PROPN - O
Stem PROPN - O
Cell PROPN - O
Transplantation NOUN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Clinical PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Acute NNP - B-PERSON
Delirium NNP - I-PERSON
Associated VERB - O
With ADP - O
Levofloxacin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Spinal ADJ - O
Cord PROPN - O
Neuromodulation PROPN - O
Therapy PROPN - O
for ADP - O
Levofloxacin NNP - B-MEDICINE
- HYPH - I-ORG
Reinduced NNP - I-ORG
Complex NNP - I-ORG
Regional NNP - I-ORG
Pain NNP - I-ORG
Syndrome NNP - I-ORG
and CC - I-ORG
Neurotoxicity NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
standard ADJ - O
triple ADJ - O
therapy NOUN - O
versus ADP - O
Levofloxacin NNP - B-MEDICINE
based VERB - O
alternate ADJ - O
therapy NOUN - O
against ADP - O
Helicobacter NNP - B-ORG
pylori NOUN - O
infection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
and CCONJ - O
posaconzole NOUN - O
emerged VERB - O
as ADP - O
the DET - O
most ADV - O
likely ADJ - O
culprit NOUN - O
drugs NOUN - O
, PUNCT - O
neither DET - O
of ADP - O
which ADJ - O
have VERB - O
a DET - O
strong ADJ - O
history NOUN - O
in ADP - O
the DET - O
literature NOUN - O
of ADP - O
being VERB - O
associated VERB - O
with ADP - O
photosensitive ADJ - O
hyperpigmentation NOUN - O
. PUNCT - O

Levofloxacin NNP - B-MEDICINE
was VERB - O
determined ADJ - O
to PART - O
be VERB - O
the DET - O
culprit NOUN - O
drug NOUN - O
when ADV - O
the DET - O
hyperpigmentation NOUN - O
gradually ADV - O
resolved VERB - O
several JJ - B-DATE
weeks NNS - I-DATE
after ADP - O
discontinuation NOUN - O
of ADP - O
levofloxacin NN - B-MEDICINE
, PUNCT - O
with ADP - O
continuation NOUN - O
of ADP - O
posaconazole NOUN - O
and CCONJ - O
all DET - O
other ADJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
medications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
and CCONJ - O
ciprofloxacin VERB - O
still ADV - O
remain VERB - O
the DET - O
commonest ADJ - O
fluoroquinolones NOUN - O
prescribed VERB - O
for ADP - O
UTIs NOUN - O
in ADP - O
many ADJ - O
settings NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Response VERB - O
to ADP - O
" PUNCT - O
Levofloxacin NNP - B-MEDICINE
- PUNCT - O
containing VERB - O
versus ADP - O
Clarithromycin PROPN - O
- PUNCT - O
containing VERB - O
Therapy PROPN - O
for ADP - O
Helicobacter PROPN - O
pylori NOUN - O
Eradication NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Who NOUN - O
Receive VERB - O
Prophylactic PROPN - O
Levofloxacin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
Unusual PROPN - O
Case NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
Pill PROPN - O
Aspiration NOUN - O
Causing VERB - O
Respiratory PROPN - O
Failure PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Resistance NOUN - O
( PUNCT - O
R PROPN - O
) PUNCT - O
Trends NOUN - O
in ADP - O
Gram PROPN - O
- PUNCT - O
Negative PROPN - O
Bacilli PROPN - O
( PUNCT - O
GNB NNP - B-ORG
) PUNCT - O
to ADP - O
Fluoroquinolones NNP - B-ORG
( -LRB- - I-ORG
FQ NNP - I-ORG
) PUNCT - O
, PUNCT - O
[ PUNCT - O
Ciprofloxacin NNP - B-ORG
( PUNCT - O
CIP PROPN - O
) PUNCT - O
, PUNCT - O
Levofloxacin NNP - B-MEDICINE
( PUNCT - O
LEV NNP - B-ORG
) PUNCT - O
, PUNCT - O
Moxifloxacin NNP - B-ORG
( PUNCT - O
MOX NNP - B-ORG
) PUNCT - O
] PUNCT - O
, PUNCT - O
Trimethoprim PROPN - O
â PROPN - O
Sulfamethoxazole PROPN - O
( PUNCT - O
TMP NNP - B-ORG
/ SYM - I-ORG
SMX NNP - I-ORG
) PUNCT - O
and CCONJ - O
Nitrofurantoin NNP - B-ORG
( PUNCT - O
NFT NNP - B-ORG
) PUNCT - O
over ADP - O
a DET - O
7-Year CD - B-CARDINAL
Period NOUN - O
: PUNCT - O
Pre- PROPN - O
and CCONJ - O
Post PROPN - O
- PROPN - O
Implementation PROPN - O
of ADP - O
FQ PROPN - O
Restriction PROPN - O
at ADP - O
a DET - O
Tertiary NNP - B-ORG
Care NNP - I-ORG
Veterans NNPS - I-ORG
Affairs NNPS - I-ORG
Medical NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
VAMC PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Benzyl NNS - B-PERSON
penicillin NOUN - O
, PUNCT - O
Ampicillin NNP - B-PERSON
, PUNCT - O
Cefotaxime PROPN - O
, PUNCT - O
Ceftriaxone PROPN - O
, PUNCT - O
Levofloxacin NNP - B-MEDICINE
, PUNCT - O
Erythromycin NNP - B-ORG
, PUNCT - O
Clindamycin NNP - B-ORG
, , - I-ORG
Linezolid NNP - I-ORG
, PUNCT - O
Vancomycin NNP - B-ORG
, PUNCT - O
Tetracycline NNP - B-PERSON
and CCONJ - O
Cotrimoxazole NNP - B-GPE
, PUNCT - O
Olea NNP - B-GPE
europaea NOUN - O
leaf NOUN - O
extracts NOUN - O
and CCONJ - O
essential ADJ - O
oil NOUN - O
were VERB - O
tested VERB - O
against ADP - O
GBS PROPN - O
isolates NOUN - O
from ADP - O
South NNP - B-GPE
Africa NNP - I-GPE
and CCONJ - O
Namibia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
, PUNCT - O
which ADJ - O
was VERB - O
not ADV - O
among ADP - O
the DET - O
suspected VERB - O
drugs NOUN - O
, PUNCT - O
was VERB - O
administered VERB - O
with ADP - O
ethambutol NOUN - O
in ADP - O
order NOUN - O
to PART - O
avoid VERB - O
drug NOUN - O
resistance NOUN - O
resulting VERB - O
from ADP - O
the DET - O
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bilosomes NOUN - O
were VERB - O
developed VERB - O
in ADP - O
order NOUN - O
to PART - O
investigate VERB - O
their ADJ - O
efficacy NOUN - O
as ADP - O
nanocarriers NOUN - O
for ADP - O
transdermal ADJ - O
delivery NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
HCl NOUN - O
( PUNCT - O
TZN NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
skeletal ADJ - O
muscle NOUN - O
relaxant NOUN - O
with ADP - O
low ADJ - O
oral ADJ - O
bioavailability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Analysis PROPN - O
of ADP - O
Drug PROPN - O
- PUNCT - O
Drug PROPN - O
Interactions PROPN - O
in ADP - O
Swiss NNP - B-ORG
Claims NNP - I-ORG
Data NNPS - I-ORG
Using VBG - I-ORG
Tizanidine NNP - I-MEDICINE
and CCONJ - O
Ciprofloxacin NNP - B-ORG
as ADP - O
a DET - O
Prototypical PROPN - O
Contraindicated PROPN - O
Combination PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
is VERB - O
not ADV - O
effective ADJ - O
treating NOUN - O
EPMS RB - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
withdrawal NOUN - O
syndrome NOUN - O
is VERB - O
caused VERB - O
by ADP - O
adrenergic ADJ - O
discharge NOUN - O
due ADP - O
to ADP - O
its ADJ - O
Î±2-agonist ADJ - O
mechanism NOUN - O
and CCONJ - O
is VERB - O
characterized VERB - O
by ADP - O
hypertension NOUN - O
, PUNCT - O
reflex ADJ - O
tachycardia NOUN - O
, PUNCT - O
hypertonicity NOUN - O
, PUNCT - O
and CCONJ - O
anxiety NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Management NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
Withdrawal PROPN - O
Syndrome PROPN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Test NOUN - O
compounds NOUN - O
included VERB - O
Tizanidine NNP - B-MEDICINE
( PUNCT - O
TIZ NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
noradrenergic ADJ - O
Î±2 NOUN - O
agonist NOUN - O
and CCONJ - O
imidazoline ADJ - O
ligand NOUN - O
selected VERB - O
for ADP - O
its ADJ - O
ability NOUN - O
to PART - O
reduce VERB - O
descending VERB - O
noradrenergic ADJ - O
drive NOUN - O
, PUNCT - O
and CCONJ - O
Isradipine NNP - B-ORG
, PUNCT - O
a DET - O
dihyropyridine ADJ - O
calcium NOUN - O
- PUNCT - O
channel NOUN - O
antagonist NOUN - O
selected VERB - O
for ADP - O
its ADJ - O
ability NOUN - O
to PART - O
post VERB - O
- ADJ - O
synaptically ADV - O
mitigate VERB - O
a DET - O
portion NOUN - O
of ADP - O
the DET - O
excitatory ADJ - O
effects NOUN - O
of ADP - O
monoamines NOUN - O
on ADP - O
motoneurons NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
that ADP - O
Tizanidine NNP - B-MEDICINE
significantly ADV - O
reduced VERB - O
expression NOUN - O
of ADP - O
the DET - O
flexion NOUN - O
synergy NOUN - O
. PUNCT - O

A DET - O
predominantly ADV - O
spinal ADJ - O
action NOUN - O
for ADP - O
this DET - O
effect NOUN - O
is VERB - O
unlikely ADJ - O
because ADP - O
Tizanidine NNP - B-MEDICINE
is VERB - O
an DET - O
agonist NOUN - O
acting VERB - O
on ADP - O
a DET - O
baseline NOUN - O
of ADP - O
spinal ADJ - O
noradrenergic ADJ - O
drive NOUN - O
that ADJ - O
is VERB - O
likely ADJ - O
to PART - O
be VERB - O
pathologically ADV - O
enhanced VERB - O
post ADJ - O
- ADJ - O
stroke NOUN - O
due ADJ - O
to ADP - O
increased VERB - O
reliance NOUN - O
on ADP - O
cortico NOUN - O
- PUNCT - O
reticulospinal NOUN - O
motor NOUN - O
pathways NOUN - O
. PUNCT - O

Although ADP - O
spinal ADJ - O
actions NOUN - O
of ADP - O
TIZ NNP - B-ORG
can VERB - O
not ADV - O
be VERB - O
excluded VERB - O
, PUNCT - O
particularly ADV - O
from ADP - O
Group NNP - B-ORG
II NNP - I-ORG
pathways NOUN - O
, PUNCT - O
our ADJ - O
finding NOUN - O
is VERB - O
consistent ADJ - O
with ADP - O
a DET - O
supraspinal ADJ - O
action NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
to PART - O
reduce VERB - O
descending VERB - O
noradrenergic ADJ - O
drive NOUN - O
and CCONJ - O
disfacilitate VERB - O
motoneurons NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
the DET - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
Tizanidine JJ - B-MEDICINE
HCl NOUN - O
( PUNCT - O
TZN PROPN - O
) PUNCT - O
and CCONJ - O
Meloxicam NNP - B-PERSON
( PUNCT - O
MLX NNP - B-ORG
) PUNCT - O
loaded VERB - O
bilayer NOUN - O
mucoadhesive ADJ - O
films NOUN - O
intended VERB - O
for ADP - O
buccal ADJ - O
administration NOUN - O
, PUNCT - O
aiming VERB - O
to PART - O
enhance VERB - O
the DET - O
bioavailability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
HCl NOUN - O
- PUNCT - O
Meloxicam PROPN - O
loaded VERB - O
mucoadhesive ADJ - O
buccal ADJ - O
films NOUN - O
: PUNCT - O
In ADP - O
- PUNCT - O
vitro NOUN - O
and CCONJ - O
in ADP - O
- PUNCT - O
vivo NOUN - O
evaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Corrigendum VERB - O
to ADP - O
" PUNCT - O
Spinal NNP - B-WORK_OF_ART
Antinociceptive NNP - I-WORK_OF_ART
Action NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Amiloride NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Its PRP$ - I-WORK_OF_ART
Interaction NN - I-WORK_OF_ART
with IN - I-WORK_OF_ART
Tizanidine NNP - I-MEDICINE
in IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Rat NNP - I-WORK_OF_ART
Formalin NNP - I-WORK_OF_ART
Test NNP - I-WORK_OF_ART
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
is VERB - O
an DET - O
Î±2-adrenergic ADJ - O
agonist NOUN - O
used VERB - O
for ADP - O
the DET - O
symptomatic ADJ - O
relief NOUN - O
of ADP - O
spasticity NOUN - O
associated VERB - O
with ADP - O
multiple ADJ - O
sclerosis NOUN - O
or CCONJ - O
with ADP - O
spinal ADJ - O
cord NOUN - O
injury NOUN - O
or CCONJ - O
disease NOUN - O
. PUNCT - O

Tizanidine NNP - B-MEDICINE
eluted VERB - O
at ADP - O
1.499 CD - B-CARDINAL
min NOUN - O
and CCONJ - O
the DET - O
total ADJ - O
run NOUN - O
time NOUN - O
was VERB - O
2 CD - B-QUANTITY
min NN - I-QUANTITY
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine VB - B-MEDICINE
for ADP - O
the DET - O
management NOUN - O
of ADP - O
acute ADJ - O
postoperative NOUN - O
pain NOUN - O
after ADP - O
inguinal ADJ - O
hernia NOUN - O
repair NOUN - O
: PUNCT - O
A DET - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
the DET - O
magnetic ADJ - O
molecularly ADJ - O
imprinted ADJ - O
polymer NOUN - O
nanoparticles NOUN - O
( PUNCT - O
MMIP PROPN - O
- PUNCT - O
NPs NOUN - O
) PUNCT - O
for ADP - O
the DET - O
selective ADJ - O
pre ADJ - O
- ADJ - O
concentration NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
have VERB - O
been VERB - O
described VERB - O
. PUNCT - O

The DET - O
polymer NOUN - O
nanoparticles NOUN - O
were VERB - O
synthesized VERB - O
by ADP - O
the DET - O
polymerization NOUN - O
of ADP - O
methacrylic NOUN - O
acid NOUN - O
as ADP - O
a DET - O
functional ADJ - O
monomer NOUN - O
, PUNCT - O
ethylene NOUN - O
glycol NOUN - O
dimethacrylate VERB - O
as ADP - O
a DET - O
cross NOUN - O
- ADJ - O
linker ADJ - O
, PUNCT - O
2,2-azobisisobutyronitrile CD - B-CARDINAL
as ADP - O
an DET - O
initiator NOUN - O
and CCONJ - O
Tizanidine NNP - B-MEDICINE
as ADP - O
a DET - O
template NOUN - O
molecule NOUN - O
. PUNCT - O

Imprinted NNP - B-ORG
Tizanidine NNP - I-MEDICINE
molecules NOUN - O
were VERB - O
removed VERB - O
from ADP - O
the DET - O
polymeric ADJ - O
structure NOUN - O
using VERB - O
acetic ADJ - O
acid NOUN - O
in ADP - O
methanol NOUN - O
( PUNCT - O
10:90 CD - B-TIME
V NN - I-TIME
/ SYM - I-TIME
V% NNP - I-TIME
) PUNCT - O
, PUNCT - O
as ADP - O
the DET - O
eluent NOUN - O
solvent NOUN - O
. PUNCT - O

The DET - O
limits NOUN - O
of ADP - O
detection NOUN - O
( PUNCT - O
L.O.D PROPN - O
) PUNCT - O
for ADP - O
Tizanidine NNP - B-MEDICINE
were VERB - O
1.13Ã10(-6)M NNP - B-CARDINAL
and CCONJ - O
1.68Ã10(-6)M NNP - B-CARDINAL
in ADP - O
ultrapure NOUN - O
water NOUN - O
and CCONJ - O
urine NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
method NOUN - O
was VERB - O
applied VERB - O
to ADP - O
the DET - O
determination NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
in ADP - O
the DET - O
human ADJ - O
urine NOUN - O
samples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
, PUNCT - O
fentanyl X - O
, PUNCT - O
alfentanil VERB - O
, PUNCT - O
gabapentin NOUN - O
and CCONJ - O
baclofen NOUN - O
produced VERB - O
no DET - O
flare NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
severe ADJ - O
interaction NOUN - O
between ADP - O
Tizanidine NNP - B-MEDICINE
and CCONJ - O
Ciprofloxacin NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
should VERB - O
be VERB - O
used VERB - O
cautiously ADV - O
in ADP - O
elderly ADJ - O
population NOUN - O
and CCONJ - O
drug NOUN - O
interactions NOUN - O
screening VERB - O
should VERB - O
be VERB - O
performed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
assess VERB - O
the DET - O
effects NOUN - O
of ADP - O
various ADJ - O
excipients NOUN - O
in ADP - O
10 CD - B-CARDINAL
different ADJ - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
tablet NOUN - O
dosage NOUN - O
forms NOUN - O
that ADJ - O
were VERB - O
prepared VERB - O
by ADP - O
direct ADJ - O
compression NOUN - O
method NOUN - O
( PUNCT - O
DC PROPN - O
) PUNCT - O
. PUNCT - O

It PRON - O
was VERB - O
observed VERB - O
that ADP - O
Formulations NNP - B-ORG
B NNP - I-ORG
, PUNCT - O
D PROPN - O
and CCONJ - O
H PROPN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
gave VERB - O
best ADJ - O
results NOUN - O
within ADP - O
USP NNP - B-ORG
specified VERB - O
limits NOUN - O
for ADP - O
the DET - O
tests NOUN - O
employed VERB - O
among ADP - O
all ADJ - O
the DET - O
formulations NOUN - O
whereas ADP - O
Formulations NNP - B-ORG
F NNP - I-ORG
and CCONJ - O
G PROPN - O
showed VERB - O
poor ADJ - O
friability NOUN - O
, PUNCT - O
disintegration NOUN - O
and CCONJ - O
dissolution NOUN - O
profiles NOUN - O
rendering VERB - O
starch NOUN - O
in ADP - O
combination NOUN - O
of ADP - O
talc NOUN - O
and CCONJ - O
sodium VERB - O
carboxy NOUN - O
- PUNCT - O
methyl NOUN - O
cellulose NOUN - O
unsuitable ADJ - O
for ADP - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
tablet NOUN - O
formulations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
plasma NOUN - O
concentrations NOUN - O
were VERB - O
determined VERB - O
by ADP - O
liquid ADJ - O
chromatography NOUN - O
/ SYM - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
bioequivalence NOUN - O
of ADP - O
two CD - B-CARDINAL
Tizanidine NNP - B-MEDICINE
4 NUM - O
mg NOUN - O
tablet NOUN - O
formulations NOUN - O
( PUNCT - O
Tizanidine JJ - B-MEDICINE
Â® NOUN - O
of ADP - O
the DET - O
Pharma NNP - B-ORG
International NNP - I-ORG
company NOUN - O
, PUNCT - O
as ADP - O
test NOUN - O
product NOUN - O
, PUNCT - O
and CCONJ - O
Sirdalud NNP - B-PERSON
Â® NN - I-PERSON
of ADP - O
Novartis NNP - B-PRODUCT
as ADP - O
a DET - O
reference NOUN - O
product NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
to PART - O
investigate VERB - O
possible ADJ - O
effects NOUN - O
of ADP - O
smoking NOUN - O
on ADP - O
pharmacokinetics NOUN - O
of ADP - O
tizanidine NN - B-MEDICINE
. PUNCT - O

ng NOUN - O
/ SYM - O
ml PROPN - O
and CCONJ - O
1.28 CD - B-CARDINAL
Â± NUM - O
1.11 CD - B-CARDINAL
ng NOUN - O
/ SYM - O
ml PROPN - O
for ADP - O
Tizanidine NNP - B-MEDICINE
PIC PROPN - O
Â® NOUN - O
and CCONJ - O
Sirdalud NNP - B-PERSON
Â® NN - I-PERSON
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
area NOUN - O
under ADP - O
the DET - O
plasma NOUN - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
profiles NOUN - O
AUC0âlast PROPN - O
were VERB - O
2.53 CD - B-CARDINAL
Â± NUM - O
2.10 CD - B-CARDINAL
ngÃh PROPN - O
/ SYM - O
ml NOUN - O
and CCONJ - O
2.46 CD - B-CARDINAL
Â± X - O
2.23 CD - B-CARDINAL
ngÃh/ PROPN - O
ml INTJ - O
, PUNCT - O
whereas ADP - O
the DET - O
AUC0ââwere PROPN - O
2.81 CD - B-CARDINAL
Â± PUNCT - O
2.27 CD - B-CARDINAL
ngÃh NOUN - O
/ SYM - O
ml PROPN - O
and CCONJ - O
2.75 CD - B-CARDINAL
Â± NUM - O
2.37 CD - B-CARDINAL
ngÃh NOUN - O
/ SYM - O
ml PROPN - O
for ADP - O
Tizanidine NNP - B-MEDICINE
PIC PROPN - O
Â® NOUN - O
and CCONJ - O
Sirdalud NNP - B-PERSON
Â® NN - I-PERSON
, PUNCT - O
respectively ADV - O
. PUNCT - O

Based VERB - O
on ADP - O
the DET - O
pharmacokinetic ADJ - O
and CCONJ - O
statistical ADJ - O
results NOUN - O
, PUNCT - O
it PRON - O
was VERB - O
concluded VERB - O
that ADP - O
; PUNCT - O
Tizanidine VB - B-MEDICINE
PIC NOUN - O
Â® NOUN - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
adverse ADJ - O
effects NOUN - O
were VERB - O
examined VERB - O
in ADP - O
100 CD - B-CARDINAL
patients NOUN - O
treated VERB - O
with ADP - O
coadministration NOUN - O
of ADP - O
tizanidine NN - B-MEDICINE
and CCONJ - O
8 CD - B-CARDINAL
CYP1A2 NOUN - O
inhibitors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Muscle NOUN - O
relaxants NOUN - O
available ADJ - O
in ADP - O
pharmaceutical ADJ - O
trade NOUN - O
suppress NOUN - O
motor NOUN - O
outflow NOUN - O
through ADP - O
different ADJ - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
, PUNCT - O
these DET - O
include VERB - O
drugs NOUN - O
such ADJ - O
as ADP - O
: PUNCT - O
Tizanidine JJ - B-MEDICINE
, PUNCT - O
botulinum ADJ - O
toxin NOUN - O
, PUNCT - O
Baclofen NNP - B-GPE
, PUNCT - O
Tolperisone NNP - B-ORG
, PUNCT - O
Methocarbamol NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
crystallizes NOUN - O
with ADP - O
two CD - B-CARDINAL
almost ADV - O
identical ADJ - O
molecules NOUN - O
in ADP - O
the DET - O
asymmetric ADJ - O
unit NOUN - O
( PUNCT - O
r.m.s VERB - O
. PUNCT - O
deviation NOUN - O
= SYM - O
0.179 CD - B-CARDINAL
Ã NOUN - O
for ADP - O
all DET - O
non ADJ - O
- ADJ - O
H ADJ - O
atoms NOUN - O
) PUNCT - O
. PUNCT - O

Tizanidine NN - B-MEDICINE
does VERB - O
not ADV - O
crystallize VERB - O
as ADP - O
the DET - O
usually ADV - O
drawn VERB - O
2-amino NUM - O
- PUNCT - O
imidazoline NOUN - O
tautomer NOUN - O
, PUNCT - O
but CCONJ - O
as ADP - O
the DET - O
2-imino CD - B-NORP
- PUNCT - O
imidazolidine NOUN - O
tautomer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
whether ADP - O
a DET - O
pharmacological ADJ - O
intervention NOUN - O
using VERB - O
Tizanidine NNP - B-MEDICINE
, PUNCT - O
an DET - O
anti ADJ - O
- ADJ - O
spastic ADJ - O
medication NOUN - O
acting VERB - O
as ADP - O
an DET - O
Î±2-adrenergic NOUN - O
agonist NOUN - O
, PUNCT - O
could VERB - O
lead VERB - O
to ADP - O
improvements NOUN - O
in ADP - O
walking VERB - O
endurance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
morphology NOUN - O
of ADP - O
gelatin ADJ - O
nanoparticles NOUN - O
loaded VERB - O
with ADP - O
three CD - B-CARDINAL
different ADJ - O
drugs NOUN - O
( PUNCT - O
Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
, PUNCT - O
Gatifloxacin NNP - B-PERSON
and CCONJ - O
Fluconazole NNP - B-PERSON
) PUNCT - O
and CCONJ - O
their ADJ - O
characteristics NOUN - O
of ADP - O
entrapment NOUN - O
and CCONJ - O
release NOUN - O
from ADP - O
gelatin ADJ - O
nanoparticles NOUN - O
were VERB - O
investigated VERB - O
by ADP - O
the DET - O
analysis NOUN - O
on ADP - O
nanoparticle NOUN - O
size NOUN - O
distribution NOUN - O
, PUNCT - O
SEM NNP - B-ORG
and CCONJ - O
FT PROPN - O
- PUNCT - O
IR PROPN - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

Nonetheless ADV - O
, PUNCT - O
the DET - O
uncrosslinked ADJ - O
case NOUN - O
of ADP - O
Gatifloxacin NNP - B-ORG
loading NOUN - O
generally ADV - O
led VERB - O
to ADP - O
a DET - O
more ADV - O
homogeneous ADJ - O
population NOUN - O
of ADP - O
nanoparticles NOUN - O
than ADP - O
the DET - O
uncrosslinked ADJ - O
case NOUN - O
of ADP - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
loading NOUN - O
. PUNCT - O

No DET - O
loading NOUN - O
was VERB - O
achieved VERB - O
in ADP - O
the DET - O
case NOUN - O
of ADP - O
Fluconazole NNP - B-PERSON
, PUNCT - O
whereas ADP - O
both DET - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
and CCONJ - O
Gatifloxacin NNP - B-PERSON
are VERB - O
observed VERB - O
of ADP - O
being VERB - O
capable ADJ - O
of ADP - O
being VERB - O
loaded VERB - O
by ADP - O
nanoprecipitation NOUN - O
. PUNCT - O

Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
- PUNCT - O
loaded ADJ - O
, PUNCT - O
blank ADJ - O
and CCONJ - O
Gatifloxacin NNP - B-ORG
- PUNCT - O
loaded VERB - O
nanoparticles NOUN - O
yielded VERB - O
, PUNCT - O
under ADP - O
crosslinked ADJ - O
condition NOUN - O
, PUNCT - O
59.3 CD - B-CARDINAL
, PUNCT - O
23.1 CD - B-CARDINAL
and CCONJ - O
10.6 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
used VERB - O
dried VERB - O
mass NOUN - O
. PUNCT - O

The DET - O
crosslinked VERB - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
- PUNCT - O
loaded VERB - O
particles NOUN - O
showed VERB - O
the DET - O
loading NOUN - O
efficiency NOUN - O
of ADP - O
13.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
which ADJ - O
was VERB - O
decreased VERB - O
to ADP - O
1.1 CD - B-PERCENT
% NN - I-PERCENT
without ADP - O
crosslinking NOUN - O
. PUNCT - O

A DET - O
crosslinker NOUN - O
such ADJ - O
as ADP - O
glutaraldehyde NOUN - O
is VERB - O
indispensable ADJ - O
to PART - O
enhance VERB - O
the DET - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
- PUNCT - O
loading VERB - O
efficiency NOUN - O
. PUNCT - O

The DET - O
80 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
loaded ADJ - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
was VERB - O
released VERB - O
around IN - B-CARDINAL
15 CD - I-CARDINAL
h NOUN - O
after ADP - O
start NOUN - O
- PUNCT - O
up NOUN - O
of ADP - O
the DET - O
release NOUN - O
experiment NOUN - O
, PUNCT - O
while ADP - O
the DET - O
20 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
loaded ADJ - O
Gatifloxacin NNP - B-PERSON
was VERB - O
released VERB - O
more ADV - O
rapidly ADV - O
, PUNCT - O
as ADP - O
free ADJ - O
Gatifloxacin NNP - B-ORG
, PUNCT - O
than ADP - O
the DET - O
loaded VERB - O
Tizanidine NNP - B-MEDICINE
hydrochloride NOUN - O
and CCONJ - O
it PRON - O
showed VERB - O
the DET - O
trend NOUN - O
of ADP - O
sustained VERB - O
slow ADJ - O
release NOUN - O
during ADP - O
the DET - O
remaining VERB - O
period NOUN - O
of ADP - O
its ADJ - O
release NOUN - O
experiment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine VB - B-MEDICINE
for ADP - O
alcohol NOUN - O
withdrawal NOUN - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
HCl NOUN - O
is VERB - O
a DET - O
centrally ADV - O
acting VERB - O
Î±-2 VERB - O
adrenergic ADJ - O
agonist NOUN - O
muscle NOUN - O
relaxant NOUN - O
with ADP - O
a DET - O
slightly ADV - O
bitter ADJ - O
taste NOUN - O
having VERB - O
short ADJ - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
of ADP - O
2.5 CD - B-CARDINAL
h. NOUN - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
Orodispersible JJ - B-ORG
Tizanidine NNP - I-MEDICINE
HCl NOUN - O
Tablets NNS - B-ORG
Using VBG - I-ORG
Spray NN - I-ORG
Dried NNP - I-ORG
Coprocessed NNP - I-ORG
Exipient NNP - I-ORG
Bases NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine NN - B-MEDICINE
may VERB - O
be VERB - O
administered VERB - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
an DET - O
immediate ADJ - O
release NOUN - O
multiparticulate VERB - O
composition NOUN - O
at ADP - O
or CCONJ - O
around ADP - O
the DET - O
time NOUN - O
food NOUN - O
is VERB - O
consumed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Tizanidine JJ - B-MEDICINE
hydrochloride NOUN - O
is VERB - O
an DET - O
orally ADV - O
administered VERB - O
prokinetic ADJ - O
agent NOUN - O
that ADJ - O
facilitates VERB - O
or CCONJ - O
restores VERB - O
motility NOUN - O
through ADP - O
- PUNCT - O
out PART - O
the DET - O
length NOUN - O
of ADP - O
the DET - O
gastrointestinal ADJ - O
tract NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ropivacaine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
over ADP - O
a DET - O
period NOUN - O
of ADP - O
2 CD - B-DATE
- SYM - I-DATE
3 CD - I-DATE
days NNS - I-DATE
, PUNCT - O
we PRON - O
achieved VERB - O
a DET - O
good ADJ - O
pain NOUN - O
reduction NOUN - O
comparable ADJ - O
to ADP - O
a DET - O
femoral ADJ - O
catheter NOUN - O
and CCONJ - O
perfusor NOUN - O
application NOUN - O
of ADP - O
2,0 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
ml NNP - I-QUANTITY
( PUNCT - O
0,2 NUM - O
% NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
a DET - O
ligand NOUN - O
of ADP - O
TAS2R10 NNP - B-ORG
, PUNCT - O
but CCONJ - O
its ADJ - O
relaxant ADJ - O
profile NOUN - O
is VERB - O
unknown ADJ - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
significantly ADV - O
relieved VERB - O
airway ADJ - O
hyperreactivity NOUN - O
in ADP - O
asthma NOUN - O
model NOUN - O
mice NOUN - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
relaxed ADJ - O
mouse NOUN - O
tracheal NOUN - O
segments NOUN - O
precontracted VERB - O
with ADP - O
carbachol NOUN - O
, PUNCT - O
KCl NOUN - O
, PUNCT - O
5-hydroxytryptamine CD - B-ORG
and CCONJ - O
U46619 PROPN - O
, PUNCT - O
and CCONJ - O
further ADV - O
dilated VERB - O
the DET - O
tracheal NOUN - O
rings NOUN - O
relaxed VERB - O
by ADP - O
isoprenaline NOUN - O
or CCONJ - O
atropine NOUN - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
did VERB - O
n't ADV - O
elevate VERB - O
cAMP NOUN - O
level NOUN - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
had VERB - O
marked VERB - O
bronchodilatory NOUN - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Precursor PROPN - O
Supply PROPN - O
for ADP - O
Erythromycin NNP - B-MEDICINE
Biosynthesis PROPN - O
: PUNCT - O
Engineering PROPN - O
of ADP - O
Propionate PROPN - O
Assimilation PROPN - O
Pathway PROPN - O

-DOCSTART- -X- - O

Erythromycin NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
solid ADJ - O
lipid NOUN - O
microparticles NOUN - O
( PUNCT - O
SLM NNP - B-ORG
) PUNCT - O
based VERB - O
on ADP - O
solidified VERB - O
reverse ADJ - O
micellar ADJ - O
solution NOUN - O
( PUNCT - O
SRMS NNP - B-ORG
) PUNCT - O
as ADP - O
an DET - O
oral ADJ - O
delivery NOUN - O
formulation NOUN - O
was VERB - O
studied VERB - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
stearate NOUN - O
- PUNCT - O
loaded ADJ - O
SLMs NOUN - O
formulation NOUN - O
could VERB - O
serve VERB - O
as ADP - O
an DET - O
alternative NOUN - O
to ADP - O
conventional ADJ - O
oral ADJ - O
formulation NOUN - O
of ADP - O
erythromycin NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Erythromycin NNP - B-MEDICINE
on ADP - O
the DT - B-ORG
Proliferation NNP - I-ORG
and CC - I-ORG
Apoptosis NNP - I-ORG
of IN - I-ORG
Cultured NNP - I-ORG
Nasal NNP - I-ORG
Polyp NNP - I-ORG
- HYPH - I-ORG
Derived VBN - I-ORG
Cells NNP - I-ORG
and CCONJ - O
the DT - B-ORG
Extracellular NNP - I-ORG
Signal NNP - I-ORG
- HYPH - I-ORG
Regulated NNP - I-ORG
Kinase NNP - I-ORG
( PUNCT - O
ERK)/Mitogen NNP - B-ORG
- HYPH - I-ORG
Activated VBN - I-ORG
Protein NNP - I-ORG
Kinase NNP - I-ORG
( PUNCT - O
MAPK PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
non ADJ - O
- ADJ - O
inferior ADJ - O
to PART - O
metoclopramide VERB - O
in ADP - O
facilitating VERB - O
post ADJ - O
- ADJ - O
pyloric ADJ - O
placement NOUN - O
of ADP - O
spiral ADJ - O
NETs NOUN - O
in ADP - O
critically ADV - O
ill ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Erythromycin NNP - B-MEDICINE
and CCONJ - O
Tetracycline NNP - B-PERSON
Resistance NNP - I-PERSON
in ADP - O
Lactobacillus PROPN - O
fermentum NOUN - O
Strains NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
intake NOUN - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
2 CD - B-CARDINAL
Â  SPACE - O
weeks NNS - B-DATE
of ADP - O
life NOUN - O
is VERB - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
pyloric ADJ - O
stenosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

" PUNCT - O
In ADP - O
Vitro PROPN - O
Activity PROPN - O
of ADP - O
Solithromycin NNP - B-ORG
against ADP - O
Erythromycin NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Streptococcus NNP - B-ORG
agalactiae NOUN - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
antibacterial ADJ - O
activities NOUN - O
of ADP - O
nine CD - B-CARDINAL
compounds NOUN - O
from ADP - O
Buddleja NNP - B-GPE
Â  _SP - I-GPE
albiflora NOUN - O
were VERB - O
evaluated VERB - O
against ADP - O
Listeria NNP - B-GPE
monocytogenes NOUN - O
, PUNCT - O
Staphyloccocus NNP - B-PERSON
aureus NOUN - O
, PUNCT - O
Escherichia NNP - B-PERSON
coli NOUN - O
and CCONJ - O
Pseudomonas NNP - B-ORG
aeruginosa NOUN - O
, PUNCT - O
either CCONJ - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
Erythromycin NNP - B-MEDICINE
( PUNCT - O
Ery PROPN - O
) PUNCT - O
, PUNCT - O
Gentamicin NNP - B-ORG
( -LRB- - I-ORG
Gen NNP - I-ORG
) PUNCT - O
and CCONJ - O
Ampicillin NNP - B-PERSON
( PUNCT - O
Amp PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Cost PROPN - O
Analysis NOUN - O
of ADP - O
Azithromycin PROPN - O
versus ADP - O
Erythromycin NNP - B-MEDICINE
in ADP - O
Pregnancies PROPN - O
Complicated VERB - O
by ADP - O
Preterm PROPN - O
Premature PROPN - O
Rupture PROPN - O
of ADP - O
Membranes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Infiltration NOUN - O
Into ADP - O
Erythromycin NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Campylobacter PROPN - O
coli NOUN - O
and CCONJ - O
Campylobacter NNP - B-PERSON
jejuni ADV - O
from ADP - O
Commercial NNP - B-ORG
Turkey NNP - I-ORG
Production NNP - I-ORG
in ADP - O
Eastern NNP - B-GPE
North NNP - I-GPE
Carolina NNP - I-GPE
: PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
ethylsuccinate NOUN - O
( PUNCT - O
EES NNP - B-ORG
) PUNCT - O
, PUNCT - O
is VERB - O
often ADV - O
used VERB - O
as ADP - O
a DET - O
pro ADJ - O
- ADJ - O
kinetic ADJ - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
GERD NNP - B-PERSON
, PUNCT - O
despite ADP - O
lack NOUN - O
of ADP - O
evidence NOUN - O
or CCONJ - O
safety NOUN - O
from ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
A PROPN - O
is VERB - O
an DET - O
important ADJ - O
antibiotic NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Noninvasive PROPN - O
Magnetogastrography PROPN - O
Detects VERB - O
Erythromycin NNP - B-MEDICINE
- PUNCT - O
Induced VERB - O
Effects NOUN - O
on ADP - O
the DET - O
Gastric PROPN - O
Slow PROPN - O
Wave PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
could VERB - O
elevate VERB - O
the DET - O
success NOUN - O
rate NOUN - O
of ADP - O
tube NOUN - O
insertion NOUN - O
, PUNCT - O
but CCONJ - O
its ADJ - O
clinical ADJ - O
efficiency NOUN - O
still ADV - O
remains VERB - O
controversial ADJ - O
. PUNCT - O

Erythromycin NNP - B-MEDICINE
significantly ADV - O
increases VERB - O
the DET - O
success NOUN - O
rate NOUN - O
of ADP - O
postpyloric ADJ - O
feeding NOUN - O
tube NOUN - O
placement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
for ADP - O
Promoting VERB - O
the DET - O
Postpyloric PROPN - O
Placement PROPN - O
of ADP - O
Feeding PROPN - O
Tubes PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
( PUNCT - O
ERY NNP - B-ORG
) PUNCT - O
is VERB - O
one CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
common ADJ - O
antibiotics NOUN - O
used VERB - O
in ADP - O
human ADJ - O
and CCONJ - O
veterinary ADJ - O
practices NOUN - O
, PUNCT - O
leading VERB - O
to ADP - O
ubiquitous ADJ - O
environmental ADJ - O
distribution NOUN - O
and CCONJ - O
possible ADJ - O
toxicity NOUN - O
to ADP - O
non ADJ - O
- ADJ - O
target ADJ - O
organisms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
resistance NOUN - O
rate NOUN - O
was VERB - O
79.2 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
the DET - O
frequencies NOUN - O
of ADP - O
ermB NOUN - O
and CCONJ - O
ermC ADJ - O
genes NOUN - O
were VERB - O
88.6 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
69.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Long NNP - B-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Erythromycin NNP - I-MEDICINE
Therapy NNP - I-ORG
on ADP - O
the DT - B-ORG
Oropharyngeal NNP - I-ORG
Microbiome NNP - I-ORG
and CC - I-ORG
Resistance NNP - I-ORG
Gene NNP - I-ORG
Reservoir NNP - I-ORG
in ADP - O
Non JJ - B-ORG
- JJ - I-ORG
Cystic JJ - I-ORG
Fibrosis NNP - I-ORG
Bronchiectasis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Quantitative ADJ - O
Screening VERB - O
Method PROPN - O
for ADP - O
Erythromycin NNP - B-MEDICINE
and CCONJ - O
Tylosin NNP - B-ORG
in IN - I-ORG
Honey NNP - I-ORG
Using VBG - I-ORG
RapidFire NNP - I-ORG
Mass NNP - I-ORG
Spectrometry NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Methylase PROPN - O
Genes PROPN - O
Confers PROPN - O
Erythromycin NNP - B-MEDICINE
and CCONJ - O
Clindamycin NNP - B-ORG
Resistance NNP - I-ORG
in IN - I-ORG
Bifidobacterium NNP - I-ORG
breve VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NN - B-MEDICINE
esterase NOUN - O
, PUNCT - O
encoded VERB - O
by ADP - O
S. NNP - B-ORG
Â  _SP - I-ORG
erythraea NOUN - O
SACE_1765 NNP - B-ORG
, PUNCT - O
inactivates VERB - O
erythromycin NN - B-MEDICINE
by ADP - O
hydrolyzing VERB - O
the DET - O
macrolactone NOUN - O
ring NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
an DET - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
sclerosing VERB - O
agent NOUN - O
for ADP - O
pleurodesis NOUN - O
in ADP - O
management NOUN - O
of ADP - O
RSP NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Magnesium NN - B-MEDICINE
Oxide NNP - I-MEDICINE
Bezoar PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nano PROPN - O
- PUNCT - O
Magnesium NN - B-MEDICINE
Oxide NN - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
is VERB - O
aimed VERB - O
at ADP - O
producing VERB - O
biofilms NOUN - O
by ADP - O
reinforcement NOUN - O
of ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
( PUNCT - O
MgO NN - B-ORG
) PUNCT - O
nanoparticles NOUN - O
in ADP - O
polylactic ADJ - O
acid NOUN - O
( PUNCT - O
PLA NNP - B-ORG
) PUNCT - O
biopolymer NOUN - O
using VERB - O
the DET - O
solvent NOUN - O
casting NOUN - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Porous PROPN - O
Aluminum PROPN - O
Oxide PROPN - O
and CCONJ - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Films PROPN - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
Supplementation NNP - I-ORG
on ADP - O
Nocturnal PROPN - O
Leg NNP - B-PERSON
Cramps NNP - I-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
on ADP - O
the DET - O
Serum PROPN - O
Duloxetine PROPN - O
Concentration PROPN - O
and CCONJ - O
Antidepressant PROPN - O
- PUNCT - O
Like PROPN - O
Effects NOUN - O
of ADP - O
Duloxetine PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Situ PROPN - O
Observation PROPN - O
of ADP - O
Carbon PROPN - O
Dioxide PROPN - O
Capture PROPN - O
on ADP - O
Pseudo PROPN - O
- PUNCT - O
Liquid PROPN - O
Eutectic PROPN - O
Mixture PROPN - O
- PUNCT - O
Promoted PROPN - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Hierarchical PROPN - O
Porous PROPN - O
Magnesium NN - B-MEDICINE
Oxide NNP - I-MEDICINE
( PUNCT - O
Hr PROPN - O
- PUNCT - O
MgO PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Demonstrated PROPN - O
Using VERB - O
Lithium PROPN - O
Titanate PROPN - O
and CCONJ - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticles PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Gold NNP - B-ORG
Nanoparticles NNPS - I-ORG
Supported VBN - I-ORG
on IN - I-ORG
Magnesium NNP - I-ORG
Oxide NNP - I-ORG
Nanorods NNP - I-ORG
for IN - I-ORG
Oxidation NNP - I-ORG
of IN - I-ORG
Alcohols NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Dietary PROPN - O
Supplementation PROPN - O
of ADP - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
( PUNCT - O
MgO PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Mechanochemically RB - B-PERSON
Activated NNP - I-PERSON
, PUNCT - O
Calcium NNP - B-PERSON
Oxide NNP - I-PERSON
- HYPH - I-PERSON
Based NNP - I-PERSON
, PUNCT - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
- HYPH - I-ORG
Stabilized VBN - I-ORG
Carbon NNP - I-ORG
Dioxide NN - I-ORG
Sorbents NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Mesoporous ADJ - O
Magnesium NN - B-MEDICINE
Oxide NNP - I-MEDICINE
Hollow PROPN - O
Spheres NOUN - O
as ADP - O
Superior PROPN - O
Arsenite PROPN - O
Adsorbent NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Functional ADJ - O
Improvement NOUN - O
in ADP - O
Rats PROPN - O
' PART - O
Pancreatic ADJ - O
Islets PROPN - O
Using VERB - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticles PROPN - O
Through ADP - O
Antiapoptotic PROPN - O
and CCONJ - O
Antioxidant NNP - B-PERSON
Pathways NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro NNP - B-ORG
Toxicological NNP - I-ORG
Assessment NNP - I-ORG
of IN - I-ORG
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
Nanoparticle PROPN - O
Exposure NOUN - O
in ADP - O
Several ADJ - O
Mammalian NNP - B-NORP
Cell PROPN - O
Types PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Magnesium NN - B-MEDICINE
Oxide NNP - I-MEDICINE
Supported VERB - O
Nanoscale PROPN - O
Zero PROPN - O
- PUNCT - O
Valent PROPN - O
Iron PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Improvement NOUN - O
of ADP - O
Cycling PROPN - O
Performance PROPN - O
of ADP - O
Lithium PROPN - O
- PUNCT - O
Sulfur PROPN - O
Batteries NOUN - O
by ADP - O
Using VERB - O
Magnesium NNP - B-MEDICINE
Oxide NNP - I-MEDICINE
as ADP - O
a DET - O
Functional PROPN - O
Additive PROPN - O
for ADP - O
Trapping VERB - O
Lithium PROPN - O
Polysulfide PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
Anticonvulsive PROPN - O
Effect PROPN - O
of ADP - O
Magnesium NNP - B-ORG
Oxide NNP - I-ORG
Nanoparticles NNP - I-ORG
in ADP - O
Comparison NNP - B-GPE
with ADP - O
Conventional PROPN - O
MgO PROPN - O
in ADP - O
Diabetic PROPN - O
and CCONJ - O
Non ADJ - O
- ADJ - O
diabetic ADJ - O
Male NNP - B-PERSON
Mice NNS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Spray PROPN - O
- PUNCT - O
Dried VERB - O
Microparticles PROPN - O
for ADP - O
Pulmonary NNP - B-ORG
Delivery NNP - I-ORG
Using NNP - I-ORG
Design NNP - I-ORG
of IN - I-ORG
Experiments NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Rapid PROPN - O
Total PROPN - O
Synthesis PROPN - O
of ADP - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
Continuous PROPN - O
Flow PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Photodegradation NOUN - O
of ADP - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
the DET - O
Aqueous PROPN - O
Solution NOUN - O

